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 Background: The alteration of Epidermal Growth Factor Receptor (EGFR) plays a major 
role in the development of Head and Neck cancer. However, the only FDA approved 
EGFR target for this neoplasm is the drug Cetuximab. Cetuximab can only be used 
where there is an over-expression of EGFR. Cetuximab works by competing with the 
ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor α (TGFα) to 
bind the extracellular domain of EGFR. Inhibition of this ligand binding blocks the 
activation of subsequent signalling pathways. It is known that not all Head and Neck 
cancers over-expressing EGFR respond to Cetuximab. It has been postulated that some 
of these tumours have additional genetic lesions. Resistance to Cetuximab has been 
associated with the genetic lesions to EGFR mutation and Ras mutations. These 
mutations are more common in Asian than Caucasian patients. More recently the 
Tyrosine kinase inhibitors (Gefitinib and Erlotinib) have been investigated as drugs to 
target tumours with EGFR mutation. These inhibitors bind to the cytoplasmic domain 
of the EGFR and compete with ATP and inhibit phosphorylation of the receptor. 
Another inhibitor of interest is PD98509 which is a selective ERK1/2 inhibitor and may 
be used in targeting tumours with a Ras mutation. None of these inhibitors has 
received FDA approval for Head and Neck cancer treatment. 
 Aim: The main aims of the project were to investigate the effect of the growth factors 
EGF and TGFα and the inhibitors; Gefitinib, Erlotinib and PD98059 on cancer cell lines 
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obtained from Asian head and neck cancer patients. The first area of study was to 
investigate the effect of the growth factors EGF and TGFα on cell proliferation, 
morphological changes, EMT marker expression, single cell migration and collective cell 
migration. Once the initial data had been collected a second part was to determine 
whether the inhibitors; Gefitinib, Erlotinib and PD98059 could block the stimulatory 
effect of EGF and TGFα in these assays. 
Methods:  Three tumour cell lines of Asian origin were used in the study and a normal 
skin keratinocyte as a control. Cell proliferation was measured using an automated cell 
counting system. Migration was studied using a cell scatter and cell scratch assay. The 
movement of the cells was documented by using photomicrographs. Epithelial to 
Mesenchymal Transition (EMT) and protein expression were determined using 
immunofluorescence and SDS-PAGE and Western blotting.  
 Results: Cell proliferation data indicated that the growth factors did not stimulate the 
proliferation of the cells investigated.  
Addition of the growth factors for 48 hours induced an EMT like morphological change, 
individual cell migration in the scatter assay and collective cell migration in the scratch 
assay. However, the specific markers of EMT (E cadherin and vimentin) as measured by 
Western blotting and immunofluorescence showed no change in intensity following the 
addition of the growth factors for 48 hours. 
Pre-treatment of the cells for one hour with the tyrosine kinase inhibitors (Gefitinib, 
Erlotinib) and the MAPK inhibitor (PD98059) inhibited these morphological changes, and 
individual cell migration. However, only the Tyrosine kinase inhibitors inhibited 
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collective cell migration. PD98059 partially inhibited collective cell migration of the TYS 
and HaCaT cell lines and fully inhibited cell migration of the HSG and AZA1 cell lines.  
Analysis of the MAPK pathway using the expression of phosphorylated MAPK was 
investigated by Western Blot and Immunofluorescence. Western blot data indicated an 
increased expression of phosphorylated MAPK202/204 was observed in cells treated 
with both EGF and TGFα for 24 hours. At the 24hour time point, tyrosine kinase 
inhibitors (Gefitinib, Erlotinib) fully inhibited the MAPK202/204 phosphorylation. In 
contrast, in ERK1/2 inhibitor (PD98059) treated dishes, phosphorylated MAPK 202/204 
was still expressed which was likely to be the same level of expression as serum free 
treated dishes. 
 
Conclusion and Possible Clinical Impact: The data indicates that the growth factors EGF 
and TGFα both stimulated single and collective cell migration. The data lead us an 
unexpected answer as to whether single cell migration and collective cell 
migration utilised the same signalling pathways. The data indicated that these are 
separate pathways; the MAPK pathway appears to be the only pathway responsible for 
morphological change and single cell migration in cell lines used in this project. The role 
of MAPK signalling pathway in collective cell migration appears to be cell line dependent 
and MAPK alone might not be responsible for collective cell 
migration.  The ability of the inhibitors may in the future lead to a more personalised 
therapy for patients in Asian countries and more clinical trials across a diverse group of 




































1.1 Biology of cancer   
Cancer is the disease which at its most basic definition is cells in specific part of body 
grow uncontrollably (NCI, 2020). These cells can invade the surrounding tissue, organs 
and eventually spread to other parts of the body which is called metastasis (Guan X, 
2015). Cancer is the second leading cause of death worldwide and accounted for 9.6 
million deaths in 2018 (WHO, 2018). 90 % of cancer deaths are caused by metastasis 
(Guan X, 2015, Chaffer & Weinberg, 2011). 
There are 6 types of cancer according to the type of the cells that they originated from:  
a) Carcinoma- derived from epithelial cells which line internal organ. 
b) Sarcomas- derived from mesenchymal origin such as connective and supporting 
tissues (examples bone, cartilage, fat, and muscle). 
c) Leukaemia -derived from hematopoietic cells such as bone marrow. 
d) Lymphomas - derived from T or B lymphocytes which are part of immune system.  
e) Myeloma-derived from plasma cells which are part of immune system. 
f) Brain and spinal cord cancer -which are called central nervous system cancer 
(CRUK, 2017) 
The word tumour simply refers to a mass. This is a general term that can refer to benign 
or malignant. A benign tumour is slow growing and does not spread to other parts of 
the body. It they are correctly removed they do not reappear. In contrast, malignant 
tumours spread to other parts of the body and are likely to recur (CRUK, 2017). All the 
cancers start with genetic changes which can lead to mutation of proto-oncogenes, loss 
of function of tumour suppressor genes and eventually acquiring the hallsmark of cancer 
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(Hanahan & Weinberg, 2000). In 2000, Hanahan and Weinberg published a review article 
titled “The Hallmarks of Cancer”. It was one of the most downloaded and most cited 
papers of all time. In 2011, they updated their list by adding four more hallmarks of 
cancer making a total of 10 hallmarks of cancer.   
The Hallmarks of Cancer are (and shown in Figure 1.1): 
a) Self-sufficiency in growth signals. 
b) Insensitivity to antigrowth signals. 
c) Resistance to apoptosis. 
d) Limitless replicative potential. 
e) Formation of angiogenesis. 
f) Activating tissue invasion and metastasis. 
g) Genomic instability and mutation.  
h) Tumour promoting inflammation. 
i) Reprogramming emergency metabolism.  
j) Avoiding immune destruction. 
All cancers acquire at least some these characteristics in the development of the 





Figure1.1 Hallmarks of cancer: Reproduced and modified from (Hanahan & Weinberg, 
2011)   
 
1.2 Head and neck cancer 
The UK National Health Service defines head and neck cancer as referring to the group 
of cancers that develop from the mucosal linings of the upper aerodigestive tract, 
comprising oral cavity, nasal cavity, lip, tongue, salivary glands, larynx, pharynx 
(nasopharynx—behind the nose; oropharynx—soft palate, base of the tongue and the 
tonsils; hypopharynx—the lowest part of the pharynx) and paranasal air sinuses (NHS, 
2018).  Oral cancer is a subgroup of head and neck cancer. Head and neck cancer are a 
heterogeneous disease that can be divided into two genetic subclasses: HPV positive 
and HPV negative which are different in the pathogenesis process.  
According to the WHO, Head and neck cancer is the 6th most common cancer worldwide 
with more than 550,000 cases with around 300,000 deaths per year. The male to female 
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ratio 2:1 to 4:1. About 90% of all head and neck cancers are reported to be squamous 
cell carcinomas (HNSCC).  Despite the recent developments in medical therapy, the 5 
years survival rate of head and neck cancer is still only 40%-50% (WHO, 2014).  
The risk of developing head and neck cancer increases with age and most of the cases 
occur in patients aged 50- years or over (Vigneswaran& Williams, 2014). Development 
of head and neck cancer is a multistep process which usually starts with potentially 
malignant disorders (PMD). PMD is the term used to describe potentially malignant 
lesions and conditions (Warnakulasuriya et al., 2007).  A potentially malignant lesion is 
a morphologically altered mucosa lesion which can transform into malignancy. Any 
potentially malignant condition arising in the oral cavity will increase the risk of oral 
cancer (Vigneswaran & Williams, 2014). It is therefore important to detect PMD as early 
as possible to avoid negative outcome. Therefore understanding the molecular 
pathogenesis of the disease will help to improve the survival of the patient.   
Patients who have been cured from an initial primary tumour have a higher risk of 
second primary tumour due to field cancerization (Chuang SC et al., 2008, Morris LG et 
al., 2011, Jones AS et al., 1995). Field cancerization can be defined as the exposure of 
the whole area to carcinogens which leads to development of multiple cancers 
(Slaughter DP et al., 1953). 
Most HNSCC patients have metastatic disease at the time of diagnosis with regional 






1.3 Aetiology of head and neck cancer 
1.3.1 Tobacco 
Smoking is the most common use of tobacco. Smoking is a major independent risk factor 
for Head and neck cancer with 70–80% of new HNSCC diagnoses being related to 
tobacco and alcohol use (Jethwa & Khariwala, 2017). Incidence of head and neck cancer 
is related to smoking and varies among the geographic regions of the world. Smokers 
have higher chance of cancer than non-smokers. The risk increases with quantity and 
duration of smoking (Radoi & Luce, 2013). Out of 7000 chemicals released from tobacco 
smoke, 250 are harmful to human body while 69 are known to cause cancer (NCI, 2018). 
Acetaldehyde, Aromatic amines, Arsenic, Benzene, 1, 3-Butadienc, Cadmium, 
Chromium, Cumene, Ethylene oxide, Formaldehyde, Polycyclic aromatic hydrocarbon 
(PAHs), Tobacco-specific nitrosamines, Vinyl chloride are examples of cancer causing 
chemicals that are found in tobacco smoke (NCI, 2018). It should be noted that 
smokeless tobacco use is common in South East Asia. Betel quid, Dry snuff, and Zarda 
are examples of smokeless tobacco (Wynder et al., 1957). Betel quid is the most 
common smokeless tobacco in South East Asian region. The composition of Betel quid 
varies from one place to another since different types of tobacco are popular in different 
regions. However, the core elements remain the same and consists of three 
components: the betel leaf, the areca nut (fresh or dried) and slaked lime (Xuan Hien & 
Reichart,2008). Research estimated Betel quid chewing is responsible for half of the oral 
cancer cases in India (Travasso, 2013).  The use of electronic cigarettes has risen in 
popularity since they were first introduced in 2013. Long term use of E-cigarettes has 
been reported to increase the incidence of oral cancer (Nguyen H et al., 2017). The most 
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common form of E-cigarettes is vaping which is a type of electronic nicotine delivery 
system utilising a heating of a solution containing liquid nicotine, propylene glycol, 
glycerol (glycerine), and flavouring agents (Grana R et al., 2014). 
Liquid nicotine, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, cresol, 
volatile organic compounds, aldehydes, Tobacco alkaloids, metals, flavouring agents, are 
found in cartridges and aerosols of e-cigarettes (Cheng T, 2014). A study conducted by 
American chemical society, reported an increased level of DNA damaging substance 
such as chemicals formaldehyde, acrolein and methylglyoxal were found in lung tissue 
of e-cigarettes users (Drewett Z, 2018). 
1.3.2 Alcohol  
Alcohol is another independent risk factor for HNSCC. Alcohol is the by-product of the 
fermentation of sugar, yeast, and starch. Different type of fruits, grains are used in the 
fermentation process with the help of yeast to making the final product (alcohol). 
Different concentrations of ethanol are found in different alcoholic drinks made from 
different sources (10% in beer, 16% in wine, 40 % in vodka) (Ogden GR, 2018). The exact 
percentage of alcohol that may cause head and neck cancer varies with different types 
of alcohol consumption and different regions of the world (Freedman et al., 2007).  
It is believed that the higher alcohol consumption over a short period of time might be 
more harmful than low alcohol consumption over a longer period of time (Lubin et 
al.,2009). 
Regular alcohol drinkers have a 2.5 times higher risk of developing head and neck cancer 
than non-drinkers and occasional drinkers. The risk of head and neck cancer in people 
with a daily alcohol consumption of 12.5-50g is 12-81% higher than non-drinkers. Daily 
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alcohol consumption of 50g increases the risk by 5 times compared with non-drinkers. 
The risk of head and neck cancer is higher in people who use both of alcohol and tobacco 
(Hashibe et al., 2009, CRUK 2018). Ogden GR, 2018 suggested that people need to be 
aware of their alcohol intake. More public health interventions and the development of 
alcohol tracking application such as AlcoDriod alcohol tracker should raise awareness 
and make it easier to track alcohol intake with everyone should be encouraged to use it. 
The risk of cancer for an ex-drinker is higher than non-drinker even 10 years after  
quitting drinking alcohol (Rehm et al., 2007) and only returns to the same level as a non- 
drinkers 20 years after quitting drinking alcohol (Marron et al., 2010, Rehm et al., 2007, 
Altieri et al., 2002). Acetaldehyde a by-product of the breakdown of alcohol is a major 
carcinogen and is much more carcinogenic than alcohol itself (Ogden GR, 2018). 
Figure 1.2 describes the break down of alcohol. Acetaldehyde is know to disrupt DNA 
synthesis and repair and this is a by-product of the breakdown of ethanol in the body 
and may lead to an increased risk of cancer. Another hypothesis is that alcohol acts as a 
solvent for carcinogens found in tobacco smoke and this might be the reason for the 





                                                                    
 Figure 1.2: Alcohol degeneration: shows that ethanol undergoes changes in the body 
to more carcinogenic substrates (Kawakita & Matsuo, 2017). 
Conversion of ethanol into acetaldehyde is induced by Alcohol dehydrogenase enzymes 
(ADH). Acetaldehyde is further broken down by Aldehyde dehydrogenase enzymes 
(ALDH). It is hypothesized that an active ADH1B and ADH1C genotypes are found in 
Asian population. Active ADH1B and ADH1C have ability to metabolize ethanol quickly 
and this could lead to an increased risk of head and neck cancer (Brennan et al., 2004). 
Asian populations who have an inactive acetaldehyde dehydrogenase 2 (ALDH2) cannot 
break down acetaldehyde resulting in the accumulation of acetaldehyde in the human 
body (Brennan et al., 2004). This may explain why light drinking (low alcohol 






1.3.3 Virus  
1.3.3.1 Human papilloma virus (HPV) 
HPV is a double stranded DNA virus that is known to be the primary aetiology of cervical 
cancer (Walboomers et al., 1999). There are over 100 types of HPV genotypes and not 
all of them causes health problems. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 
66 are known as high risk strains causing cancer while HPV 6 , 11, 40, 42, 43, 44, and 54 
are low risk strains and do not cause cancer (Muñoz et al.,2003). HPV 16 and HPV 18 are 
known to cause oral cancer. Incidence of HPV+ head and neck cancer vary by country or 
region (Mehanna H, 2012).  A study found that about 23.5 % of HNSCCs are related with 
HPV (Kreimer et al., 2005) and that HPV 16 is responsible for 90% to 95% of HPV+ HNSCC 
(Ram et al., 2011). HPV positive head and neck cancer is related to sexual behaviour such 
as oral sex and an increased number of sexual partners and is predominantly seen in 
younger people compared with traditional (or HPV negative) head and neck cancer 
(Nuyts & Dok, 2016). Oncoproteins (proteins that are coded for by an oncogene) E6 and 
E7 are expressed in HPV infected cells. E6 binds to tumour suppressor protein p53 and 
induces degradation of this protein. E7 induces inactivation of pRb tumour suppressor 
protein (Moody & Laimins, 2010). HPV+ HNSCC are commonly found in the oropharynx 
as a small primary tumour generally around the lymph nodes, are poorly differentiated, 
but have better prognosis than classic HNSCC (Fakhry et al., 2008, Ang KK et al., 2010, 
Lassen et al., 2009, Schwartz  et al., 2001, Dayyani et al., 2010). However, prognosis of 
HPV positive HNSCC patients who are exposed to any form of tobacco may not be as 




1.3.3.2 Other Viruses  
HSV-1 or oral herpes is believed to enhance risk of oral cancer (Schildt et al., 1998, 
Kassim & Daley, 1988, Starr et al., 2001).  
Coinfection of EBV and HPV might increase the risk of oral cancer (Al Moustafa et al., 
2009). Hepatitis C virus (HCV) is related with risk of oral cancer (Nagao & Sata, 2009). 
1.3.4 Genetic disease  
Fanconi anemia is an autosomal recessive disorder that causes genetic instability with 
congenital malformations leading to bone marrow failure and cancer. There is a clear 
link between fanconi anemia and increased risk of oral cancer.  Several reports have 
shown that 19 out of 754 fanconi anemia patients developed oral cancer (Kutler et al., 
2003, Gasparini et al., 2006). 
1.3.5 Candida  
Candida infection can increase the risk of patients developing Leukoplakia, dysplasia and 
malignant transformation (Sankari et al., 2015). 
1.3.6 Diet  
Certain diets such as salted fish, preserved meat and vegetables, are related with an 
increased risk of head and neck cancer while a diet rich in fruit and vegetables can 
protect against cancer  (Jia et al., 2010, Yu MC et al., 1986). 
1.3.7 Organs transplant patients 
Solid organ transplant patients have a higher rate of lip cancer and have poor prognosis 
compared with the general population (Öhman et al., 2015). This might be due to 
immunosuppression in organ transplant patients that leads them not being able to stand 
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up to immune destruction. Although why this would lead to a high rate of lip cancers 
remains to be resolved. 
1.3.8 Family history   
As with other cancers, family history of oral cancer is associated with early age onset of 
cancer (Ankathil et al., 1996, Garavello et al., 2007). 
 
1.3.9 Potentially malignant disorders: 
 
1.3.9.1 Leukoplakia, Erythroleukoplakia, Erythroplakia 
Oral Leukoplakia is a white patch which cannot be characterized as any other disease 
(WHO, 1978). It is more frequently found in smokers than non-smokers. The malignant 
transformation of leukoplakia ranges from 0.13% to 34.0% showing that leukoplakia has 
malignant potential (Warnakulasuriya & Ariyawardana, 2015). Overexpression of EGFR 
in oral leukoplakia patients was reported to increase the chance of transformation into 
a carcinoma, whilst normal expression of EGFR did not lead to this (Ries et al., 2013). 
Early detection of transformation could be investigated by testing for EGFR expression 
with over expression in oral leukoplakia patients being utilised as a diagnostic tool. 
Leukoplakia can be divided into two subtypes: Homogenous (uniformly flat, uniformly 
white) and non-homogenous (speckled or nodules, mixture of red and white lesion) 
which is also known as Erythroleukoplakia (Yardimci et al., 2014). Non-homogenous 
leukoplakia has higher risk for malignant transformation than homogenous leukoplakia 
(Vigneswaran & William, 2014). Erythroplakia is red patch which cannot diagnosed as 
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any other disease is not as common as leukoplakia but is more likely to become 
dysplastic in nature (Waal, 2009, Reichart & Philipsen, 2005). 
 
1.3.9.2 Oral submucous fibrosis 
Oral submucous fibrosis is a premalignant condition common among betel quid chewing 
south Asian countries. Eating chilies, genetic changes and nutritional deficiencies are 
also thought to increase the incidence of OSMF. Clinical features of OSMF are limitations 
of mouth opening, burning sensation, difficulty in mastication, speech and 
swallowing(Tilakaratne et al,2006).The malignant transformation rate of OSMF is in the 
range from 8% to 12 % (Vigneswaran & William, 2014). OSMF is considered as collagen‐
metabolic disorder resulting from exposure to areca nuts. Arecoline (component of 
betel nut) play an important role in stimulating collagen production. Constant irritation 
of oral mucosa due to direct contact with arecoline leads to chronic inflammation, 
leading to activation of T cells and macrophages. This activation is followed by an 
increase in cytokines and growth factors production such as IL-6, TNF and TGFα. TGFα is 
major inducer of collagen synthesis. Overall increase in collagen production and 
decrease in collagen degradation leads to collagen deposition and fibrosis (Rajalalitha P 
et al 2005, Tilakaratne et al 2006). 
1.3.9.3 Oral lichen planus 
Lichen planus is a chronic autoimmune, mucocutaneous disease which affects the oral 
mucosa (oral lichen planus or OLP), skin, genital mucosa, scalp and nails. In the oral 
mucosa, it presents with white striations (Wickham's striae), white papules, erythema, 
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erosions or blisters. Malignant transformation of oral lichen planus is in the range from 
0% to 5.3% (Ismail et al., 2007). 
This means that a routine dental check-up is important to detect these lesions before a 
transformation into a cancer (discussed detailed in 1.7 clinical feature of head and neck 
cancer).  
 
1.4 Geographic variation of head and neck cancer rate 
 
The incidence of head and neck cancer has been reported to be higher in southern Asian 
countries (such as India, Pakistan, Sri Lanka, Taiwan), parts of Europe (France, Hungary), 
areas of south America (Brazil), and the Pacific region such as Papua New Guinea, 
Melanesia (Warnakulasuriya, 2009). 
1.5 Betel quid chewing in Myanmar and oral cancer statistics 
Even though betel quid chewing is uncommon in west, it is practised in South East Asia 
(SEA) region which has more than 600 million people (10% of total world population) 
(Cheong et al., 2017). Myanmar is second largest country in SEA with a population of 
more than 50 million people. About 70% of the population live in rural areas where it is 
difficult to access health care. Betel quid chewing habit is more common in these rural 
areas than in the city. It has been reported that more than 50% of Myanmar men use 
smokeless tobacco (Cheong et al., 2017). The actual number of head and neck cancer 
incidences in Myanmar is difficult to access, political conflicts, internally displaced 
persons and struggles with a weak economy are a major challenge in the data collection. 
According to the official publication of Asia Pacific Journal of Cancer Prevention, oral 
cancer is the fourth most common cancer among Myanmar males and sixth most 
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common cancer among Myanmar females (Kimman et al., 2012). A retrospective 
hospital-based study conducted in Toungoo district in Myanmar from 2012 to 2015, 
found that head and neck cancer accounted for 19.51% of all cancer patients. Out of 
these, 5.22% were stage 1, 33.33% were stage 2, 46.4% were stage 3 and 15.03% were 
stage 4 (Ngwe et al., 2016). The risk of oral cancer is four times higher in areca nut 
chewers who keep the quid overnight in their mouth (Oo et al., 2011). This might be due 
to prolonged contact time with betel quid and the oral mucosa. In one study with oral 
screening targeting betel quid chewers (n=86), 3 patients had already developed 
carcinoma while a further 16 presented with pre-malignant lesion (unpublished data of 
Shwe Yaung Hnin Si cancer foundation). These figures are indicating a high incidence of 
head and neck cancer in Myanmar. In Myanmar, patients usually arrive at Hospital at a 
very late stage of oral cancer with a large ulceration. Most of these have already tried 
traditional plant base medicines as a therapy before presenting at the health care 
centre. The effect of traditional non evidence-based medicine in cancer treatment is 
questionable. Their molecular pathogenesis might be different from people who never 
receive traditional plant-based medicine. There are only a few studies of head and neck 
cancer in Myanmar at molecular level. At present there has been no report of EGFR 
overexpression/mutation status in Myanmar patients. Further work to investigate EGFR 
status of betel quid chewing HNSCC patients in Myanmar would be a basis of further 
work to be discussed later in this thesis.  
1.6 Anatomical location of head and neck cancer 
 
The anatomical location of head and neck cancer varies with different geographical 
location based on difference in aetiology. Carcinoma of tongue is most common in US 
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with high rate of nodal metastasis (Vigneswaran & Williams, 2014). Hard palate cancer 
is common in the areas where they practice reverse smoking (Vigneswaran & Williams, 
2014). Lower lip cancer is more common in pipe smokers (Vigneswaran & Williams, 
2014). 
Buccal mucosa and cheek cancer are observed mostly in SEA where the betel quid 
chewing habit is common (Travasso, 2013). 
1.7 Clinical features of head and neck cancer 
 
Clinical features of head and neck cancers are persistent mouth sores, unhealed ulcers 
that have been present for more than 3 weeks, a lump in oral cavity, difficulty in 
swallowing and chewing, voice changes, unexplained tooth mobility without periodontal 
disease, numbness in any area of mouth, Erythroplakia, Leukoplakia, Erythroleukoplakia, 
and weight loss (Bagan et al.,2010).  
Since early detection is key to increased survival rate, dental professionals need to 
understand early signs of head and neck cancer and are able to detect them at very early 
stage. Unexplained ulceration for more than 3 weeks, persistent and unexplained  lumps 
in the neck or oral cavity, leukoplakia , erythroplakia and erythroleukoplakia are listed 
in the referral guidelines (NICE, 2017). 
 
1.8 Diagnosis of head and neck cancer 
Diagnosis of head and neck cancer is usually done by clinical examination, a biopsy such 
as scalpel biopsy may be an initial event, other methods such as endoscopy, chest X ray, 
orthopantomogram, computed tomography (CT), magnetic resonance imaging (MRI), 
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positron emission tomography combined with computed tomography (PET–CT) (SIGN, 
2006). 
1.9 Staging of head and neck cancer 
In 2017, the American Joint Committee on Cancer published 8th edition of AJCC cancer 
staging manual.  Major changes were introduced around the different staging systems 
for HPV associated oropharyngeal cancers, and incorporation of depth of invasion and 
extra nodal extension. Extra nodal extension is used in all head and neck cancers apart 
from HPV associated p16+ oropharyngeal cancer and nasopharyngeal cancer (Lydiatt et 
al., 2018, Ettinger et al., 2019). 
Table 1.1 HPV negative staging of Head and neck cancer  
 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
Stage IV A T4a N0 M0 
 
 
T4a N1 M0 
 T1 N2 M0 
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 T2 N2 M0 
 T3 N2 M0 
 T4a N2 M0 
Stage IV B Any T N3 M0 
 T4b Any N M0 
Stage V C Any T Any N M1 
 
 
Legend: TNM staging is common system used for many types of cancer. T stands for 
Tumour, N stands for Node and M stands for Metastasis. TNM system reports the size of 
tumour, lymph node metastasis present or not, distant structure metastasis presence or 
not. 
Tx= Primary tumor cannot be assessed 
Tis= Carcinoma in situ = group of abnormal cells or precancer stage  
T1, T2, T3, T4 = increasing size and or involvement of primary tumour.  
T1 = tumour 2 cm or  less than 2cm in greatest dimension, depth of invasion (DOI) is less 
than 5mm 
T2= Tumour 2 cm or less with more than 5mm but less than 10mm DOI or tumour more 
than 2 cm but not more than 4 cm and DOI not greater than 10mm. 
T3= Tumour is bigger than 4 cm in greatest dimension, DOI is larger than 10mm  
T4= (Lip) Tumour infiltrated into cortical bone, inferior alveolar nerve, floor of mouth, 
skin of face 
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T4a=Tumour infiltrated into cortical bone, muscle of tongue, maxillary sinus or skin of 
face 
T4b= Tumour infiltrated into masticator space, pterygoid plate, skull base and external 
carotid artery 
Nx= Regional lymph node cannot assess.  
N0= no evidence of nodal metastasis  
N1, N2, N3= involvement of regional lymph node metastasis. 
N1= Metastasis in single ipsilateral lymph node 3 cm or less than 3 cm in greatest 
dimension and  extranodal extension (ENE) negative 
N2a= single ipsilateral lymph node more than 3cm but not more than 6cm in greatest 
dimension and ENE negative 
N2b= multiple ipsilateral lymph nodes none more than 6cm in greatest dimension and 
and ENE negative. 
N2c= bilateral contralateral lymph nodes none more than 6cm in greatest dimension and 
ENE negative. 
N3a=lymph node >6cm in dimension, and ENE negative 
N3b= metastasis in a single ipsilateral node ENE positive or multiple ipsilateral, bilateral 
or contralateral nodes ENE positive 
ENE now N3b so higher proportion of patients in stage IVb group 
MX= Distant metastasis cannot assess 
M0= No distant metastasis 
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M1= Distant metastasis present   
TNM staging for HPV positive Oropharyngeal cancer  
In HPV positive OPC staging, T classification is largely unchanged apart from Carcinoma 
in situ and T4b are removed. In N classification, there are difference between clinical 
and pathological staging. Clinical staging is based on laterality and size of nodes while 
pathological staging is based on number of nodes and for surgical patients only. ENE not 
included in HPV+ oropharyngeal cancer. M classification is unchanged. Overall stage for 
HPV positive cancer is changed. Stage IV reserved for M1 disease (Lydiatt et al., 2018, 
Ettinger et al., 2019). 
1.10 Treatment of head and neck cancer 
 
Treatment of head and neck usually starts with a multidisciplinary team which includes 
medical oncologists, radiation oncologist, surgical oncologist, plastic surgeon, 
prosthodontist, otolaryngologist, physical therapist, Speech-language pathologist, 
Audiologist, Psychologist/psychiatrist, Registered dietitian nutritionist (Cancer.Net, 
2017). Treatment can be varied depending on cancer stage, size and the location of the 
tumour, histological grading, patient’s medical status, expected side effects, metastasis 
status (American cancer society, 2018).For example, in carcinoma in situ, the usual 
treatment is surgical stripping or thin resection. Follow up with the patient is important 
to check against recurrence and a second primary tumour. 
In stage 1 and stage 2, cancer seen in the following places; floor of mouth, tongue, hard 
palate, buccal mucosa and gum are usually treated by surgery or radiotherapy or surgery 
followed by radiotherapy or chemoradiation. Radiation alone can be used as main 
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treatment in some patients who are medically not fit for surgery or patient with cancers 
in the oropharynx area such as the soft palate, and tonsils. Lip cancer usually has better 
prognosis.  
In stage 3 and 4 cancer, treatment is combination of surgery (include nodal dissection), 
radiotherapy and chemotherapy (CRUK 2014, American cancer society 2018). Early-
stage tumours have a more favourable prognosis. 
Patients who were cured from initial primary tumor have higher risk of second primary 
tumour due to field cancerization (Jones AS et al., 1995, Chuang et al., 2008, Morris et 
al., 2011). Field cancerization means the exposure of whole area to carcinogens which 
leads to development of multiple cancers (Slaughter et al., 1953). 
Common drugs used in oral cancer are cisplatin, bleomycin, Carboplatin, 5-fluorouracil, 
Paclitaxel, Methotrexate, Docetaxel, Hydroxyurea (CRUK, 2014) which are cell cycle 
target therapeutic agents. 
Other drugs such as Cetuximab and Nivolumab have FDA approval to treat head and 
neck cancer in 2006 and 2016 respectively (Bonner et al., 2010, Bonner et al., 2006, NCI, 
2016). 
 
1.11 Overview of cell signalling  
 
Cell signalling is one of the most fundamental processes in biological life. The human 
body is composed of organs and systems. Organs are composed of tissues. Tissues are 
composed of cells. Cells need to communicate with each other in order to perform their 
normal function and that communication is based on a phenomenon called cell 
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signalling. Dysregulation of cell signalling leads to cells performing abnormal functions 
which could eventually lead to cancer. Cancer in fact is dysregulation of cells signalling 
(Weinberg, 2006). 
There are three basic steps in cell signalling: 
 
Figure 1.3 Three stages of cell signalling 
 
Legend: Reception- When a signal (also known as a ligand) from outside of the cell binds 
to a receptor which is located on the cell membrane. 
Transduction -When ligand binding leads to receptor shape change. These changes 
leading to the activation of signalling process known as cascades. Each molecule in 
cascade activates the next molecule in correct sequence. 
Response -When cellular response occurs as the result of signalling (Alberts et al., 1983). 
Membrane receptors transfer information from the environment to the cell's interior. 
Once signal molecules (often called ligands) bind to a receptor which is located on the 
membrane, information enters the cells usually without the ligands themselves entering 
the cell. Ligand binding leads to a structural change of receptor which in turn activates 
the second messenger system within the cell. Secondary messengers relay information 
from the ligand receptor complex into the cell nucleus. It should be noted that the signal 




There are three types of cell communications: 
 Autocrine signalling: the cells produce its own molecules and receptor.  
 Paracrine signalling: the cells receive signals from adjacent cells. 
 Endocrine signalling: hormones are produced by endocrine gland and sent 
through the blood stream to distant cells. 
Protein phosphorylation is a common way of transferring information. Phosphorylation 
is the process of introducing a phosphate group onto a molecular protein at the amino 
acid level. Only three amino acids can be phosphorylated; serine, tyrosine and 
threonine. Dephosphorylation is the process of removing the phosphate group from 
these amino acids. Phosphorylation and dephosphorylation can mean activation or 
deactivation of the protein depending on the specific protein involved. Protein kinases 
are enzymes which transfer phosphate groups on to a protein. Protein phosphatase are 
enzymes that remove phosphate groups from amino acids on proteins. Phosphorylation 
and dephosphorylation play a critical role in the regulation of cellular processes such as 
the cell cycle, proliferation, growth, apoptosis, and signal transduction pathways. It is 
the most common means of regulating protein function and the transmission of signals 
throughout a cell (Ardito et al., 2017). 
1.12 Genomic alterations in Head and Neck cancer 
At least 20 genes are known to be mutated in head and neck cancer (Sarode et al., 2018). 
A vast amount of literature links the following genes; p53, PIK3CA, FAT1, NOTCH1, 
CASP8, CDKN2A as the most mutated genes in head and neck cancer (Iglesias Bartolome  
et al., 2013, Pickering et al., 2013). In contrast however, other genes, such as EGFR and 
CCND1, were not include in highly mutated gene lists, but their alteration also play a 
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significant role in head and neck carcinogenesis (Stransky et al., 2011, Leemans et al., 
2011). 
1.12.1 p53 
p53 is a tumour suppressor gene and it has been cited as the most common tumour 
suppressor gene to undergo mutation in head and neck cancer.  A mutation of p53 is 
found in more than 70% of traditional head and neck cancer while HPV positive head 
and neck cancer does not harbour a p53 mutation (Zhou G et al., 2016). Smokers and 
alcohol drinkers have higher chance of having a p53 mutation (Brennan et al., 1995). In 
HPV positive head and neck cancer, p53 is inactivated by Oncoprotein E6. The p53 level 
within the cell is regulated by MDM2 which binds to p53 and induces its degradation 
(Pant & Lozano, 2014).  It is known that p53 plays an important role in the activation 
and transcription of genes important in cell-cycle control, DNA repair, senescence, 
metabolism, and cell death (Brady & Attardi, 2010).  
1.12.2 Ras  
The vast majority of the literature does not list Ras as a highly mutated gene.  Mutation 
of Ras is low in the west (Europe and North America). In fact, only 5% of head and neck 
cancer patients in UK harboured the H-Ras mutation (Chang et al., 1991). Another study 
conducted in USA also found low occurrence of H-Ras mutation (Xu J et al., 1998). In 
contrast, 35% of betel quid chewing related oral SCC in western India have the H-ras 
mutation (Saranath et al., 1991). Further studies conducted in Eastern India, reported 
that H- and K-ras genes mutations in head and neck cancer patients have a frequency of 
28 % and 33%, respectively (Das N et al., 2000). A study conducted in Taiwan (which is 
another betel quid chewing region) found that 18% tumour specimens contained K‐ras 
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mutation (Kuo et al., 1994). This leads to questions of whether Ras mutation is caused 
by a specific carcinogen in areca nuts or mutations that are found in certain ethnicities. 
1.12.3 PIK3CA  
 
About one third of HNSCC have reported a PI3K pathway mutation and on that pathway 
the protein PIK3CA shows the highest level of mutation (HNSCC-PI3K mutational profile 
(Lui et al., 2013). Multiple PI3K pathway mutations are only found in the advanced stage 
of the disease (Lui et al., 2013).  A detailed analysis of the PI3K pathway mutational 
events showed that PIK3CA is mutated in a range between 12.6% (Lui et al., 2013) to 
17.5% of all head and neck cancer (Cai et al., 2017). PIK3CA mutation is more frequent 
in HPV positive cancer than HPV negative (Nichols et al., 2013). PIK3CA mutation is found 
in 30% of HPV positive head and neck cancer while PI3KCA amplification and loss of PTEN 
were found in 20% and 33% of the case respectively (Chiosea et al., 2013). One study 
believed that even though PIK3CA overexpression alone is not sufficient for initiation of 
HNSCC, it increases invasion and metastasis by inducing the Epithelial to mesenchymal 




Figure 1.4    PI3K pathway: Reproduced and modified from (Giudice, 2013). 
 
 
1.12.4 PRAD-1 (CCND1) 
PRAD-1 (CCND1) is a proto-oncogene localized on chromosome 11q13 which encodes 
the protein cyclin D1. Cyclin D1 plays an important role in controlling the cell cycle. 
Overproduction of CyclinD1 leads to uncontrolled cell division and proliferation. Both 
CCND1 amplification and overexpression of the protein cyclin D1 was found in head and 
neck cancer patients and could be related with poor prognosis. One study reported more 
than 30 % of head and neck cancer patients have CCND1 amplification (Callender et al., 
1994). Co-amplification of EGFR and CCND1 was also found in head and neck cancer 
patient samples (Sheu et al., 2009). Another study reported oral cancer patients have 
higher Cyclin D1 expression than normal control group and related with poor outcome 
(Swaminathan et al., 2012, Zhao et al., 2014, Mineta H et al., 2000). 
1.12.5 Notch  
The Notch family is a family of highly conserved cell signalling molecules and has 4 
receptors (Notch 1-4). Notch 1 mutation is found in 10 to 15% of the HNSCC tumours 
(Fukusumi & Califano, 2018, Agrawal et al., 2011, Stransky et al., 2011). Notch 1 is a 
transmembrane receptor which plays an importance role in cell to cell interaction, 
differentiation and embryogenesis. Notch 1 acting as tumour suppressor or activator is 
dependent on cellular context and very complex (Yap et al., 2015). Whether the 
mutation of Notch1 is related to ethnicity is questionable. One study found that 43.1 % 
of Chinese oral squamous cancer patients harboured Notch mutation and these patients 
had shorter overall and disease-free survival rate (Song et al., 2014). Another study 
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conducted in Japan reported completely different findings where only 9.5% of Japanese 
oral squamous cell cancer patients had the notch mutation, interestingly, Notch 
mutated Japanese patients had longer disease-free survival than patients without the 
notch mutation (Aoyama et al., 2014). This leads to the question of whether tumour 
suppressive or oncogenic role of Notch is dependent on ethnicity. 
1.12.6 Caspase 8  
CASP8 mutation was reported in 9% of HNSCC patients and appeared to be related to 
tumour migration, invasion and resistance to death receptor‐mediated apoptosis (Li et 
al., 2014). 
1.12.7 FAT1    
FAT1 mutation in head and neck cancer patient studies varies in the range from 6.7% to 
26.9% (Morris et al., 2013) and seems dependent on HPV status. FAT 1 mutation is 
higher in HPV‐negative HNSCC (26.9%) than HPV‐positive HNSCC (7.9%) (Kim et al., 
2016). FAT proteins belong to the Cadherin superfamily of proteins. The function of FAT1 
in cancer can be either tumour suppressive or oncogenic dependant on the context 
(Katoh, 2012). In oral cancer, FAT 1 mutation or knockdown is related with disease 
progression and recurrence (Lin et al., 2018). However, FAT1 inhibits tumour growth via 
Hippo signalling while FAT1 has been reported to upregulate tumour migration through 
actin polymerization at lamellipodia and filopodia (Katoh, 2012). 
 
1.12.8 Cyclin‐dependent kinase inhibitor 2A (CDKN2A) 
Cyclin dependent kinase inhibitor 2A is located on chromosome 9p21, it encodes two 
tumour suppressor genes p16INK4a and p14 ARF which control the cell cycle. Alteration 
of CDKN2A expression due to mutation, loss of heterozygosity or DNA hypermethylation 
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is commonly found in head and neck cancer (Pérez-Sayáns et al., 2011, Lim et al., 2014, 
Zhou C, 2018). The loss of CDKN2A leads to the loss of function of p16 and p14. p16 
inhibits CDK4 and CDK6 activity and prevents Rb phosphorylation a feedback loop exists 
between p16 and Rb, by which p16 expression is controlled by Rb. p14ARF activates p53 
by inhibiting MDM2. Loss of p14 lead to loss of p53 function (Bates et al., 1998). 
1.13 Biomarkers of head and neck cancer 
 
Biomarker are a measurable indicator of the presence of disease and whether they can 
be used in the pathology service either diagnostically or prognostically. Biomarkers are 
always gene products which can be translated or untranslated products. Ideal 
biomarkers need to be easily detected in body fluids such saliva or serum and useful for 
either early detection, diagnosis or prognosis. 
There are some controversial literature which produce different lists of the biomarkers 
for head and neck cancer. (Dahiya & Dhankhar, 2016) stated that Microsatellite 
instability, HPV, Chemokine receptors, Methylation markers, Interleukins, MMPs, 
miRNA, MAGE, Centrosome abnormalities, actin and myosin, Cytokeratins, p53, 
Eukaryotic translation factor 4 E, Loss of heterozygosity (LOH) in chromosome 3p, 
9q,13q,17p are useful biomarkers of head and neck cancer. However, (Tsuda  & Ohba, 
2012) reported that EGFRs, cyclin D1, cyclin B1, Ki-67, PCNA, Akt1. p53/p63, p21/p27, 
Bcl-2 family members, pRb, Survivin, HIF-1α, CA IX, GLUT-1, EPOR, VEGF, CD105, CD34, 
Eph receptor tyrosine kinase /Eph A2, MMP-7,-9,-13,-14, CD44, E-cadherin, N-cadherin, 
β and γ-catenin, versican, Parathyroid hormone related protein, Endothelins and their 
receptor, inflammatory cytokines and chemokines, and receptor activator of NF-KB 
ligand as functional biomarkers of OSCC. Therefore one set of markers are very specific 
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at a molecular and protein level and the former are more molecular indicators. Thomas 
GR et al., 2005 argues that p16, p53, Cyclo-oxygenase 2 (Cox-2), CCND1 (gene encode 
Cyclin D1), EGFR, VEGF, MMPs, FHIT genes are also molecular markers of head and neck 
cancer.(Quon et al., 2001) reported that EGFR, TGF-α, cyclin D1, p53 protein expression 
are useful biomarkers. 
The majority of the literature indicates that EGFR, TGF-α, cyclin D1, p53, HPV and p16 
are prognostic markers of head and neck cancer. Previously the role of cyclin D1 and p53 
were discussed. EGFR and TGFα will be discussed in the next section. HPV and p16 will 
be discussed below. 
HPV status is an independent prognostic factor for survival of HNSCC patients. Oral 
cancer patients who are HPV positive have a better prognosis than patients who are 
HPV negative. The 3 years overall survival rate for the HPV positive group is 82.4% 
compared with 57.1% in the HPV negative group (Ang KK et al., 2010). Tonsil and 
oropharynx are the most common anatomical location to detect HPV virus in the oral 
cavity (Hobbs, 2006). In HPV positive HNSCC patients the oncoproteins E6 and E7 
inactivate p53 and pRb, respectively. In HPV positive cancers, the inactivation of pRb 
by HPV E7 protein may lead to p16 over-expression since Rb normally represses p16 
transcription (Ang KK et al., 2010). 
In HPV+ HNSCC, p16 was expressed as a consequence of pRb inactivation by the E7 but 
is minimally detected in classic HNSCC (Ang KK et al., 2010, Pérez-Sayáns et al., 
2011).There is a strong correlation between HPV16 DNA detection and p16INK4A 
expression (Lassen P et al., 2009). 
30 
 
p16 expression is found in HPV positive HNSCC and related with favourable prognosis 
(Sedghizadeh et al. ,2016). The 3-year rate of overall survival was 83.6% in the group 
with p16 positive group and 51.3% in the group negative for p16 expression showing 
that p16 positive with HPV positive HNSCC has better prognosis (Ang KK et al., 2010, 
Lassen P et al., 2009). This leads to the potential use of p16 as a prognosis marker in the 
future.   It should be noted that expression of p16INK4A is not limited to HPV-positive 
tumours(Lassen P et al., 2009) .One study argued that testing p16 alone is sufficient and 
HPV testing may be unnecessary since they found p16+ HPV- HNSCC has survival 
comparable to p16+ HPV+ HNSCC and statistically significantly better than p16 - HPV- 
HNSCC (Lewis et al., 2010). 
1.14 EGF like ligands 
 
Growth factors are naturally occurring substances such as protein or hormone which 
have ability to stimulate cell growth. Epidermal growth factor (EGF), Transforming 
growth factor α (TGFα), Amphiregulin (AR), Betacellulin (BTC), Epiregulin, Heparin- 
binding EGF like growth factor (HB-EGF), Epigen are all ligands that bind to Epidermal 
growth factor receptor. Some ligands are more potent than other. In here, Epidermal 
growth factor (EGF), Transforming growth factor α (TGFα) will mainly discussed since 
they are most widespread ligands for EGFR (Roskoski, 2014). 
1.15 Epidermal growth factor (EGF) and Transforming growth 
factor alpha (TGFα) 
 
EGF is 6-kDa protein with 53 amino acid and three disulphide bonds. EGF was discovered 
as a contaminant when isolating nerve growth factor. EGF was originally isolated from 
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submaxillary gland of mouse and human urine (Carpenter & Cohan, 1979). Precocious 
eyelid opening and incisor eruption were found when EGF was injected into newborn 
mice (Carpenter & Cohan, 1979). 
 EGF is heat stable, low molecular weight and accounted for 0.5% submaxillary gland 
protein (Carpenter & Cohan, 1979). 
TGFα gene is known to be associated with cleft lip and palate (Ardinger et al.,1989). 
Precocious eyelid opening was also found in newborn mice when TGFα was injected into 
the developing foetus (Smith et al., 1985). TGFα was first isolated from retro virus 
transformed cells (De Larco & Todaro, 1980). TGFα is widely expressed in both normal 
epithelium and tumour cells, and it is considered as normal physiologic ligand for EGFR 
(Ebner & Derynck ,1991). TGFα is structurally similar with EGF and showed similar effects 
in a number of assays.  TGFα is more potent than EGF which might be related with 
receptor recycling (Ceresa & McClintock 2010, Ebner & Derynck, 1991). Even though 
both EGF and TGFα induce DNA synthesis, wound healing (Schultz et al, 1991) and 
angiogenesis, the angiogenic effect of TGFα is more potent than EGF (Schreiber et al., 
1986). TGFα also induces more bone resorption than EGF does (Stern et al., 1985). 
EGF and TGFα display around 35% sequence homology with 6 cysteine residues in similar 
positions (Winkler et al., 1987). The location of the 3 disulfide bridges in both EGF and 
TGFα allows them bind to same receptor, EGFR (Schreiber et al., 1986). 
Knock-out mice of each ligand showed mild defects, EGF knock-out mice had abnormal 
mammary gland development (Luetteke et al., 1999). TGFα knock-out mice had hair 
follicle and eye abnormalities (Luetteke et al., 1993). In contrast, knock-out of 3 of the 
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ligands for EGFR (amphiregulin, EGF and TGF-alpha) together lead to growth retardation 
(Luetteke et al., 1993). 
TGFα, EGFR mRNAs and protein levels are elevated in oral cancer patients compared 
with disease free control and its elevation might be related with poor prognosis (Grandis 
et al., 1996,  Grandis et al., 1998). Another study reported that TGFα mRNA and EGFR 
mRNA are elevated in histologically normal mucosa of oral cancer patients compared 
with disease free patients. This suggests that TGF α/EGFR gene transcription is an early 
event during carcinogenesis and could be a precursor to a tumour (Grandis &Tweardy, 
1993, Grandis et al., 1996). This hypothesis could lead to an assay for early detection of 
oral cancer being developed in the future especially in a subset of the population who 
have strong history of smoking and alcohol use. A number of studies reported that 
tobacco smoke induces the production of amphiregulin which is ligand that binds to 
EGFR (Du et al., 2005, Grandis et al., 1998). It has also been reported that TGF-α and 
EGFR play an important role in the proliferation of oral cancer cells but not for normal 
oral epithelium cell growth (Grandis et al.,1997). 
There is also a changing pattern of expression of at least one of these factors during the 
different stages of cancer. For example, in early stages of prostate cancer, TGFα is 
produced as a paracrine signal while in late stage of the diseases it is believed to be a 
localised autocrine signal (Scher et al., 1995).  
Stability of ligand receptor complex is different between EGF and TGF-α. The iso-electric 
point (PI) of EGF is 4.6 while the PI value of TGFα is 5.9. The difference in PI value 
between EGF and TGFα suggests that TGFα dissociates from EGFR at higher pH than EGF 
(Ebner &  Derynck, 1991).  Half maximum dissociation value pH for TGFα is 6.9 while pH 
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value for EGF is 5.6 (Ebner &  Derynck, 1991). After receptor internalization, intracellular 
TGF-α is more rapidly dissociated from EGFR and cleared than EGF.  TGF-α induces 
receptor recycling whilst EGF induces receptor down regulation (Ebner & Derynck, 
1991).  
Studies also indicate a difference between TGFα ligand binding to EGFR is different from 
EGF binding to EGFR.  The 13A9 monoclonal antibody raised against EGFR blocked 
binding of TGFα ligand but not EGF ligand to the receptor (Winkler et al.,1987). 
1.16 ErbB receptor family  
 
The ErbB receptor are a group of receptor tyrosine kinases (RTKs) involved in cellular 
function. ErbB receptor family has 4 receptors, EGFR (ErbB-1), HER2 (ErbB-2), 
(HER3/ErbB-3) and (HER4/ErbB-4). Several different ligands bind to each of ErbB 
receptors and overexpression of these receptor are found in cancers. In this section 
EGFR (ErbB-1) will be mainly discussed. 
ErbB receptor and their corresponding ligands are represented in the Table below 
Table 1.2 ErbB receptor and their corresponding ligands 
 EGFR / ErbB1 
(HER1) 








EGF like growth 
factor (HB-EGF) 
Epigen(EPI) 


















Type of ErbB receptors and their relationship in different types of cancer are 
represented in the Table below: 
Table 1.3 Type of ErbB receptors and their relationship in different type of cancer  
 
Name of receptor  Ligand  Type of alteration  Cancer types 
EGFR/ErbB1 EGF,TGFα and 
 
 various 
Overexpression Non small cell lung 
cancer, ovarian 
cancer,  head and 






cancer, prostate  
ErbB2/HER2 No ligand Overexpression  Breast 
Adenocarcinoma, 
oral HNSCC 
ErbB3/HER3 Various  Overexpression  Oral HNSCC 
ErbB4/HER4 Various Overexpression Oral HNSCC 
 
 (Salomon et al., 1995, Grandis & Sok, 2004). 
 
1.17 Epidermal growth factor receptor 
 
The epidermal growth factor receptor (EGFR) is a member of ErbB family. EGFR is a 
transmembrane protein receptor which has tyrosine kinase activity.  It has extra-cellular 
domain, which is important for ligand binding, a single hydrophobic transmembrane 
domain, and an intra cellular domain which has 3 portions: juxtamembrane region, 
tyrosine kinase domain and carboxy terminal tail (Ullrich et al 1984, Lemmon et al 2010). 
EGFR was the first receptor tyrosine kinase discovered by Carpenter and co-workers in 
1978. It was also the first cloned transmembrane receptor and has since been shown to 
have a clear connection with cancer. Most breast cancer diagnostic screening in UK 
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involves investigation of EGFR expression (Milanezi et al., 2008). EGFR is involved in 
various cellular process such as cell proliferation, differentiation, migration, cell death. 
It is expressed in both epithelial and mesenchymal cells. Cellular processes mediated by 
EGFR family and their ligands are very complex (Carpenter & Cohan, 1979). 
Mice with mutated EGFR gene die at early age because of multi organ failure indicating 
a role for EGFR in development (Sibilia et al., 2007). 
In a normal cell, 40,000 to 100,000 EGFR protein molecules are seen while cancer cells 
have been shown to have up to 2x106 receptor molecules per cell being expressed 
(Carpenter & Cohan, 1979, Herbst, 2004). 
1.18 EGFR overexpression 
 
Overexpression of EGFR is seen in a variety of cancers such as non-small cell lung 
carcinoma (NSCLC), central nervous system, head and neck, bladder, pancreas, and 
breast (Salomon et al., 1995). EGFR overexpression has been reported in 80%- 90% of 
head and neck cancers (Kalyankrishna & Grandis, 2006) (Reuter et al., 2007). Over-
expression of EGFR can hypersensitize malignant cells to low concentrations of growth 
factors (Salomon et al., 1995). EGFR over-expression is also related with drug resistance, 
poor prognosis and shorter survival rate (Ang KK et al., 2002, Maurizi et al., 1996). EGFR 
overexpression was found in both HPV+ and HPV- HNSCC (Romanitan et al., 2013) 
EGFR upregulation has been reported as a two steps process. Firstly, the intensity of 
EGFR level in histologically normal epithelium adjacent to tumour is higher than mucosa 
of disease-free controls (Shin et al., 1994, Ang KK et al., 2002). Secondly, the EGFR level 
increases dramatically from dysplasia to carcinoma in HNSCC patients (Shin et al., 1994).   
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However, it has also been reported that EGFR level are different at different sites of 
head and neck cancer (Takes et al., 1998).  
1.19 Co-expression with other ErbB family members 
 
Other ErbB family members are also overexpressed in cancer. For example, HER2 
overexpression/amplification is common in breast cancer (Burstein HJ, 2005). In HNSCC, 
the individual expression of either ErbB2 or ErbB3 or ErbB4, was rarely observed while 
coexpression with EGFR is much more common (Bei et al., 2001). EGFR is more 
important than the other ErbB members for head and neck cancer development (Sheu 
et al., 2009).  A study stated HER2/ ErbB2 expression is less common than HER3 and 
HER4 overexpression (Pannone et al., 2013) while results from another study found that 
HER2/ErbB2 expression higher than ErbB3 and ErbB4 expression (Bei et al.,2001). (Xia et 
al., 1997) reported that HER2 overexpression is limited to oral SCC but not other head 
and neck cancers. They also reported that HER2 overexpression in oral SCC is related 
with high nodal metastasis and poor survival rate. 
EGFR has been reported to crosstalk with other cell surface receptors such as G protein 
couple receptor, insulin like growth factor I receptor, c-Met/ hepatocyte growth factor 
receptor and reported to induce signalling pathways (Kalyankrishna & Grandis, 2006, 
Adams et al., 2004, Jo et al., 2000). 
EGFR is 170 kDa protein containing 20% carbohydrate and being heavily N glycosylated. 
Glycosylation is important in ligand to receptor interaction and also determines the 
protein structure. Out of 11 possible sites for glycosylation, 8 sites are fully glycosylated 
while 1 site is glycosylated a fraction (Zhen et al., 2003). When the ligand does not bind 
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to EGFR, it stays as the inactive form. When the ligand binds to receptor it changes shape 
and leads to activation (Goodsell, 2003).  
Some reports in the literature suggest that an increase in EGFR gene copy number is 
related with poor outcome in HNSCC patients (Chung et al., 2006, Temam et al., 2007). 
EGFR amplification occurs in about 30% of HNSCCs, and often overlaps with EGFR 
overexpression. Fifty percent of head and neck cancer specimens carried genetic 
alterations which promote the activation of EGFR signalling (Sheu et al., 2009). 
1.20 Architecture of EGFR 
 
The extra-cellular region of EGFR has four sub-domains which are arranged in sequence 
of L1-CR1-L2-CR2. Domain I and III is important for ligand binding. However, the majority 
of energy which is important for ligand binding comes from domain III (about 400nM for 
EGF).  Domain I and III are called L domain which represent leucine rich family and they 
are 37% similar in structure (Ward & Garrett 2001, Lax et al., 1991, Lemmon et al., 1997). 
Domain II and IV are called Cysteine rich domains and contain multiple disulfide bonds. 
Binding of ligands to domain I and III creates the whole EGFR shape change and domain 
II then participates in either homo-dimerization or hetero-dimerization with other 
receptors (mostly with ErbB2 / HER2). Hetero-dimerization is more potent signaling than 
homo-dimerization. When the ligand binds to EGFR, a dimerization loop (beta hairpin) 
is protruded from the receptor and interacts with other ErbB molecules. ErbB 2/HER 2 
have no known ligands but its protrusion loop enhances hetero-dimerization with other 
ErbB receptors. Dimerization with HER2 is common in many cancer and has the worst 
prognosis than single receptor dimerization (Normanno et al., 2006). Dimerization leads 
to activation of intracellular tyrosine kinase domain and the receptor undergoes 
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phosphorylation of internal tyrosine residues.  About 6 EGFR tyrosine residues from 
carboxyl terminal are phosphorylated during ligand mediated EGFR dimerization 
(Schulze et al., 2005). These phosphorylation sites serve as docking site for intra-cellular 
proteins containing Src homology 2 (SH2) or Phosphotyrosine binding (PTB) domains to 
become activated which then leading to activation of multiple downstream pathways. 
 
Figure 1.5   EGFR signalling pathway 
 
1.21 Activation of specific tyrosine kinase residues 
Once ligand induced dimerization has occurred activation of intracellular tyrosine kinase 
domains happens and the receptor undergoes phosphorylation of specific tyrosine 
residues. The phosphorylated tyrosine kinase residues act as docking site for adaptor 
proteins and enzymes and provide a crucial connection between the external stimuli 
and internal signalling pathways. There are 6 tyrosine residues phosphorylated by EGF 
and TGFα induce EGFR activation (Guo et al., 2003). They are Y1068, Y1148, Y1173 
(Downward et al., 1984), Y1086 (Hsuan et al., 1989, Margolis et al., 1989), Y992 (Walton 
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et al., 1990) Y1045 (Levkowitz et al., 1999). .At low concentrations of EGF and TGFα 
ligands produce the highest phosphorylation of Y992 while other sites did not reach 
maximum phosphorylation even at highest concentration of ligands (Guo et al., 2003). 
There is only a slight difference between EGF and TGFα induced phosphorylation (Guo 
et al., 2003). 
1.22 Inhibition of tyrosine kinase residues 
 
Some phosphorylation sites are sensitive to inhibitors while others are not (Guo et al., 
2003). In human epidermoid cancer cell lines with high EGFR overexpression, tyrosine 
kinase inhibitors blocked all ligand phosphorylation sites except for Y992 and Y1068 
(Guo et al., 2003). Research conducted at the University of Dundee discovered 
phosphorylation of EGFR Tyr-residue 974 triggers EGFR endocytosis while 
phosphorylation of Tyr-residue 1045 causes Cbl dependent ubiquitination (Coachrane, 
master thesis). This indicates that different phosphorylation sites lead to different 
downstream pathways. Different ligand binding can cause activation of different 
tyrosine kinase activity. EGF and TGFα use different proteins that initiate signaling 
pathways. p70S6K and CD44 are required for EGF to induce signaling while the integrin 
αVβ3 is needed for TGFα ligand (Ellis et al.,2007). 
1.23 EGFR internalization  
 
Prior to ligand binding, EGFR is located in caveolae (which is a specialized plasma 
membrane micro-domain). Ligand binding leads to induction of EGFR and the departure 
of EGFR from caveolae (Mineo et al., 1999). Ligand induction followed by activation of 
the tyrosine kinase on the receptor leads to EGFR being internalized into an intracellular 
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endosomal compartment. From there, the receptors are either degraded via lysosomes 
or recycled back to the cell surface depending on which ligands are bound to the 
receptor (Henriksen et al., 2013, Carpenter, 2000). 
It has been reported that EGF induced binding induces the majority of receptor down a 
degradation pathway while TGFα induced receptor leads to recycling (Decker, 1990). 
This is likely to be caused by difference in pH sensitivity making TGFα to be able to rapidly 
dissociate from EGFR allowing recycling. Longer binding by EGF would send most of the 
receptor down the degradation pathway. Similarly, HB-EGF- and BTC stimulation leads 
to receptor internalization followed by degradation of large portion of internalized 
receptor. TGF-α and EPI ligands, lead to an intermediate internalization followed by the 
complete recycling of internalized receptor.  AREG also induce receptor internalization, 
but the receptor did not readily return to the surface and it was not broken down. It was 
suggested that this was probably because of slow recycling (Henriksen et al.,2013) 
(Roepstorff etal.2009). 
Table 1.4 EGFR status after ligands binding on whether degraded or recycled.  
 
 Receptor degradation  Receptor recycling  
 Majority of EGF, HB-EGF- and BTC Small amount of EGF, TGF-α , EPI ligands 
AREG 
 
1.23.1 EGFR endocytosis 
Once the receptor has been internalized there are two pathways that endocytosis can 
follow. The Clathrin dependent pathway is the main route of EGFR endocytosis while the 
clathrin independent pathway is less common. One study reported that EGF-, TGF-α-, 
AR- and EPI-induced receptor internalization was almost completely inhibited by clathrin 
knockdown, whereas HB-EGF- and BTC-induced internalization was only partly inhibited 
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(Henriksen et al.,2013). This could means EGF, TGF-α, AR and EPI use a clathrin 
dependent receptor endocytosis while HB-EGF and BTC use clathrin independent 
pathway. In contrast, one study reported that the dose of ligand is major factor deciding 
on whether cells use clathrin or non clathrin pathway. They stated that clathrin 
dependent endocytosis was reported to be induced by low dose EGF while high EGF 
induce clathrin independent endocytosis (Sigismund et al., 2005).  However, how this 
occurs is secondary to the effect this has on the cell. Receptor degradation leads to the 
temporary down regulation of EGFR on the cell surface and decrease EGFR signaling 
(Sorkin & Waters, 1993). 
When talking about EGFR internalization, HER2 should not ignored since co-expression 
of EGFR-HER2 is common. HER2 also has an effect on EGFR endocytosis. Dimerization 
with ErbB2 increases the stability of EGFR by decreasing the rate of dissociation of the 
ligand receptor complex to prolong activation of signaling. EGF ligand induced 
heterodimerization with ErbB2 decreases receptor endocytosis and increases receptor 
recycling (Lenferink et al., 1998). TGFα directs EGFR recycling regardless of presence or 
absence of any co-receptor (Lenferink et al., 1998). 
It should be noted that EGFR has the potential to be translocated to the nucleus. Nuclear 
internalization of EGFR has been reported to acts as a transcription factor (Lin et al., 
2001). It should be noted that the transcription factors Cyclin D1 and STAT 3 interact 
with nuclear EGFR (Lo et al., 2005, Lin et al., 2001). A recent study reported that EGFR 
could also be internalized into mitochondria but it was assumed that it was not related 
with receptor endocytosis (Yao et al., 2010).  
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Patients with a high nuclear EGFR content were shown to have a high rate of disease 
recurrence and poor survival (Psyrri et al.,2005). Cetuximab (see later) resistant cells 
also have high levels of nuclear EGFR expression and src family kinase which are known 
to mediate ligand induced translocation of EGFR (Li et al., 2009). 
 
1.24 EGFR variant III or ΔEGFR, or de2–7EGFR 
 
EGFR variant III which is commonly found in glioblastoma has also been found in head 
and neck cancer. EGFR variant III mutant is 145kDa protein that is missing the 
extracellular domain I and domain II which are encoded by the segment in exon 2 to 
exon7. These missing two domains of EGFR mean that the receptor cannot bind any 
ligands. This leads to the weak constitutive activation of any ligand independent 
signalling pathway and as such might not be strongly oncogenic (Gan et al., 2013, Sok et 
al., 2006). 
Sok et al., (2006) stated that EGFR variant III expression was only detected in the 
presence of EGFR wild type. The truncated form of EGFR type III mutant is known to 
coexist with EGFR overexpression. This EGFR variant III mutant does not activate MAPK 
pathway and only activates the PI3Kpathway (Moscatello et al., 1998, Chang et al., 
2013). The EGFR variant III expression is unique to cancer and not observed in normal 
tissues (Sok et al., 2006). This could lead to its potential use as a diagnosis marker.  
There is some controversy about the prevalence of EGFR variant III. One study found 
EGFR variant III mutation in 42% of HNSCC tumour samples conjunction with EGFR 
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wildtype while in another study stated EGFR variant III mutation is less than 1%. (Sok et 
al., 2006, Khattri et al., 2015). 
Even though there is limited information about the communication between EGFRvIII 
and other EGFR family members. There is some evidence that heterodimerization 
between EGFRvIII and either wildtype EGFR or HER2 is possible.  Ligand independent 
signalling of EGFRvIII induce down-regulation and internalization of both wtEGFR and 
erbB2 (Zeineldin et al., 2010) 
EGFRvIII also interacts with other receptors such as c -Met receptor and enhances the 
production of HGF and in turn enhances HGF signalling (Garnett et al., 2013, Gan et al., 
2013). EGFRvIII also activates STAT3 pathway.  STAT3 was found to be important in c-
Met-mediated HGF expression in EGFRvIII/ ΔEGFR expressing cells (Garnett et al.,2013). 
There is an evidence of a direct interaction between the EGFRvIII and OSMR (Oncostain 
M receptor) protein. Knock-down of OSMR in EGFRvIII-expressing mouse can reduce 
EGFRvIII expression with the loss of STAT3 activity (Greenall & Johns, 2016). Some 
studies concluded that EGFR vIII might be responsible for cetuximab resistance (Sok et 
al., 2006) while it is not related with resistance to TKIs. EGFRvIII enhanced proliferation 
of head and neck cancer cells and induce resistance to chemotherapy induce apoptosis 
(Sok et al., 2006). 
1.25 EGFR mutation  
 
EGFR mutation is more prevalent in non-small cell lung cancer than head and neck 
cancer, and a lot of research had been done in NSCLC patients. A number of mutations  
in EGFR have been reported. One of the most studied is known as the kinase domain 
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mutation of EGFR. It is known as an activating mutation since they are independent of 
ligands and signal even when no ligand is available. All somatic activating EGFR 
mutations involve an ATP binding pocket in the tyrosine kinase domain which is the 
binding site for the inhibitors gefitinib and erlotinib (Gazdar AF, 2009).  The activating 
mutation of EGFR has been isolated to the first 4 exons (18 to 21) of the tyrosine kinase 
domain.  This EGFR mutation has be studied extensively in a lung cancer model.  
There are three classes of mutation of EGFR. Class I mutations are in-frame deletions in 
exon 19, class I in frame deletions include the amino acid leucine residue at 747 to 
glutamic acid at 749 and are located in N-terminal region of kinase domain C-helix. These 
class I mutations are responsible for about 44% of tyrosine kinase domain mutations 
(Kumar et al., 2008). 
Class II mutations are single nucleotide substitutions that cause alteration in the amino 
acid sequence. The most frequent single point mutation is in exon 21 in which there is 
an exchange of an arginine for a leucine at codon 858 (L858R) and this is responsible for 
about 41% of tyrosine kinase mutations. Glycine mutation to either serine, alanine or 
cysteine was responsible for 4% of TKs mutations while the result 6% responsible for 
other missense mutation (Kumar et al., 2008).  
Class III mutations are in-frame duplications and/or insertions in exon 20 and are 
responsible for the remaining 5% of TKs domain mutations (Kumar et al., 2008). 
In lung cancer, Exon 19 deletion mutations and the single-point substitution mutation 
L858R in exon 21 are the most frequent and termed classical mutation (Gazdar AF, 
2009). There is difference between EGFR mutation of HNSCC and that of Non-small cell 
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lung carcinoma. In head and neck cancer, a large amount of the EGFR mutation are 
scattered throughout exons 18 to 21 (Perisanidis et al., 2017). There is no report of EGFR 
mutation in HPV positive HNSCC patients (Na et al., 2007). 
Mutation in head and neck cancer appears to be less common than overexpression (Lee 
et al., 2005). However, EGFR tyrosine kinase domain mutation varies with geographic 
location. The EGFR mutation had not been studied world-wide. Limited data has been 
produced from Africa, the Middle East, Central Asia, and Australia. Reports suggest that 
the EGFR mutation is uncommon in the West (Loeffler-Ragga et al., 2006) whilst its 
mutation is found more frequently in South Korea and South East Asia region 
(Perisanidis, 2017, Vatte et al.,2017). The mechanisms behind the different rates of EGFR 
mutation in different ethnicities remains to be determined. The South East Asia region 
is densely population area of the world with a population of around 600 million people 
and it definitely needs attention in terms of more research. It is a worry since none of 
TKIs targeting EGFR mutations has received FDA approval for HNSCC. Although EGFR 
mutation is associated with sensitivity to gefitinib and erlotinib treatment, not all the 
tumours with an activating EGFR mutation respond to these drugs. It is believed that 
these tumours might have an additional genetic lesion (Wakeling et al., 2002, Massarelli 
et al., 2007). 
1.26 Secondary EGFR mutation 
 
Secondary mutations of EGFR or EGFR T790M mutation have been reported in lung 
cancer patients who at first responded to gefitinib and erlotinib treatment (Xu S et al., 
2017). The T790M mutation is the substitution of threonine 790 with methionine. 
T790M mutation is responsible for about half of all patients who develop resistance to 
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gefitinib and erlotinib (Kosaka et al., 2006, Kobayashi et al., 2005). The first time that 
the EGFR T790M mutation was reported in research conducted in HNSCC patients was 
in Saudi Arabia (Vatte et al., 2017). 
The secondary mutation of EGFR results in an alteration of the topology of the ATP-
binding pocket or increasing ATP affinity. Since TKIs compete with ATP for binding to the 
kinase site an increase in ATP affinity is expected to decrease the potency of TKIs (Yun 
CH et al., 2008). Since T790M reduces the efficacy of ATP-competitive inhibitors, it might 
be good idea to develop distinct, non-ATP competitive inhibitors or irreversibly binding 
inhibitors to the tyrosine kinase domain (Gazdar AF, 2009).  A more recent study 
reported that EMT is a common mechanism underlying the resistance to different 
generations of EGFR TKIs (Weng et al., 2019). It leads to question that T790M 
mutation is related with EMT in HNSCC patients. 
1.27 Activation of signalling pathways 
 
The activation of EGFR leads to a variety of signaling pathways such as ERK MAPK, PI3K 
AKT mTOR, PLC-γ1-PKC, JNK, and STAT pathways being activated. These signalling 
pathways are connected (by cross talk) with each other and lead to a wide variety of 
cellular responses such as proliferation, migration, differentiation, inhibition of 





Figure 1.5   EGFR signalling pathway 
 
1.28 RAS-RAF-MAPK pathway   
 
MAPKs are serine/threonine protein kinases which are involved in cell proliferation, 
migration, differentiation, and apoptosis. Signals from ligands such as cytokines, growth 
factors, and mitogens all stimulate the activation of these MAPKs kinases. MAPK is one 
of the major pathways initiated by EGFR activation (Peng et al., 2018). In mammals, 
there are more than a dozen MAPK genes. The best known MAPKs cascades are four 
sub-pathways: extracellular signal-regulated kinase 1 and 2(ERK1/2), c Jun N terminal 
kinase (JNK)/ stress-activated protein kinase SAPK, p38 isoforms (p38α, p38β, p38γ, 
p38δ) and ERK5 (Plotnikov et al., 2011).  Each cascade has three enzymes which activate 
in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase 
(MAPK).  MAPKKKs is the first phosphorylated which in turn activates downstream MAPK 
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kinase (MAPKK). Then MAPK kinase (MAPKK) in turn phosphorylates and activates 
MAPKs (Plotnikov et al., 2011). MAPKs phosphorylation leads to a change in gene 
expression and protein function and results in specific biological responses such as EMT, 
increased cell proliferation, invasion, and resistance to apoptosis, and angiogenesis 
(Plotnikov et al., 2011).  
The Erk1/2 cascade has received most attention because of it has 3 important 
components Ras, Raf and MEK (Peng et al., 2018). Phosphorylated tyrosine residues 
serve as binding sites for proteins which contain Src homology 2 (SH2) domain or 
phosphotyrosine-binding (PTB) domains, such as growth factor receptor bound protein 
2 (Grb2).  Grb2 is key factor in the activation of Ras. Following the auto-phosphorylation, 
the SH2 domain of Grb2 binds to EGFR directly via Y1068 and Y1086 or indirectly via Shc. 
Following ligand induce EGFR activation, Shc is phosphorylated and associated with 
EGFR via the SH2 domain. Shc binds in turn to the SH2 domain of Grb2 protein leading 
to relocation of Grb2 SOS complex from the cytosol to the plasma membrane (where 
SOS stimulates the exchange of GDP for GTP on Ras, converting to active stage; Walker, 
1998).  
Ras, is a proto oncogene and is a small, monomeric G protein with very low GTPase 
activity on its own. All three family genes (KRAS, NRAS, HRAS) have been reported to be 
mutated in cancer patients. The mutation of the Ras family is more common in Asia 
when compared with the West (Saranath et al., 1991, Chang et al., 1991, Xu J et al., 
1998, Das N et al., 2000). Ras activates the MAPK and PI3K pathways. When Ras is bound 
to GDP it is in an inactive state. Upon binding to GTP, it is converted into the active form. 
GTP bound Ras directly binds and recruits Raf to the plasma membrane. Then Raf is 
phosphorylated and activates MEK which induces phosphorylation and activation of 
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ERK. Activated ERK1/ERK2 induce expression of genes responsible for cell proliferation, 
migration, angiogenesis, and cell death (Plotnikov et al., 2011, Peng et al., 2018). 
According to a study conducted in Germany, the B raf mutation is rare seen in about 3% 
of HNSCC patients (Weber et al., 2003). Unlike Ras, B-Raf mutation can only activate the 
PI3K pathway (Peng et al., 2018). It has been reported that Ras mutation is related with 
resistance to Cetuximab (Rampias et a.,l 2014,  Misale et al., 2012). 
 
Figure 1.6 MAPK pathway      Reproduced and modified from (Plotnikov et al., 2011) 
(Peng et al., 2018).   
 
1.29 PI3K -AKT-MTOR pathway   
 
The PI3K/Akt pathway is important for cell growth, differentiation, development and 
survival (Philippon et al., 2015). The PI3K/Akt pathway is the most commonly mutated 
pathway in head and neck cancer patients, with approximately 3 times higher levels than 
RAS/MAPK and JAK/STAT pathway The PI3K pathway appears to play an important role 
in HPV positive HNSCC as well (Lui et al., 2013).  
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PI3K are classified into classes I, II, and III. Class I is sub divided into 1A and 1B and they 
consist of regulatory subunit (p85 for class IA and p101 and p87 for class IB) and P110 
catalytic units (p110α, p110β, and p110δ). Class IA which will be described here is 
activated by receptor tyrosine kinases such as EGFR, Met receptor, PDGFR, VEGF, and 
insulin-like growth factor 1 receptor (IGF-1R) while class IB is activated primarily by G 
protein couple receptor. Class IA consist of P85 regulatory subunit and P110 catalytic 
units (p110α, p110β, and p110δ). p110α, p110β, and p110δ are encoded by PIK3CA, 
PIK3CB, and PIK3CD genes, respectively (Cai et al., 2017). EGFR signalling activates PI3K 
by recruitment of the p85 regulatory sub-unit to the activated receptor. Ras activates 
the PI3K pathway via p110α. Activated PI3K converts PIP2 to PIP3 by adding a phosphate 
group. PIP3 then act as a second messenger and subsequently activates AKT. 
Phosphatase and tensin homolog (PTEN), is a tumour suppressor protein and is a 
negative regulator of PI3K. Activation of the PI3K pathway is a potential mechanism of 
resistance to anti-EGFR therapy (Rebucci et al., 2011). Patients with a mutated PI3K 
pathway are sensitive to BEZ-235 which is dual inhibitor of PI3K and mTOR (Lui et al., 
2013). 
EGFR is overexpressed in cell lines with mutated PTEN are less sensitive to Gefitinib 
(Bianco et al., 2003). Reduced PTEN expression was found in about 30% of HNSCC 
(Squarize et al., 2013). Loss of PTEN expression is related with poor prognosis (Lee et al., 
2001). 
AKT or protein kinase B is an important downstream effector of PI3K. Following PI3K 
activation, AKT is recruited into the membrane and activated by the phosphorylation of 
PDK1 at threonine 308 and the mTORC2 complex at serine 473(Alessi et al., 1997, 
Vanhaesebroeck & Alessi, 2000 , Sarbassov et al., 2005).  Akt-308 is important for cell 
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proliferation, cell shape and protein synthesis, whereas Akt-473 is important for the 
phosphorylation of pro-apoptotic protein Foxo3a and inhibits apoptosis (Liu and Dean, 
2010). 
AKT activation stimulates cell proliferation by controlling CyclinD1 and p27Kip1 which 
are cell cycle protein and cell cycle inhibitor respectively (El-Naggar et al., 2009).  The 
phosphorylation of Akt on Thr308 is a more reliable biomarker than phosphorylation of 
Akt on Ser473 in non small cell lung carcinoma (Vincent et al., 2011). The mutation of 
retinoblastoma Rb1 leads to phosphorylation of AKT473 but not Akt-308 (Liu and Dean, 
2010). And also to the overexpression of mTOR, constitutive phosphorylation of Akt at 
Serine 473, resistance to anoikis, a blocking in c-Raf activation, and the blocking of the  
phosphorylation of Erk1/2(El-Naggar et al., 2009). Activated Akt, in turn, phosphorylates 
a series of molecules including Mechanistic target of rapamycin (mTOR) which is an 
important downstream effector of the PI3K pathway (Amornphimoltham et al., 2017) 
(Molinolo et al., 2012). The mTOR pathway can be inhibited by Rapamycin 
(Amornphimoltham et al., 2005). As discussed above, PIK3CA mutation is more common 
in HPV positive HNSCC than HPV negative. Unlike traditional HNSCC, HPV positive HNSCC 
showed p16 activation which is regarded as having good prognosis. p16 positive HNSCC 
have activates the mTOR pathway.  This could lead to potential use of mTOR inhibitors 
in HPV positive HNSCC (Molinolo et al., 2012).
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Figure 1.4 PI3K pathway: Reproduced and modified from (Giudice, 2013). 
The PI3K pathway activates CDK1 and can also cross talk with TGFβ pathways suggesting 
a potential role of CDK1 and TGFβ in Head and Neck cancer (Du et al., 2016). A study 
reported that dual inhibition of PI3K and mTOR can overcome radio resistance in HNSCC 
patients (Yu CC et al., 2017). 
Activation of the PI3K pathway is a potential mechanism of resistance to anti EGFR 
therapy. Cetuximab resistance was found in tumour with PI3K pathway activation and 
inhibition of PI3K pathway restored cetuximab sensitivity in a cetuximab resistant cell 
line (Rebucci et al., 2011, Keysar et al., 2013, Simpson et al., 2015). 
1.30 STAT signal transducer and activator of transcription 
 
STAT is another downstream effector of EGFR signalling. STAT can also be activated via 
EGFR independent mechanisms (Sriuranpong et al., 2003). Activation of the STAT 
pathway occurs via one of two mechanisms; JAK dependent or independent. STATs are 
53 
 
downstream transcription factors of JAK and other kinases. Signal transducers and 
activators transcription (STAT) proteins family consists of STAT1, STAT2, STAT3, STAT4, 
STAT5a, STAT5b, and STAT6. Out of these proteins, STAT1, STAT3, STAT5a, STAT5b have 
a role in certain cancers (Quesnelle et al., 2007). In general, STAT3 and STAT5a/b 
promote carcinogenesis, in contrast STAT1 activation has an opposing effect (Thomas SJ 
et al., 2015). EGF and TGFα activate STAT1 and STAT3 in EGFR overexpressed cells. Ras 
stimulated cells also see an activation of STAT3 and that stimulation is blocked by EGFR 
specific kinase inhibitors (Song &Grandis, 2000). Upregulation of STAT3 has been found 
in variety of cancers. STAT3 activation has been shown to be an early event of HNSCC 
(Song &Grandis, 2000). 
EGF and TGFα induces EGFR dimerization leading to phosphorylation of tyrosine residue 
and through the JAK dependent pathway, activation of (STAT) occurs when tyrosine 
residues are phosphorylated by JAK which initiates formation of the dimer. This is 
transferred into the cell nucleus and activates c-myc and cyclin D (Reich &,Liu, 2006). 
JAK dependent STAT pathway signalling could be abolished by using JAK inhibitors (Sen 
et al., 2015). In JAK independent pathway, STAT was directly activated by EGFR kinase. 
Tyrosine residues Y1068 and Y1086 are critical for STAT activation (Coffer &Kruijer , 
1995.) After activation, STAT dimerizes, and translocates into the nucleus and regulates 
the expression of genes involved in proliferation, differentiation, cell survival. Even 
through STAT is involved in carcinogenesis, there has been no drug specifically targeting 
of the STAT pathway (Quesnelle et al., 2007). Co-localization of STAT3 and EGFR was 
found in the cell nucleus (Lo et al., 2005). Intrinsic EGFR kinase activity is necessary for 
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STAT activation while autophosphorylation of EGFR is not required for STAT activation 
(David et al., 1996). 
There are some controversial findings in related with nuclear STAT3 and prognosis. 
(Macha et al., 2011) reported nuclear accumulation of STAT3 is found in premalignant 
stage and related with poor prognosis while (Masuda et al., 2002) and (Pectasides et al., 
2010) stated that high nuclear level of STAT3 is predictor of better prognosis.  Abolishing 
STAT3 function in oral carcinogenesis leads to an increase in apoptosis and 
downregulation of Bcl-xL (Song &Grandis, 2000). 
There is a strong association between high STAT3 and cyclin D1 overexpression in HNSCC 
(Masuda et al., 2002). This study found that EGFR overexpression in oesophageal 
keratinocytes activates STAT in a JAK dependent manner leading to increase cell 
migration, which can be blocked by JAK inhibitor (Sen et al., 2015, Andl et al., 2004). 
JAK1 and JAK2 are needed for STAT 1 and STAT3 activation in response to EGFR 
overexpression which leads to cell migration which might be mediated by MMP1(Andl 
et al., 2004). EGFR collaborates with STAT3 to induce EMT in cancer cells via up-
regulation of TWIST (Lo et al., 2007). Erlotinib was found to inhibit oral cancer in mouse 
model via EGFR-STAT3 signaling pathway (Leeman et al., 2011, Grandis et al., 1998, 
Psyrri et al., 2013). 
1.31 JNK pathway or c-Jun N-terminal kinases 
 
JNK is member of MAPK family. JNK pathway is associated with activation of MAPKKK. 
JNK pathway is commonly activated by cytokines, DNA damaging substances, UV 
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radiation and less frequently activated by growth factors (Gkouveris & Nikitakis, 2017). 
The role of JNK in cancer is controversial. First, it was thought to be oncosuppressive but 
more recently was described as having a tumorigenic role (Gkouveris & Nikitakis, 2017). 
Now oncogenic or tumour suppressive effect of JNK signalling is believed to be tissue 
specific and cell type dependent (Gkouveris & Nikitakis, 2017).  In head and neck cancer, 
it is believed that JNK is acting alone or may cross talk with other signalling molecules 
such as STAT pathway (Gkouveris et al., 2016). 
 
1.32 Phospholipase C gamma (PCLγ) pathway   
 
PCLγ is another downstream target of EGFR signalling. High levels of PCLγ 1 was reported 
in tumour samples when compared with adjacent normal mucosa.  A study reported 
that inhibition of PCLγ blocked cell migration but not cell proliferation (Thomas SM et 
al., 2003). 
1.33 Cell proliferation 
 
Cell proliferation is an essential component of carcinogenesis. Cell proliferation is tightly 
regulated in normal healthy person. In contrast, cancer is the over proliferation of cells 
leading to big mass or tumour which can either benign or malignant. One of the 
hallmarks of cancer is the overproduction of growth factors. The overproduction of 
growth factors or overexpression of receptors lead to the activation of signalling 
pathways and this may then lead to dysregulation of the cell cycle proteins such as cyclin 
D which are involved in cell proliferation (Poch B, 2001). 
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The classic eukaryotic cell cycle has two major stages which are interphase and M phase. 
Interphase can be divided into three stages, Gap1 (G1), Synthesis(S) and Gap2 (G2). Cells 
grows and prepare for cell division in interphase.  DNA replication occurs in S phase 
(Romar et al., 2016). 
Cell division occurs in M phase. M phase is the phase where mitosis and cytokinesis 
occurs. Mitosis is the division of nucleus with equal chromosomes separation. Mitosis 
has prophase, metaphase, anaphase and telophase. Division of cell membrane and 
cytoplasm occurs in cytokinesis (Romar et al., 2016). 
Progression through each of cell cycle phases and transition from one phase to the next 
is monitored by three checkpoints. They are G1/S check point, G2/M check point and M 
phase spindle checkpoint. Function of the check point is to  detect the DNA damage and 
not letting the cells enter into next phase until repair has been done G0 is called resting 
phase of cell cycle where cell has left the cell cycle and stopped growing.  
Cell cycle proteins such as cyclin dependent kinases (CDK) and cyclin control the cell 
division and DNA replication. For example, Cyclin D is stimulated by growth factors (Poch 
B, 2001). Activity of CDK are dependent on specific cyclins and are regulated by CDK 
inhibitors, phosphorylation and dephosphorylation events (Malumbres & Barbacid, 
2009).  
Cyclins, CDKs, inhibitory enzymes, Rb protein, p21, p27 and p53 regulate cell cycle 
progression. Overexpression of Cyclin and CDKs and loss of CDK is related with cancer.  
Cyclin D drives the cell cycle from the G1 to the S phase by following mechanism. Cyclin 
D is the first cyclin increase in cell cycle. G1 is the first phase of the cell cycle. In G1 phase, 
cells are grows in size, synthesizes mRNA and protein and prepare for mitosis. G1 phase 
lasts about 18 hours in human somatic cells. The transition to G1 to S phase is controlled 
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by Cyclin D-CDK4/6 and Cyclin E-CDK2. Cyclin D bind to CDK4/6 resulting Cyclin D-CDK4/6 
complex. CyclinD/CDK4 and/or CDK6 complexs phosphorylates the retinoblastoma 
protein. Phosphorylation of pRb leading to dissociation of pRb/E2F complex, released 
E2F transcription factor which bind to DNA, regulate gene expression and cell enter into 
S phase (Sherr CJ, 1994). 
Deregulated expression of cyclin D 1 is associated with resistance to EGFR inhibitors in 
head and neck cancer (Dhingra et al., 2017, Kalish et al., 2004). Cell proliferation marker Ki-
67 and Cyclin B1 are also higher in HNSCC (Watanabe et al., 2010). 
In a healthy individual the P16INK4a, tumour suppressor protein prevents 
phosphorylation of pRb by inhibiting cyclin D-CDK 4/6 to phosphorylate pRb (Serrano et 
al., 1993). pRb is mainly hypophosphorylated and is found in complexes with E2F 
transcription factor, blocking cells enter into S phase (Pande et al., 1998). Down 
regulation of p16 is commonly found in classic head and neck cancer (Perez Sayans et 
al., 2011). E2F1 transcriptionally up-regulates expression of p14ARF (Bates et al.,1998). 
p14ARF promotes p53 by inhibiting MDM2 which binds and degrades p53. Loss of 
P14ARF will lead to elevated level of MDM2 and then to loss of p53 function and cell cycle 
control (Bates et al., 1998). p53 is called the ‘guardian of the genome’ and is responsible 
for determining whether the cell should enter S phase where DNA replication occurs. 
INK4a/AFR is one of mechanism involved in cellular senescence (Collado et al., 2007). 
Normal cells will divide between 50-70 times before cell death. Each time when a cell 
undergoes mitosis, the telomeres which is located at the ends of each chromosome 
shorten slightly. Once they reached certain length then apoptosis will be invoked in the 
cell. Cellular senescence is a phenomenon in which normal cells cease to divide and was 
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first reported by Hayflick in 1961. However, cancer cells can overcome senescence by 
using an enzyme called telomerase which maintains the telomere length (Hanahan & 
Weinberg, 2011). One of the hallmarks of cancer includes resistance to apoptosis by 
producing excess telomerase and gaining limitless replicative potential (Hanahan & 
Weinberg, 2011). Cellular senescence can be triggered by multiple mechanisms 
including telomere shortening, the epigenetic derepression of the INK4a/ARF locus, DNA 
damage and aging (Collado et al., 2007). 
It is expected that EGF and TGFα ligands might use two discontinuous pulses for cell proliferation 
like PDGF: initial pulse from resting cells into G1 (after 8 hrs introduction with ligands) and is 
followed by a second pulse (7 to 9 h later) which drives the cells into S phase (Pennock 
& Wang , 2003). 
1.34 Epithelial to mesenchymal transition (EMT) in HNSCC 
Epithelial to mesenchymal transition (EMT) is an important process in cancer since it 
facilitates cells migration, invasion and metastasis. There are a lot of signalling pathways 
that initiate or regulate EMT. EMT can be triggered by different signalling molecules, 
such as by epidermal growth factor (EGF), fibroblast growth factor (FGF), hepatocyte 
growth factor (HGF), transforming growth factor β (TGFβ), hypoxia-inducible factor 
(HIF), bone morphogenetic proteins (BMPs), WNTs and Notch  (Thiery & Sleeman, 2006). 
EMT is the transdifferentiation of epithelial cells into mesenchymal cells. Epithelial cells 
are cuboidal in shape, have an apical basal polarity and are closely connected to each 
other by specialized membrane structures, such as tight junctions, gap junction, 
adherens junctions, and desmosomes (Thiery & Sleeman, 2006). During the EMT 
process, epithelial cells  lose their cuboidal shape, cell to cell adhesion, apical basal 
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polarity and then undergo cytoskeleton remodelling, forming a mesenchymal or 
elongated shape,  front-to-back leading edge polarity, motile and therapy resistance 
(Thiery & Sleeman, 2006).In vitro, mesenchymal cells have a spindle-shaped fibroblast-
like morphology, whereas epithelial cells grow as cell clusters (Thiery & Sleeman, 
2006). Growth factors such as EGF, TGFα, FGF, HGF, bone morphogenesis proteins 
(BMPs), and extracellular matrix components such as collagen, hyaluronic acid, and 
cellular processes such as chronic inflammation and hypoxia are known to induce EMT. 
There are three types of EMT. Type I EMT is found in embryogenesis, type II EMT is found 
in wound healing, tissue regeneration, and organ fibrosis. Type III EMT is found in 
carcinogenesis (Kalluri &, Weinberg, 2009). EMT is a reversible process and conversion 
into MET is frequently seen in cancer (Neilson & Zeisberg, 2009, Thiery & Sleeman, 
2006). In EMT, epithelial markers such as E cadherin are downregulated with 
upregulation of mesenchymal markers such as Vimentin. The following are examples of 










Table 1.5 Epithelial and mesenchymal markers associated with EMT 
Epithelial markers Mesenchymal markers  
E cadherin                                   














N cadherin                                            




 smooth muscle actin 






MMP2, MMP3, MMP9                               
 
 From (Neilson & Zeisberg 2009, Lee JM 2006) 
 
a) E-cadherin is a calcium dependent cell adhesion molecule (CAMs). It is the most 
famous epithelial marker. The cytoplasmic domain of E-cadherin is linked to the 
actin cytoskeleton through interactions with catenins, and cadherins-catenin 
complexes localized in cell to cell contact area known as the adherens junction 
(Pećina-Slaus, 2003).  The loss of E-cadherin in cancer means loss of the epithelial 
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morphology and the acquisition of mesenchymal phenotype. Reduced 
expression of E-cadherin is one of the main molecular events in EMT and cell 
migration. E-cadherin is regarded as tumour suppressor gene (Pećina-Slaus, 
2003). Down regulation of E-cadherin and upregulation of N-cadherin which is 
called cadherin switching can be seen in EMT (Wheelock et al., 2008). In cancer, 
E cadherin is downregulated by a number of mechanisms, including mutation, 
and transcriptional repression. In cancer, transcription factors such as snail, slug, 
ZEB1 and FOXC2 bind to the E box of E-cadherin promoter and repress its 
transcription (Batlle et al., 2000).The relationship between E-cadherin and EGFR 
is quite controversial. One study reported that E-cadherin-mediated-cell–cell 
adhesion can trigger a ligand-independent activation of the EGFR, followed by 
activation of PI3-K and ERK while another study reported that E cadherin inhibits 
ligand dependent activation of EGFR (Reddy et al., 2005, Qian X 2004). E-
cadherin-mediated cell-cell adhesion promotes anoikis resistance via ligand-
independent activation of EGFR and downstream MAPK pathway (Shen & 
Kramer, 2004).The methylation of E-cadherin and the degradation of 
membranous β-Catenin can also induce cell migration (Kudo, 2004). 
b) Vimentin is intermediate filament (IF) protein expressed in mesenchymal cells. 
Vimentin is important for maintaining the integrity of the cells in cytoskeleton, 
orienting microtubules for directional migration, morphological changes and the 
migration of cells (Liu et al., 2015, Mendez et al., 2010). Loss of E-cadherin and 
acquired vimentin is correlated with metastasis (Nijkamp et al., 2011). 
c) Snail is transcription factor elevated in EMT cells (Summary: Figure 1.6). 
Signalling pathways such as PI3K, MAPK, TGFβ, Notch, BMP and Wnt pathway 
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activate snail. Snail downregulates epithelial markers, upregulates mesenchymal 
markers, participates in cell morphology changes, cell proliferation and cell 
survival (Barrallo & Nieto, 2005). 
       
                                
Figure 1.7: Role of snail in EMT (Barrallo & Nieto, 2005) (Yokoyama et al., 2003). 
 
d) Micro RNA play an important role in controlling EMT. Some miRNA induce EMT 
while others supress EMT (Ding XM, 2014). 
It has been suggested that EMT promotes the generation of cancer stem cells (Mani et 
al., 2008). To corroborate this it was also shown that cells undergoing EMT have stem 
cells like characteristic such as self- renewal and resistance to cancer therapeutic drugs 
(Singh & Settleman, 2010). 
As discussed in above, EGFR collaborates with STAT3 to induce EMT in cancer cells via 
an up-regulation of TWIST (Lo et al., 2007). However, it has also been suggested that 
EMT is related to the resistance to TKIs which is going to discuss in next sections (Weng 
et al., 2019). 
63 
 
1.35 Cell migration 
One of the other important hallmarks of cancer is invasion and metastasis. Cancer cells 
degrade the ECM and basement membrane, pass through surrounding tissue, travel into 
blood or lymphatic stream, attach at new site and grow into secondary tumour mass. 
Cells that are closely attached to each other under normal condition (homeostasis) by 
cell to cell adhesion and cell to extracellular matrix adhesion have these adhesions 
broken down by the secretion of substances which degrade the ECM and basement 
membrane (Guan X, 2015). Loss of cell to cell adhesion allows cancer cells to dissociate 
from the primary tumour. Loss of cell to matrix adhesion allow cells to invade 
surrounding stroma (Manzanares & Horwitz, 2011). 
Cell to cell adhesions are stabilized by catenins which link cadherins to the cytoskeleton. 
Down-regulation of E-cadherin breaks down this link, disassembly of the adherent 
junctions and translocation of membrane bound β-catenin into the cell nucleus where 
it acts as a transcription factor (Hajra & Fearon, 2002). It is known that cell surface 
receptors called integrin are responsible for cell to ECM adhesion (Guan X, 2015). They 
are members of a glycoprotein family which allow the cell surface to contact with ECM 
molecules such as fibronectin, laminin, and collagen (Manzanares & Horwitz, 2011). 
Normal cells undergo anoikis (apoptosis caused by detachment from the ECM) once they 
detached from ECM. In contrast, cancer cells have ability to resist anoikis (Guan X, 2015). 
The loss of contact inhibition not only leads to cell migration but also uncontrolled cell 
growth allowing for the spread and survival of tumour cells (Roycroft & Mayor, 2016) 
(Buchheit et al., 2014). 
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There are two types of cell migration in cancer. Individual/single cell migration and 
collective cell migration. In individual/single cell migration, cell to cell contacts are lost.  
1.35.1 Single cell migration 
Cells which used mechanism of single cell migration have different phenotype- ameboid 
or mesenchymal phenotype (Figure 1.7). In amoeboid-like migration, cells are rounded 
shape and come in different variants: 1) they change their shape very fast, have short 
thin protrusions, show no blebbing, are fast moving 0.4–5 μm/min. 2) Slow and 
disorganize migration with a blebbing morphology. 3) Cells with short protrusion which 
are slow moving ∼0.1 μm/min (Clark & Vignjevic, 2018, Friedl & Gilmour, 2009). In 
mesenchymal migration, cells are elongated spindle shape morphology with slow 
moving with cells pulling or pushing themselves across a surface. 
 




1.35.2 Collective cell migration: 
In collective cell migration, cell to cell adhesion is maintained. Cells that are migrating to 
distant site do so as a group or sheets. This requires force generation of pulling cells a 
65 
 
large group of cells together. In collective cell migration, the free end of the cell group 
forms a dynamic cytoskeleton leading to multiple ruffled borders resulting in traction. 
Tensile stress created by these contractile forces is   responsible for direction of the cell 
movement. Moving cells sheets modify the tissue along the route and secondary 
remodelling of ECM and rearrangement of basement membrane takes place (Friedl & 
Gilmour, 2009, Friedl & Illina, 2009). 
There are two cell types involved in collective cell migration. First is the leader cells or 
the pioneer cells which lead. The second cell type is known either as the follower cells 
or rear cells. The phenotype may be different between the leader cells and the follower 
cells. Collective cell migration is slowest mode of migration in cancer 0.01–0.05 μm/min 
while it is faster during embryonic development 0.2-1 μm/min. In cancer, remodelling 
of the cellular junctions, reorganization of actin cytoskeleton and the formation of F-
actin rich membrane protrusions are formed during collective cell migration (Ganjre et 
al., 2017). 
 
Figure 1.9   Example of collective cell migration (yellow indicate leader cells and green 
indicate follower cells). 
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The protrusion of the cell membrane is an initial step in cell migration. These dendritic 
and spiky protrusion are formed at the leading edge of the migratory cells and they are 
called; filopodia, lamellipodia, podosomes and invadopodia. Formation of these 
structures is controlled by actin polymerization. Lamellipodia are flat broad 
membranous protrusions. These are located at the leading edge of the migrating cells 
and control the direction of the cell movement. Filopodia are a thin finger like projection 
at the leading edge of the cells. It also controls the direction of the cell movement. 
Lamellipodia and filopodia are also present in normal epithelial cells (Guan X, 2015). 
Podosomes are found in normal highly motile cell. They have a shorter life span usually 
minutes while invadopodia (similar to lamellipodia) are mostly found in cancer and have 
a longer life span which vary from minutes to hours (Guan X, 2015). Both invadopodia 
and podosomes are rich in actin and able to degrade the ECM (Yamaguchi et al., 2005). 
WASP (Wiskott-Aldrich Syndrome protein) and N-WASP (neutral WASP) protein play an 
important role in formation of cellular protrusion (Yamaguchi et al., 2005). 
The tumour microenvironment plays an important role in carcinogenesis. Chemokines, 
growth factors, cancer associated fibroblast, tumour associate macrophage (TAMs), 
Rho, Rac, Cdc42 play an important role in cell migration (Alizadeh et al., 2014). 
The secretions of tumour associate macrophage from primary tumours increase 
metastasis (Pollard, 2004). Macrophages can express colony stimulating factor receptor 
1 and secrete EGF whilst cancer cells have EGFR and secrete CSF-1. Therefore these two 
cell types reciprocally induce each other to migrate in the tumour microenvironment 
allowing tumour cells to be able to metastasize (Wyckoff et al., 2004). 
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Matrix metalloproteinase (MMPs) are group of enzymes which cleave/degrade the 
extracellular matrix and enhance the migration process.  Head and neck cancer is 
composed of multiple cell types each with different types of MMP expression. MMP-1, 
MMP-2, MMP-9, and Membrane-type matrix metalloproteinase MT-1 MMP are most 
commonly found in HNSCC and are associated with disease progression. MMP and tissue 
inhibitors of MMP (TIMPs) have been reported as being related with invasion and nodal 
metastasis (Kurahara et al., 1999). 
In general, HPV+ head and neck cancer patients have lower MMP expression than HPV 
negative head and neck cancer patients (Hauff et al., 2014). Hepatocyte growth factors 
are also reported to upregulate MMP genes (Hanzawa et al., 2000). 
1.36 Drug target EGFR signalling 
A number of drugs have been reported to affect EGFR signalling. They are summarised 





• Dual inhibitors of EGFR and HER2 
EGFR/HER2 dimerization(HER2 
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Figure 1.10 Drugs targeting EGFR pathway 
 
There are two types of drug specifically targeting EGFR. The first group are monoclonal 
antibodies which are for targeting EGFR overexpression.  The second group are small 
molecules tyrosine kinase inhibitors which target EGFR mutations. 
The monoclonal antibodies bind to the extra-cellular domain of EGFR and block ligand 
binding. FDA has approved only two MoAbs for clinical use, cetuximab (for HNSCC and 
colorectal cancer) and panitumumab (for colorectal cancer, Martinelli et al., 2009). 
1.36.1 Cetuximab  
 
Cetuximab is the only EGFR target drug which has received FDA approval to treat head 
and neck cancer (NCI, 2019). Cetuximab is chimeric mouse/human monoclonal antibody 
which targets domain III of the extracellular region of EGFR. Once cetuximab binds to 
EGFR, ligands cannot bind to the receptor, the receptor is internalized and then 
degraded leading to downregulation of EGFR on the cell surface. Autophosphorylation 
and activation of the EGFR was inhibited using this therapy (Dutta & Maity, 2007). 
(Mandic, 2006) proposed that the cetuximab might transiently stimulate EGFR 
phosphorylation prior to downregulation. Cetuximab may also induce antibody-
dependent cellular cytotoxicity mediated by the host immune cells (Bleeker, 2004). 
• Ras inhibitors
Ras mutation or active Ras





Cetuximab which got FDA approval in 2004 for use in EGFR expressing colorectal cancer 
resistant to irinotecan based chemotherapy (Wong, 2005). 
In 2016, FDA approved Cetuximab in combinantion with radiotherapy to treat locally 
invasive head and neck cancer. Studies found that head and neck patients receiving 
radiation plus cetuximab show better overall survival than patients with radiation 
therapy alone (Bonner et al., 2006,Bonner et al., 2010). 
Inhibition of EGFR can improve the efficacy of radiotherapy. There appears to be a 
connection between radiation-induced EGFR activation and DNA repair. Radiation 
induces translocation of EGFR into the nucleus while C225 (cetuximab) plus radiation 
prevents this EGFR translocation to the nucleus, and inhibits DNA damage repair by 
decreasing the nuclear level of the DNA repair enzyme DNA-PK (Bandyopadhyay et al., 
1998, Dittmann et al., 2005, Huang & Harari, 2000). Cetuximab plus radiation also 
induced cells cycle arrest at G1, G2-M which are radiosensitive phases of cell cycle instead 
of the radioresistant S phase (Huang & Harari, 2000). 
Vermorken et al., (2008) reported that Cetuximab plus platinum fluorouracil-based 
chemotherapy improved overall survival compared with compared with platinum–
fluorouracil chemotherapy alone in metastasis or recurrent HNSCC.  
1.36.2 Resistance to Cetuximab/ monoclonal antibodies 
 
Although, EGFR overexpression is observed in more than 90% of HNSCC only 10% of 
HNSCC patients respond to cetuximab and often only for a short period of time(Matta 
& Ralhan,2009). There are conditions where cetuximab cannot be effective. First of all, 
NIH press released that Cetuximab with radiotherapy was inferior to standard treatment 
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in HPV positive HNSCC (NIH, 2018). (Mirghani et al., 2015) also concluded that anti-EGFR 
is not effective in HPV positive HNSCC. Further research needs to be carried out to find 
out why cetuximab is not effective in HPV+ HNSCC. Mirghani et al., (2015) suggested it 
is important to analyse the Patient HPV status before cetuximab treatment and that use 
alternative drugs should be prescribed in HPV positive patients.   
Secondly, co-expression of EGFR with other members ErbB family receptors such as 
HER2, ErbB3, ErbB4 are common in head and neck cancer (Bei et al., 2001). Therefore 
targeting of EGFR alone may not be effective in those cases. A series of papers has 
supported the suggestion that HER2 activation is related with cetuximab resistance 
(Yonesaka et al., 2011, Wheeler et al., 2008).  
Currently, there are no available drugs targeting ErbB3 and ErbB4. However, drugs 
targeting EGFR-HER2 are on the way to the clinic. More research has been done for 
EGFR- HER2 overexpression or EGFR/HER2 heterodimerization. In the past, HER2 
overexpression/ or dimerization was thought to be rare in head and neck cancer. 
However, these reports were focusing on tumour specimens from specific areas such as 
larynx and pharynx. HER2 overexpression is characteristic of oral SCC but not other 
forms of head and neck cancer (Xia et al., 1997). They also found HER2 overexpression 
in oral cancer is related with high nodal metastasis and poor survival rate (Xia et al., 
1997). They hypothesised that failure to target HER2 might be the reason of poor 
survival in oral SCC cases.  
 In this case, dual inhibitors of EGFR-HER2 should be used to block both receptors. 
Lapatinib is dual inhibitor of EGFR-HER2 which is commonly used in breast cancer 
patients (Burstein HJ, 2005) .However, Lapatinib produced controversial results in 
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clinical trial in HNSCC patients. One study reported that Lapatinib was only effective in 
HPV positive head and neck cell lines (Fumagalli et al., 2014). Dual inhibitor targeting for 
HPV negative head and neck cancer should be developed in the future.  One study 
reported that the dual kinase inhibitors of EGFR and HER2 could overcome cetuximab 
resistance (Quesnelle & Grandis, 2011). 
Thirdly, in EGFR variant III mutation which was found in 42% of HNSCC to coexist with 
Wild type EGFR overexpression. This variant is missing extracellular domain I and II of 
EGFR meaning ligands could not bind to receptor, leading to constantly weak activating 
of tyrosine kinase. EGFR variant III mutation is related with cetuximab resistance   
(Tinhofer et al., 2011).In this case, treatment with TKIs which inhibit the tyrosine kinase 
domain could overcome the problem ( Sok JC et al.,2006). 
Fourthly, EGFR mutation is more common in south East Asia region compared with the 
West. Like EGFRvIII, EGFR activating mutation leads to the activation of the tyrosine 
kinase. This could also be overcome by using TKIs (Gazdar AF, 2009). 
Fifthly, a secondary mutation of EGFR or EGFR T790M mutation. This secondary 
mutation of EGFR is found in patients who were initially responsive to TKIs. For the first 
time secondary mutation of EGFR was found in Saudi head and neck cancer patients 
(Vatte et al., 2017). Treatment of patients with this secondary mutation of EGFR might 
be overcome by using non-ATP competitive inhibitors or irreversibly inhibitors or second 
or third generation TKIs (Gazdar AF, 2009, Li et al., 2008, Engelman, 2007). 
Sixthly, mutation or constitutive activation of downstream signalling pathways such as; 
mutation or constitutive activation of the Ras/Raf/MAPK, STAT3 and PI3-K/AKT/mTOR 
are not uncommon in head and neck cancer patients. As discussed above about 30% of 
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areca nut related head and neck cancer patients in India have a Ras mutation (Saranath 
et al., 1991, Das N et al., 2000). PIK3CA mutation has also been found in both HPV- 
(12.6% to 17.5%) and HPV+ (30%) head and neck cancer patients (Lui et al., 2013, Cai et 
a.,l 2017, Chiosea et al., 2013). Mutation of these downstream pathways has been 
suggested to be related with resistance to anti-EGFR drugs (De Roock et al., 2010).  
1.36.3 Cross talking within signaling pathways 
A number of studies have found that inhibition of one pathway can lead to the activation 
of another pathway (Turke et al, 2012, Serra et al., 2011).Therefore multiple inhibitors 
have been used to good effect in the laboratory. The combination of therapy of PI3K and 
MEK pathway inhibitors enhanced the efficacy in both sensitive and resistant cell lines 
(Engelman et al.,2008). 
1.36.4 Other monoclonal antibodies 
Fully humanized monoclonal antibodies might be less prone to stimulate neutralizing 
antibodies or hypersensitive reactions. Panitumumab is a fully humanized monoclonal 
antibody which might inhibit ligand binding leading to internalization of EGFR but not 
EGFR degradation (Yang et al., 2001, Dutta & Maity, 2007). In 2006, Panitumumab got 
FDA approval to treat colorectal cancer with wildtype KRAS. In clinical trials of recurrent 
or metastatic HNSCC patient, Panitumumab did not increase overall survival while it 
increased progression free survival in p16 negative patients (Vermorken et al., 2013). 
Zalutumumab is a fully humanized monoclonal antibody which has had controversial 
results. One study showed encouraging result with zalutumumab (Schick et al., 2012) 
while another study reported that zalutumumab plus the radiotherapy did not show any 
significant improvement in HNSCC patient compared with control(Eriksen et al., 2014). 
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Nimotuzumab, a humanized monoclonal antibody has been granted approval for use in 
HNSCC in some countries such as India, Cuba, Argentina, Colombia, Ivory Coast, Gabon, 
Ukraine, Peru and Sri Lanka (Ramakrishnan et al., 2009). Nimotuzumab has lesser affinity 
to the receptor and has a transient binding interaction, it spares healthy tissues, and has 
no toxic cutaneous effect and showed promising results in clinical trials (Ramakrishnan 
et al., 2009, Subramanium et al., 2015). The receptor binding mechanism is reportedly 
different from cetuximab (Talavera et al., 2009).  
1.36.5 Tyrosine kinase inhibitors 
Tyrosine kinase inhibitors bind to the cytoplasmic region of EGFR by competing with ATP 
and inhibit phosphorylation of the receptor. Example of tyrosine kinase inhibitors are 
Erlotinib, Gefitinib which both selectively and reversibly inhibit tyrosine kinase activity 
(Herbst, 2004). None of these TKIs has been approved to treat HNSCC. Some of them 
are currently under clinical trials (Chapman et al., 2016). 
The advantages of tyrosine kinase inhibitors is they can be orally administered, they can 
block EGFR overexpression, EGFRvIII and EGFR mutation. The main disadvantages of 
tyrosine kinase inhibitors is their lack of specificity or cross-inhibition of other receptor 
or non-receptor tyrosine kinase activity (Dutta & Maity, 2007). 
Gefitinib got FDA approval in 2003 and is used to treat metastatic non-small cell lung 
carcinoma .Gefitinib is a reversible TKI which prevents EGFR auto-phosphorylation by 
competing with adenosine triphosphate for its binding site on the intracellular domain 
of EGFR. Gefitinib induces neither receptor internalization nor degradation and thus 
did not reduce EGFR protein level on the cell surface(Dutta & Maity, 2007).Gefitinib 
has undergone clinical trials in head and neck cancer patients and did not produce 
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encouraging results(Chua et al., 2008) .One side effect reported in the clinical trials 
was skin toxicity when the Gefitinib dose was escalated, while it failed to show 
significance improvement in patient outcome(Perez et al., 2012) .Patients with the 
EGFRvIII mutation did respond to gefitinib treatment (Argiris et al., 2013). 
Erlotinib got FDA approval to treat NSCLC in 2004. Erlotinib is also reversible TKI of 
EGFR wildtype and the EGFRvIII mutant. Like Gefitinib, Erlotinib did not downregulate 
EGFR protein level. In head and neck cancers Erlotinib has already undergone clinical 
trials for HNSCC and known to have some toxic effect such as skin toxicity (Li & Perez-
Soler, 2009, Soulieres et al., 2004). Patients receiving erlotinib with cisplatin and 
radiotherapy failed to show significant increase in complete response rate and 
progression free survival (Martin et al., 2013). Erlotinib did however inhibit 
carcinogenesis via EGFR-STAT 3 pathway in a mouse model (Leeman-Neill et al., 2011). 
The reason of why these two TKIs are not producing encouraging results in those trials 
might be activation of downstream signalling pathways such as ERK (Wakeling et al., 
2002).  Other research has shown that the K-ras mutation is related with resistance to 
tyrosine kinase inhibitors in non-small cell lung cancer (Massarelli et al., 2007). 
Another possible reason of drug resistance to Tyrosine kinase inhibitors is EMT. EMT is 
believed to be underlying mechanism of drug resistance to TKIs (Weng et al., 2019, 
Maseki et al., 2012, Frederick BA et al., 2007). 
Second generation TKIs targeting EGFR secondary mutation are under clinical trials. 
Irreversible EGFR inhibitors such as Afatinib /BIBW 2992, HKI-272 and dacomitinib 
/PF00299804 inhibit EGFR secondary mutation or EGFRT790M mutation in preclinical 
models with Afatinib also targeting HER2 (Li DM et al., 2008, Engelman et al., 2007). 
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Osimertinib (AZD9291) was found to be more effective than Afatinib in clinical trial 
with EGFR T790M mutated lung cancer patients (Jänne PA et al., 2015). 
 
1.36.6  Pathway inhibitors under clinical trials for head and neck cancer 
Table 1.6 Pathway inhibitors under clinical trials for head and neck cancer 
MAPK inhibitor Binimetinib 
PI3K inhibitor Buparlisib (BKM120), Alpelisib (BYL719), 
PX-866, Copanlisib 
AKT inhibitor MK2206 
mTOR inhbitor rapamycin (sirolimus), Temsirolimus 
(CCI-779), Everolimus (RAD001) 
PI3K/mTOR dual inhibitor SF1126, Gedatolisib, Dactolisib (BEZ235) 
 
 From: (Cai et al., 2017) (Wang et al., 2017) (Jung et al., 2018). 
 
1.37 The need for development of drugs targeting EGFR 
mutation and Ras mutation  
As discussed detail in literature review, Cetuximab is targeting to EGFR overexpression 
and not effective in patients with EGFR variant III mutation,EGFR tyrosine kinase 
mutation and Ras mutation.  So, it is important to develop target drugs for people with 
these kinds of mutation. Currently, Tyrosine kinase inhibitors Gefitinib and Erlotinib 
are used to treat EGFR mutated non small cell lung cancer patients. PD98059 have 
ability to target the down stream of Ras by inhibiting ERK phosphorylation. So, it is 
important to see the effect of Tyrosine kinase inhibitors (Gefitinib, Erlotinib) and 
selective MAPK inhibitor (PD98059) in EGFR signalling pathway. Data we have 
produced during this study  will backup/contradict  the current and ongoing research 







Chapter 2 Aim and Hypothesis 
 
 
This chapter will set out the aims and a hypothesis for the project. It is easier to do this 
























2.1 Aims of the project 
 
1) To  investigate the effect of EGF and TGFα on proliferation of cancer and control 
cell lines. 
2) To investigate effect on EGF and TGFα on cell morphology. 
3)  To investigate the status of EMT marker in response to EGF and TGFα. 
4) To investigate the effect of EGF and TGFα on migration of cancer and control cell 
lines. 
5) To investigate the phosphorylation of MAPK 202/204 and AKT473 in response to 
EGF and TGFα. 
6) If EGF and TGFα has an effect, to investigate whether Tyrosine kinase inhibitors 
(Gefitinib, Erlotinib) and the selective ERK1/2 inhibitor (PD98059) inhibit these 
effect of EGF and TGFα. 
 
The specific studies carried out towards these objectives include:  
 
a) To observe the effect of EGF and TGFα on cell proliferation of HSG, AZA1, TYS 
and HaCaT cell lines by using automated cell counter. 
b) To observe the EMT markers E cadherin and Vimentin on the HSG, AZA1, TYS and 
HaCaT cell lines treated with EGF and TGFα by using immunofluorescence and 
Western blot. 
c) To observe the localization of total EGFR in response to EGF and TGFα treatment 
by using immunofluorescence. 
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d) To observe the effect of EGF and TGFα on morphology of HSG, AZA1, TYS and 
HaCaT cell line by using photograph as different time point. To investigate 
whether an hour pre-treatment with tyrosine kinase inhibitor (Gefitinib, 
Erlotinib) and ERK1/2 inhibitor (PD98059) inhibit the effect of EGF and TGFα. 
e) To observe the effect of EGF and TGFα on migration of HSG, AZA1, TYS and HaCaT 
cell lines by using scratch assay. To investigate whether Gefitinib, Erlotinib and 
PD98059 inhibit the effect of EGF and TGFα.  
f) To observe effect of EGF and TGFα on phosphorylation of EGFR1068, MAPK 
202/204 and AKT473 on HSG, AZA1, TYS and HaCaT cell lines.  To investigate 
whether Gefitinib, Erlotinib and PD98059 inhibit the effect of EGF and TGFα.  
g) To observe localization of MAPK202/204 and AKT473 on HSG, AZA1, TYS and 
HaCaT cell line by using immunofluorescence. To investigate whether Gefitinib, 
Erlotinib and PD98059 inhibit the effect of EGF and TGFα. 
2.2 Hypothesis of the study 
 
The hypothesis is that EGF and TGFα would induce the cell proliferation, EMT like 
morphological change, migration, phosphorylation of tyrosine kinase residues, 
activation of MAPK and AKT pathway and EGFR internalization.  
There was also a hypothesis that Tyrosine kinase inhibitor and downstream 
inhibitor inhibit the effect of EGF and TGFα.  
Null hypothesis would be that growth factors have no effect on cell proliferation, 
EMT, migration, phosphorylation of tyrosine kinase residues, activation of MAPK 
and AKT pathway and EGFR internalization.  
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Pilot experiments were performed by the author during her master thesis to test 





Chapter 3 Materials and methods 
 
This chapter will be mainly the general methods used in the project. More detailed and 




3.1 The cell lines used in the study and source 
 
Table3.1 The cell lines used in the study and source 
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Justification of the cell lines 
The cell lines were chosen upon ethnicity of the patients(asian) rather than location of 
tumour. HaCaT cell was kind gift from Dr Norbett Fusenig. HaCaT cell line was selected 
as control cell line due to unavailabbility of normal oral cell line. The morphology and 
function is similar to oral squamous epithelial cells. TYS cell line was a kind gift from Prof. 
Mitsunobu Sato from University of Tokushima. The cells were obtained from biopsy of 
primary oral cancer from 81 years old japanese female. Despite isolating from well 
differentiated squamous cell carcinoma located from flooe of the mouth, it was 
histopathologically interpreted as acinic cell carcinoma with squamoid lesion. 
HSG cell line was also a kind gift from Prof. Mitsunobu Sato from University of 
Tokushima. The cells were obtained from 54 years old japanese man who received 
therapeutic radiation for cancer at the floor of the mouth. 
AZA1 cells are HSG cells treated with 5-Azacytidine. It is a potent growth inhibitor and 
cytotoxic gagent. It has ability to inhibits DNA methyltransferase causing DNA 
demethylation and allow transcription factors to bind DNA and reactivate tumour 
suppressor genes. In clinic, Azacytine is mainly used to treat myelodysplastic syndrome 
and some case of acute myeloid leukemia as hypomethylation agent. In vitro, it can be 
used to remove methyl group. In research 5-azacitidine is used to promote 
cardiomyocyte differentiation of stem cells. In contract, it promote transdifferentiation 
of cardiac cells into skeletal myocyte.5-Azacytidine inhibit T cell proliferation, block the 





3.2 List of equipment 
 
Table 3.2 List of equipment 
   
Name Make/Origin  
Class II biological safety cabinet  Medical Air Technology, Manchester, Uk  
Incubator  Thermo Scientific, Waltham, MA,USA  
Water bath  Grant Instruments, Cambridge, UK  
Centrifuge machine (Mistral 1000)  MSE,London,UK  
Pipette  Thermo Scientific, Waltham, MA,USA  
Pipette boy  Integra bioscience, Zizers, Switzerland  
Nunclone cell culture dish  Thermo Fisher Scientific, Denmark  
Light microscope, IX50  Olympus, Tokyo,Japan  
Automated cell counter TC10  Bio-Rad, Hercules, CA,USA  
Orbital shaker   Stuart scientific, Staffordshire, UK  
Centrifuge (Sigma 1-13)  Sigma, Osterode am Hartz, Germany  
Inverted fluorescence microscope (IX70)  Olympus, Tokyo, Japan  
Plastic pipette  Alpha laboratotories Catalogue LW4061 





3.3 List of reagents and antibodies 
Table 3.3 List of reagents and antibodies 
 
Cell culture reagents  Company  Catalogue no.  
Foetal Calf Serum (FCS)  Sigma-Aldrich, 
St.Louis,MO,USA  
F-2442  
Minimum essential Medium 




DMEM – Dulbecco’s Modified 
Eagle Medium (GlutaMAX™ 
Supplement)   
Thermo Fisher Scientific, MA, 
USA  
61965026  
EGTA  Sigma-Aldrich, 
St.Louis,MO,USA  
E-8145  
Trypsin  Sigma-Aldrich, 
St.Louis,MO,USA  
T-4549  
L-Glutamine  Sigma-Aldrich, 
St.Louis,MO,USA  
G-7513  
PBS  Sigma-Aldrich, 
St.Louis,MO,USA  
P-4417  





Methanol  VWR BDH,PA, USA  101586B  
Epidermal growth factor  insight biotechnology  Cat No: 10-1033-B,  
Transforming growth factor α  insight biotechnology  Cat No: 10-1033  
DMSO Sigma-Aldrich, St. Louis, MO, 
USA  
Cat No:D-5859 
Gefitinib Cell signalling technology 4765 
Erlotinib Cell signalling technology 5083 
PD98059 Cell signalling technology 9900 
E cadherin Cell signalling technology 3195-135KDA 
Vimentin Cell signalling technology 3932-57KDA 
Anti EGFR Rabbit monoclonal 
antibody(EP38Y) 
Abcam Ab 52894 
Phospho EGF receptor 
pathway antibody sampler kit 
(Phospho-EGF Receptor 
(Tyr1068) (D7A5) XP® Rabbit 
mAb #3777 








AKT473 Cell signalling technology 4060 
Antirabbit IgG, HRP linked 
antibody 
Cell signalling technology 7074 
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3.4 Measuring cell proliferation 
          
Cell proliferation can be measured by a number of methods. These can include 
everything from the humble Haemocytometer to the labelling of cells with radioactive 
thymidine (Romar et al., 2016). Work in our laboratory has in the past investigated these 
other methods and found that the most simple method for studying was to use an 
automated cell counter. In the last year a major workshop has concluded that for 
consistency in this area a logical system should be devised (Lin-Gibson et al., 2018). 
Using our own system which is a fully automated system (TC10 from Biorad) allows us 
the investigated cell growth in this manner. Automated cell counter is also one of the 
easiest ways to measure the cell proliferation giving both accurate counting and quick 
and reproducible results. Comparison studies have shown that they are quicker and 
easier than Haemocytometer (Cadena- Herrera et al., 2015). In this chapter, 4 different 
cell lines are used three from various Head and neck tumours being epithelial in 
character and one “normal” epithelial cell line.  
3.5 Cell culture 
 
All the cells were cultured at 37° Celsius (°C)and 5% CO2 in MEM with 10% Foetal calf 
serum (FCS) and 200mM glutamine. All the tasks such as sub culturing, passaging, 
cryopreservation and resuscitation were done according to standard laboratory 
protocol set up by the Unit of Cellular and Molecular Biology, the Dental School, 
University of Dundee, UK.The cells were sub-cultured 1 to 2 times a week depend on 
confluency of the cells. Growth medium was changed every 3 to 4 days the spent 
medium was aspirated off and replaced with fresh medium. All the stock cells were 
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grown on 90mm dishes.  Once the dish (35mm or 60mm) was decided upon would 
ascertain how the dishes were prepared. A 90mm stock dish was taken out of  the 
incubator. Media was aspirated off washed twice with HBSS and replace with 2 ml of 
trypsin. Then the dish was placed into incubator for 5 mins. The cells need to be 
scrapped off if they are firmly attached to dish. 4mls of 10% FCS was added into dishes 
to neutralised the trypsin and suspension were then transferred into a universal tube 
using a plastic pastette and centrifuge for 5 mins at 900rpm.  The trypsin/media mixture 
was aspirated off and then cell pellet was re- suspended in the appropriate volume of 
10% FCS either 2mls for 60mm dishes or and 1ml for 35mm. Fresh dishes were prepared, 
the number and size would depend on the intention of the experiments, adding 2mls of 
10% FCS to each of 60mm dish or 1ml to each of 35mm dishes. The cells suspension was 
then added into the prepared dishes and the cultures incubated at 37°C.  This is 
described as day 0 and dishes were placed in the incubator overnight. The next day, the 
cells were checked for their confluency, healthiness and sign of any bacterial and fungal 
contamination.  
3.6 General cell culture for maintenance of stock cells 
 
For sub-culturing, 90mm culture dish was taken from incubator and check for confluency 
and heathiness and sign of bacteria and fungal contamination. Once they became 
confluence, spent medium was aspirated off. The dishes were washed twice with Hank 
balanced salt solution (4mls) and then 2mls Trypsin/EGTA was added. The dishes were 
transferred onto 37°C hot plate or in incubator for 5minutes. The cells were normally 
float off from the dish.The cells need to be scrapped off if they are firmly attached to 
dish. 4mls of 10% FCS was added into dishes to neutralised the trypsin and suspension 
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were then transferred into a universal tube using a plastic pastette. The cells were 
counted using a cell counter and then centrifuged at 900rpm for 5 minutes. The 
trypsin/media mixture was aspirated off and then cell pellet was re- suspended in the 
appropriate volume of 10% FCS 2mls for each 90mm dish. Fresh dishes were prepared 
and 5mls of 10% FCS were added to each of 90mm dish. The cells suspension was then 
added into the prepared dishes and the cultures incubated at 37°C and 5% CO2. On the 
next day, cells were checked for confluency and heathiness. Media (10%FCS) was 
changed every 2 to 3 days. 
3.7 Cryopreservation and resurrection 
 
The dishes were washed twice with Hank balanced salt solution (4mls) and then 2mls 
Trypsin/EGTA was added. The dishes were transferred onto 37°C hot plate or in 
incubator for 5minutes. The cells were normally float off from the dish.The cells need to 
be scrapped off if they are firmly attached to dish. 4mls of 10% FCS was added into dishes 
to neutralised the trypsin and suspension were then transferred into a universal tube 
using a plastic pastette. The cells were then centrifuged at 900rpm for 5 minutes. The 
trysin/media mixture was aspirated off and then the pellets were re-suspended in 1ml 
freeze mix (10% DMSO/40% FCS/50% media) for each of cryovials. The vials were then 
stored in -80°C.  
For resuscitation of cells, cryovials were put in 37°C water baths to defrost.  At the same 
time 90mm dishes were prepared by adding 5mls of 10% FCS. Cryovial became warm 
within few mins in the water bath. Once the cells defrosted, the cells were poured into 
cluture dishes (1 dish for 1 vial) and then incubated overnight. Next day, when the cells 
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are fully attached, the medium was changed. All the procedure were written in cell 
culture log book. 
3.8 Scatter assay  
 
Scatter assay is a simple low-cost method used to investigate the cell morphology and 
individual migration of the cells. The cells were first passaged and plated at 1x 105 per 
dish and allowed to attach until it reach to mid confluency. The cells were serum starve 
overnight. Next day, different concentration of growth factors and inhibitors were 
added into the dishes. The photographs were taken at appropriate time out to monitor 
the cell morphology and migration of the cells. Detail step by step procedure for each of 
the experiments were described in 4.3.2 
3.9 Definition of epithelial characteristic characteristics   
                                                                                                          
 






3.10 Definition of mesenchymal characteristic characteristics      
                               
As seen in Figure 3.2:  
 
Figure 3.2 Mesenchymal shape cells- note the green line indicates loosely connected 
cells with and elongated shape. 
3.11 Scratch assay  
 
Scratch assay is a simple low-cost method which is used to measure the differences in 
cell migration rates between treated and untreated cells. The cells were seeded at 
1x105per dish.  Once the cells reached 90% to 100% confluence. They were put into 
serum free and left overnight. Next day, the scratch line was made by using white 
pipette tip. The dishes were  washed with serum free for two times to remove the debris. 
Different concentration of growth factors and inhibitors were added into the dishes. 
Photographs were taken at appropriate time point. Detail step by step procedure for 





3.12 Immunofluorescence   
 
Immunofluorescence is a technique using specific antibodies and antigens conjugated 
to fluorescent dyes which allows visualization of the distribution of the target molecule 
inside the cell or tissue (Cell signal, 2019).    
Cells are grown on plastic tissue culture dishes and incubated in test conditions. The first 
step is cell fixation. After the pre-requisite time the cells to be analysed need to undergo 
fixation. The dishes containing the test cells were washed with PBS and then fixed with 
ice-cold methanol for 20 minutes. After that, the dishes were washed with PBS 3 times 
for 5 minutes during which time each dish was placed on an orbital shaker. Then each 
dish was washed with 0.2% Triton X-100 in PBS for 5 minutes (placing dish on orbital 
shaker). The dishes were washed a further 3 times with PBS for 5 minutes and each time 
placed on an orbital shaker. After that a number of circles were drawn onto an area of 
the dish using an immuno pen.  
The second step is known as blocking. The circles had a few hundred µl of 5% Normal 
serum/PBS-T (TBS+ 0.1% Tween 20) placed onto them (enough to cover the circle and 
for it to not dry out) at room temperature for 60 minutes. After 60 minutes the blocking 
buffer was removed and circled area was incubated with primary antibody in a 
humidified chamber (in the fridge, 4°C) overnight. The best temperature was set 4°C. 
Note the primary and secondary antibody is diluent was 5% normal serum in PBS-T 
(PBS+0.1% Tween 20). The next morning, the dishes were equilibrated to room 
temperature for 60 minutes. The dishes were then rinsed with PBS gently and then 
washed with PBS. Secondary antibody was added to the circled areas and dishes were 
kept in a humidified chamber for 1 to 2 hours. After that dishes were then washed gently 
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with PBS. And then washed again with PBS. Dishes were mounted with DPX and 
coverslips before examination under microscope and stored in the dark cold room at 
4°C. 
 
3.13 Example of weak, moderate and strong staining (Figure 
3.3) 
The three photomicrographs below are examples of the staining described in the results 
chapters. The upper picture is weak staining, the middle picture is moderate and the 




Figure 3.3:  Example of staining patterns 












3.14 Cell lysis  
In order to lyse the dishes, ice trays were prepared. One tablet of Protease and one 
tablet of phosphatase inhibitor were put into 10ml  RIPA buffer and put it on the ice tray 
for few minutes until it dissolved. Placed the cell culture dishes on the ice. Dishes were 
washed with ice cold PBS. Then aspirate PBS and add ice cold lysis buffer (0.5ml per dish) 
for 10 minutes on ice tray. The cells were than scraped with cell scraper and transfer the 
cell lysate into label microcentrifuge tube. The tubes were stored in the fridge. 
3.15 Protein assay -Pierce BCA protein Assay Kit (23225) 
 
It is used to determine the concentration of protein in solution. Copper (Cu2+) salt was 
utilized in this method to cuprous state by proteins. The Cu2+ion form an intense 
coloured complex with bicinchninic acid reagent. Intensity of colour is proportionate 
with amount of protein in the sample. 96 well plate was used in this experiment with 
Standards were in triplicate and samples were either duplicate or triplicate. Lysate 
samples were defrosted and Needle and syringe were used to break down the gelation 
of lysate samples. Lysates samples were spun for 5minutes (1200rpm) in bench top 
microfuge and supernatants were used. Standards were made up as follows and Diluent 








Preparation of Diluted Albumin (BSA) Standards 
Table3.4 Preparation of Diluted Albumin (BSA) Standards 
 




Vial Volume of 
Diluent 
Volume and 
source of BSA( µL) 
Final BSA 
concentration(µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock  1000 
D 175 175 of vial B 
dilution  
750 
E 325 325 of vial C 
dilution 
500 
F 325 325 of viral E 
dilution 
250 
G 325 325 of viral F 
dilution  
125 
H 400 100 of viral G 
dilution  
25 




25µl of standards and samples were pipetted into appropriate wells according to plan. 
BCA working reagent was made by mixing 50 parts BCA reagent A with 1 part of reagent 
B. 
Total volume WR required= (no of standard+ no of unknown) x (number of replicate) x 
(volume of WR sample). 
200µl of working reagent were added into wells. The plate was put on the shaker for 30 
seconds. The plate was wrapped in cellophane and then incubate for 2hrs at 37’C. The 
plate was cool to room temperature for 10-20 minutes before reading on OPTIMA plate 
reader. 
3.16 SDS PAGE  
 
SDS PAGE is a technique used to separate proteins present in cell lysates according to 
their sizes. Prior to SDS PAGE, the cell lysates and loading buffer which contain SDS and 
2 Mercaptoethanol were denatured by heating at 95 degree Celsius water bath. Heating 
allows denaturing of the proteins and loss its 3D structures. SDS is anionic detergent 
which bind to denatured protein. The proteins are migrated according to the size. Magic 
marker XP from Invitrogen were run for reference to estimate the protein fraction. The 
separated proteins were transferred into nitrocellulose membrane or PVDF by western 
blot. Different antibodies were used to probe the specific proteins. 





Mini-Protean Precast Gel (TGX) set up overview 
10 % gels which fractionate proteins between 30 and 150kDa Biorad TGX precast gels. 
First is to remove the comb by pushing the ridges of the comb with two thumbs. Then 
the orientation is of the wells were checked and correct with disposable pipette if it has 
dis alignment. Then remove the Green tape at the bottom of cassette. The wells were 
then rinse with TGS running buffer. Cassette were then assembling into the running 
module of mini PROTEAN system. TGS running buffer were prepared by diluting 10x 
stock to 1x (100ml with 900 ml of distilled water). Then TGF running buffer was added 
to inner and outer chambers of the electrophoresis tank. 
For SDS-PAGE, cell lysates were thawed and spun at 13,000 rpm for 5 minutes. Suitable 
amount of sample were aliquot into labelled 500µl Eppendorf tube. Samples were then 
mixed with appropriate volume of loading buffer including 5% (v/v) 2 – 
mercaptoethanol. Samples were then heated at 95’C in a water bath for 5 minutes then 
centrifuge briefly. Samples were loaded onto wells which fractionate proteins between 
30 and 150kDa Biorad TGX precast gels. Gels were then connected to a power pack set 
at the voltage of 150V (which may be increase to 180-200V in the middle of running 
depend on the current) and run for approximately 40-45 minutes. The electrophoresis 
was continued until the blue line reach line reaches the black line at the bottom of the 
cassette. Then power was turn off, disconnect the gel rig, remove the cassettes and the 
running buffer was pour into the sink. 
98 
 
 After removing the gels gently from the cassette they were placed into distilled water 
and viewed under the UV of gel doc machine to know whether it is transfer properly. 
Then gels were placed into transfer buffer. 
3.17 Western blot 
 
Western blot is a method used to transfer the proteins bands from SDS-PAGE onto a 
membrane using an electric current. After transfer, the non-specific binding sites on the 
blot were blocked by incubation in blocking buffer. The immobilised bands were then 
probed with specific antibodies against the target proteins (primary antibodies). The 
primary antibody was then added and labelled with the enzymes horse radish peroxide 
for visualisation. The substrate was added to the enzyme HRP generating 
chemiluminescene in in order to locate the antibody. Protocol for western blotting are 
described as follow. 
 After SDS-PAGE, the low fluorescence PVDF membrane was cut into appropriate size 
enough to cover the gel and marked with pencil for orientation. Then PVDF was soaked 
into methanol for 30 seconds then placed in transfer buffer. BioRad extra thick paper 
was cut into two pieces, slightly bigger than gel size. Then placed into transfer buffer. 
BioRad extra thick paper was placed on the centre of the electrode. Then PVDF was 
placed on top of think paper. Acrylamide gel was placed carefully on the top of PVDF. 
Then covered with remaining BioRad thick paper. Roller was used to eliminate air 
bubbles between layers. Then run at a constant voltage of 15V for 42 minutes. Blocking 
buffer (1% w/v dried milk or 5% BSA depend on primary antibody in 1x TBST) was 
prepared and incubated with the blots for 10 to 30 minutes. Blots were then incubated 
with primary antibody anti E-cadherin(1:1000), anti-Vimentin(1:1000), anti-
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EGFR(1:1000), anti-P44/42MAPK(Erk1/2)Antibody(1:2000), anti-phospho p44/42 
MAPK(Erk1/2)( Thr202/Tyr204)(1:2000), anti-phospho -akt( Ser473)(1:2000) for 
overnight. Maintained the temperature according to manufactures instructions. 
Antibody solutions were rinsed off with 1xTBST. Then blots were washed three times in 
1x TBST, 20 minutes per wash. The blots were incubated with goat anti-rabbit secondary 
antibody (1:2000) in blocking buffer on orbital shaker at room temperature for an hour. 
Blots were then washed 2 times in 1xTBST 20 minutes per wash. Rinsed the blot 
thoroughly with 1xTBST and then 1xTBS for 5 minutes and transferred into clean vessel. 
Developed the blot with 3.5ml of each reagent of the chemiluminescent substrate: 
BioRad Clarity Western ECL Substrate. Incubate for 5 minutes. Chemiluminescence was 




Chapter 4: To study the effect of the growth 
factors EGF and TGFα on proliferation, morphology 
and the migration of head and neck cancer cell 
lines using changes in cell shape as a marker of 




















In this chapter, we investigated cell proliferation, morphology changes (EMT), and cell 
migration. Each of these was measured by using an automated cell counter, a scatter 




One of the hallmarks of cancer is the overproduction of growth factors (Hanahan & 
Weinberg, 2000). Cell proliferation is a normal process in which an increase in cell 
numbers is the result of cell growth and cell division. In a normal healthy individual cell 
proliferation is balanced. This means that as cells become worn out they are replaced 
and there is no overall increase in the total. In contrast, the cell proliferation rate can be 
increased in cancer leading to an overall increase in the number of cells that are present 
in tissues. This has implications on cell blood supply and the amount of nutrients within 
a tissue and also the removal of waste products. One of the major factors in any tumour 
growth is interaction of growth factors with cellular receptors. The EGFR family of 
receptors has been implicated in a large number of tumour situations (Salomon et al., 
1995). In fact, in breast cancer EGFR status is part of the diagnosis of the cancer (Milanezi 
et al., 2008). It has been reported that EGFR could be used either as a prognostic factor 
in HNSCC (Bossi et al., 2016). Data in this paper also suggested that ligands of the 
receptor may also be factors that can be used as prognostic markers. TGFα and EGF are 
two of a family of ligands that bind to EGFR (Roskoski, 2014). Experimental data indicates 
that these growth factors have an effect on cellular proliferation. However, this data is 
cell and tissue dependent.  
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Cell proliferation is a major important part of cancer development and progression 
(Schafer, 1998). Assessing cell proliferation is one of the fundamental research areas in 
medicine. There are various ways to determine the cell proliferation such as measuring 
cell number, DNA synthesis (BrdU, EdU), cellular metabolism (MTT, WST01), 
proliferation proteins (Ki-67, PCNA, MCM-2).  
4.1.2 EMT and migration 
The majority of cancer deaths are caused by metastasis of tumour cells to secondary 
sites (Chaffer & Weinberg, 2011). Metastasis is defined as the spread of a cancer from 
the primary site to other parts of the body. Cell migration is a pivotal process in 
metastasis.  Cancer cells degrade the extracellular matrix and basement membrane, 
break through surrounding tissue, enter blood or lymphatic stream, attach at a new site 
and grow into a secondary tumour mass(Guan X, 2015). Cancer cells have the ability to 
breakdown cell to cell adhesion and cell to extracellular matrix adhesion. These 
adhesions are broken down by secretion of substances collectively known as matrix 
degrading enzymes (usually ascribed to a family of proteins known as Matrix 
Metalloproteases MMP’S) which degrade both the ECM and the basement membrane. 
Loss of cell to cell adhesion allows the cancer cells to dissociate from the primary 
tumour. Therefore these cells become individual cells so they can change shape and 
migrate by the loss of cell to matrix adhesion the cells will be able to invade the 
surrounding stroma(Manzanares & Horwitz, 2011).For this to occur there is a down-
regulation of E-cadherin leading to a break down in cadherin- catenin link(Hajra& 
Fearon, 2002). 
Epithelial cell shape plays an important role in a tissue. In the oral mucosa they form a 
barrier to keep important molecules in the body and invasive bacteria and other things 
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out. However, when it all goes wrong this barrier can break down and the cells can 
invade into the outlying area. To migrate away from this area the cells need to break 
down the tight cell-cell junctions and be able to move to distant sites. One theory is that 
this occurs by epithelial to mesenchymal transition (EMT). Normal epithelial cells grown 
in tissue culture grow as tight colonies but once the cells undergo EMT they have a more 












EMT is the process by which cells transform from closely connected cuboidal shaped 
epithelial colony to a more elongated motile mesenchymal shape (Thiery & Sleeman, 
2006). EMT is reversible process and can be found in both normal and disease conditions 
(Kalluri & Weinberg, 2009). EMT is the initial first step in cancer cell migration, invasion 
and metastasis. Invasion and metastasis is another hall mark of cancer (Hanahan & 
Weinberg, 2000). Growth factors such as EGF, TGFα, FGF, HGF, bone morphogenesis 
proteins (BMPs), and extracellular matrix such as, collagen, hyaluronic acid (HA), as well 
Figure 4.1 EMT a) Epithelial cells- HaCaT are typical epithelial cells when grown in culture as tight 
colonies- blue arrow. They are a regular shape. b) Epithelial cell line (EMT6-picture provided by Dr I 
Ellis) a cell line that has undergone EMT- cells do not grow in tight colonies and have irregular 
shape (red arrow) and different projections (yellow arrows). 80X magnification  
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as chronic inflammation and hypoxia are known to induce EMT (Thiery & Sleeman, 
2006). It has also been reported that cells undergoing EMT have stem cell like 
characteristics and are resistant to therapy. The restoration of E-cadherin can increase 
the sensitivity to EGFR-inhibitors (Mani et al., 2008, Singh & Settleman, 2010). 
One of the indications of EMT are the changes in the so-called markers of EMT. These 
markers are described in detail in the introduction (Chapter 1.34). EMT induces the 
down-regulation of epithelial markers such as E-Cadherin, Z0-1, Desmoplakin, 
cytokeratins, occudin and the upregulation of mesenchymal markers such as vimentin, 
N-cadherin, integrins ανβ6, Fibronectin, FOXC2 (Neilson& Zeisberg, 2009, Lee JM, 2006). 
One of the most studied areas is the down regulation of the epithelial marker E-cadherin 
and the subsequent up regulation of the mesenchymal marker vimentin which have 
been reported in both EMT and cancer metastasis (Neilson & Zeisberg, 2009, Nijkamp 
et al., 2011). E-cadherin is a calcium dependent adhesion molecule which links actin 
cytoskeleton through interaction with catenins. The cadherin-catenin complex plays an 
important role in the adherens junction which are essential for the homeostasis of 
epithelial tissues (Pećina-Slaus, 2003). In contrast, vimentin is an intermediate filament 
(IF) protein expressed primarily by mesenchymal cells. Vimentin is important for 
maintaining the cells integrity via the cytoskeleton, orienting microtubules, 
morphological changes and the migration of cells (Liu et al., 2015, Mendez et al., 2010).  
Dysregulation in EGFR signalling has been reviewed with cancer cell proliferation, 
migration, invasion and metastasis, resistance to apoptosis (Wee & Wang 2017,  Ohnishi 
et al., 2017, Lu et al., 2001, Andl et al., 2004). 
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There are two types of cancer cell migration. Individual cell migration and collective cell 
migration. The contrast between collective cell migration where cells move as groups or 
sheets (Figure 4.2 a, b) and individual cell movement where cells need to break contacts 
and move individually is quite stark (Figure 4.3 a, b) (Friedl, 2009). Collective cells 
movement follows three principles in that cells remain: 1) attached both physically and 
functionally. 2) The polarity causes the actin filaments to generate traction.  3) The cells 






                      a                                                          b 






In individual cell migration, cells to cell contacts are lost with and there is the formation 
of ameboid or mesenchymal phenotype (Figure 4.3 a. and b). Cell produce different 
types of extensions when they migrate: Filopodia (finger like projection), lamellipodia 
(broad like protrusion), podosomes and invadopodia are cellular protrusion which forms 
at the edge of migrating cells (Yamaguchi et al., 2005). 
 
Figure 4.2 collective cell migration: HSG cells plated onto the surface of a plastic tissue 
culture dish were grown to confluency. They surface was scratched and the migration 
noted after 24 hours. Note the gap has narrowed No single cell are visible in the gap so 
we surmise that the cells have moved as a collective a) HSG cells in time 0, b) HSG cells 









                                     a                                                                      b 
 
                                                                                                                                        
 
 
Using the Scatter assay it should be important to reflect on the different types of cell 
movement. In this assay the cells start as a colony and appear to reduce the cell-cell 




4.2 Aim and hypothesis 
 
The study in this Chapter of the thesis will investigate the addition of the growth factors 
EGF and TGFα to head and neck cell lines and measure their response of cells in terms 
of proliferation, EMT like morphology changes, and migration.  




Figure 4.3 Cell scattering : HSG cells plated onto the surface of a plastic tissue culture 
dish were grown to 50% confluency. EGF 50ng/ml was added into the dish. After 48 
hours, the cells became scattering with some projection appeared.  a) HSG cells in 
serum free, b) HSG cells in EGF 50ng/ml (200X magnification) 
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Previous work in this laboratory using a limited number of concentrations of EGF and 
TGFα (1 and 10ng/ml) indicated that they had no effect on the proliferation of a cancer 
cell line (TYS) and a normal oral mucosa stromal cell line (MM1). The aim of this part of 
the study was to investigate the role of a wider range of concentrations of the growth 
factors on cell proliferation. The working hypothesis was that neither growth factor 
would stimulate the proliferation of these cell lines.  
The literature has suggested that EGF can stimulate the morphological change in cell 
shape that is consistent with EMT. Our aim is investigate changes in morphology and 
migration in response to EGF and TGFα. Our hypothesis is that both growth factors will 







4.3 Materials and methods 
 
4.3.1 Experimental details using Automated cell counter 
Cells were sub-cultured as described in chapter3 (3.5). Once the dish (35mm or 60mm) 
was decided upon would ascertain how the dishes were prepared. The trypsin/media 
mixture was aspirated off and then cell pellet was re- suspended in the appropriate 
volume of 10% FCS either 2mls for 60mm dishes or and 1ml for 35mm. Fresh dishes were 
prepared, the number and size would depend on the intention of the experiments, 
adding 2mls of 10% FCS to each of 60mm dish or 1ml to each of 35mm dishes. The cells 
suspension was then added into the prepared dishes and the cultures incubated at 37°C.  
In the initial pilot experiment the cells were first passaged and then plated at an initial 
density of 5x104 density. However, due to wanting to investigate cell proliferation over 
a greater number of days an initial pilot study was performed using the AZA1 cell line. 
This involved plating cells at an initial density of 5x103, 1x104, 2x104, 2.5x 104 and 5x 104 
and counting the cells on Day 1-5. In later experiments, it was changed into 2.5x104 
(Figure 4.4) indicates that this density was the best for cell proliferation assays due to 
normal growth phases (lag phase, log phase and saturation density). Cells were 
passaged and then plated onto 35 mm dishes and this is described as day 0 and dishes 
were placed in the incubator overnight. The next day, the cells were checked for their 
confluency, healthiness and sign of any bacterial and fungal contamination. Medium 
was prepared for each of the test condition (1ng/ml, 10ng/ml, and 50ng/ml) of both EGF 



















The control was 1% FCS. Medium was changed into the test condition on day 1 and a 
base line count was performed on day 1. Overlay was changed day 3 or day 4. At first 
the experiment was set for 3 days. However, data from the pilot experiment enabled us 
to change to 5 days cell count. In order to count the cells, the cells were first trypsinized 
for 5 mins. Then pipette 10µl of the cell suspension into chamber of cell counting slide. 
While loading the sample, the pipet tip was placed 45˚ angle at the bottom of loading 
area. And then simply inserting the slide into slide slot of instrument. Within 30 seconds 
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) onto 35mm dishes in 10% FCS. The cells were allowed to attach overnight and 
transferred to test conditions (1% FCS) the following day. Cell number was determined by 
cell counting by using automated cell counter. The data shown is from a plating density of 
2.5x10
4
 cells. This shows a typical growth curve to a saturation density of around 1.3x10
5
 




4.3.2 Experimental details for scatter assay  
Cells were sub-cultured as described in the General method Chapter 3 (3.5, 3.6) 
Once the dish (35mm or 60mm) was decided upon would ascertain how the dishes were 
prepared. The trypsin/media mixture was aspirated off and then cell pellet was re- 
suspended in the appropriate volume of 10% FCS either 1.5mls for 60mm dishes or and 
1ml for 35mm. Fresh dishes were prepared, the number and size would depend on the 
intention of the experiments, adding 2mls of 10% FCS to each of 60mm dish or 1ml to 
each of 35mm dishes. The cells suspension was then added into the prepared dishes and 
the cultures incubated at 37°C and 5% CO2. On the next day, the cells were serum sterve 
for 24 hours before addition of (1ng/ml,10ng/ml,50ng/ml) of EGF and 
(1ng/ml,10ng/ml,50ng/ml) of TGFα. The cells were monitored for 48hours. The 
photomicrographs were taken at appropriate time. Results were summerized in section 
4.5.2 (figure 4.13). 
 
4.3.3 Experimental detail for scratch assay 
The cells were seeded at 1x10 5 per dish. Once the cells reached 90% to 100% 
confluence, they were put into serum free and left overnight.  After  24  hours,  the  
scratch  line  was  made  by  using  white pipette tips  (which  is  the smallest one). The 
dishes were washed with serum free for two times to remove the debris and then added 
test condition of EGF(1ng/ml,10ng/ml,50ng/ml) and TGFα(1ng/ml,10ng/ml,50ng/ml). 
Serum free is used as control. The cells were monitored for 48 hours. Photographs were 





4.3.4 Experimental detail for Immunofluorescence  
After the scatter assay, dished used in the scatter assay were fixed, washed and then 
blocked with Ecadherin and Vimentin antibodies with dilution 1:200 and 1:50 
respectively as described in chapter3 (3.12). Once it finished photographs were captured 
the areas inside circled areas and recorded. 
4.3.5 Experimental detail for Protein assay, SDS PAGE and Western blot  
The four cell lines were grown to confluence, treated with the respective growth factors 
for 24 hours and then the cells lysed (as described in Chapter 3(3.14). Protein assay, SDS 
PAGE and Western blot were performed with Ecadherin and Vimentin antibodies as 
described in Chapter 3(3.15,3.16,3.17). 
4.4 Results 
The results part of the chapter are split into the effect of the growth factors EGF/TGFα 
on proliferation,  scattering/morphology changes, migration/gap closure, localisation of 
markers/immunofluorescence/SDS-PAGE/Western blotting into a number of different 
sections:  
4.4.1 Proliferation rates of the 4 cells lines as determined by automated 
cell counter 
Cells proliferate at different rates depending on their origin, growth factor receptor 
expression and availability of resources within the cell. The cell lines used in this study 
were from a number of different sources. They all had characteristics of being epithelial 
in nature. However, they obtained from different sites of the oral cavity. The HaCaT cell 
112 
 
line is from skin and so not directly from the oral cavity but they come from a stratified 
squamous phenotype origin and can grow this way in culture.  
The experimental pilot indicated that the AZA1 cell line grew in such a way as to follow 
classic cell biological standard in that Figure 4.4 has an initial plating density, a lag phase, 
log phase and a saturation density. It is interesting to note that the 3 cancer cell lines 
used have a very standard saturation density whilst the HaCaT cell line was lower. 
Table 4.1 saturation density for each cell line 
Cell lines Saturation density for 
1%FCS 
HSG  2x105 
AZA1 2x105 
TYS 1.8x105 
HaCaT  1x105 
 
Cell proliferation studies monitored the effect of the growth factors EGF and TGFα upon 
each. As described in the methods section we originally determined a plating density of 
2.5 x104 cells per dish was best for a 5 days growth curve. Cells were plated at this 
density and allowed to attach overnight. After an initial count the medium was changed 
into the test conditions. Cell number was determined over the next four days using an 
automated cell counter. For ease of understanding the data is presented in two different 
formats. The first Figure breaks down the graphs into each growth factor (e.g.  Figure 
4.5 ) across the days and the second Figure puts all the data on two graph so that we 
can compare the effect each factor has on that proliferation (e.g. Figure 4.6 A and B). 
Data is presented in Figure 4.5 for the cancer cell line HSG. This cell was originally 
isolated from the collecting duct of an irradiated human salivary gland.  The data shows 
each individual growth conditions and Figure 4.6 A and B then grouped on two graphs. 
The data indicates that for the HSG cell line the cells reach a saturation density at around 
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2x105 cells for 1% FCS. However, addition of the growth factors indicates lower growth 
and a lower saturation density (Figure 4.6). This finding is inconsistent over a number of 
experiments.  
Data is presented in Figure 4.7 for AZA1 cells. This cell was originally HSG cells treated 
with 5-Azacytidine.  The data shows each individual growth condition and Figure 4.8 (A 
and B) then grouped on two graphs. The data indicates that for AZA1 cells, the cells also 
reach a saturation density at around 2x105 cells for 1% FCS. In contrast, addition of 
growth factors reduce growth and a lower saturation density (Figure.4.8). 
Data is presented in Figure 4.9 for TYS cells. This cell was derived from floor of the 
mouth.  The data shows each individual growth condition and Figure 4.10 (A and B) then 
grouped on two graphs. The data indicates that for TYS cells, the cells also reach a 
saturation density at around 1.8x105 cells for 1% FCS. However, addition of growth 
factors reduce growth and lower saturation density (Figure 4.10). 
Data is presented in figure 4.11 for HaCaT cells. HaCaT cell was derived from skin. The 
data shows each individual growth condition and figure 4.12(A and B) then grouped on 
two graphs. The data indicates that for HaCaT cells, the cells reach a saturation density 
at around 1.5x 105 for 50ng/ml EGF and 50ng/ml TGFα. In contrast, 1%FCS, 1ng/ml EGF, 
10ng/ml EGF, 1ng/ml TGFα, 10ng/ml TGFα reduce growth and a lower saturation 






































Figure  4.5  The HSG cell line was plated at an initial 2.5 
x10
4
 cells onto 35mm dishes in 10%FCS. The cells were 
allowed to attach overnight and transferred to test 
conditions the following day. Cell number was 
determined by automated cell counter. The data shown 
is from one of four separate experiments and the 
Standard error of the mean is displayed as the error bars. 
(A= 1%FCS; B=1ng/ml EGF,C=10ng/ml EGF, D= 50ng/ml 
EGF,E=1ng/ml TGFα,F=10ng/ml TGFα, G=50ng/ml TGFα) 













































Day 1 Day 2 Day 3 Day 4 Day 5
1%FCS 1ngTGFa
10ngTGFa 50ngTGFa
Figure 4.6 B HSG  proliferation data grouped for TGFα: 
The HSG cell line was plated at 2.5x10
4
 onto 35mm dishes in 10% FCS etc. The cells 
were allowed to attach overnight and transferred to test conditions the following 
day. Cell number was determined by automated cell counter. The data shown is from  
one of four separate experiments and the Standard error of the mean is displayed 
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Figure 4.7: The AZA1 cell line was plated at an initial 
2.5 x10
4
 cells onto 35mm dishes in 10%FCS. The cells 
were allowed to attach overnight and transferred to 
test conditions the following day. Cell number was 
determined by automated cell counter. The data 
shown is from one of four  separate experiments and 
the Standard error of the mean is displayed as the 
error bars. (A= 1%FCS; B=1ng/ml EGF,C=10ng/ml 
EGF,D=50ng/ml EGF,E=1ng/ml TGFα,F=10ng/ml 
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Day1 Day2 Day3 Day4 Day5
1%FCS 1ngTGF 10ngTGF 50ngTGF
Figure 4.8 B AZA1 proliferation data grouped for TGFα: 
The AZA1 cell line was plated at 2.5x10
4
 onto 35mm dishes in 10% FCS etc. 
The cells were allowed to attach overnight and transferred to test conditions 
(1%FCS, 1ng/ml EGF, 10ng/ml EGF, 50ng/ml EGF, 1ng/ml TGFα, 10ng/ml TGFα, 
50ng/ml TGFα) the following day. Cell number was determined by automated 
cell counter. The data shown is from one of four separate experiments and the 
































Figure 4.9 TYS     proliferation data 
A       B 
D C 
E F   
G 
Figure 4.9: The TYS cell line was plated at an initial 2.5x10
4
 
cells onto 35mm dishes in 10%FCS. The cells were allowed 
to attach overnight and transferred to test conditions the 
following day. Cell number was determined by automated 
cell counter. The data shown is from one of four  separate 
experiments and the Standard error of the mean is 
displayed as error bars. (A= 1%FCS; B=1ng/ml 
EGF,C=10ng/ml EGF,D=50ng/ml EGF,E=1ng/ml 












































1%FCS 1ngTGF 10ngTGFa 50ngTGFa
Figure 4.10 B TYS proliferation data grouped for TGFα: 
The TYS cell line was plated at 2.5x10
4
 onto 35mm dishes in 10% FCS etc. The cells were 
allowed to attach overnight and transferred to test conditions (1%FCS, 1ng/ml EGF, 
10ng/ml EGF,50ng/ml EGF, 1ng/ml TGFα,10ng/ml TGFα, 50ng/ml TGFα) the following day. 
Cell number was determined by automated cell counter. The data shown is from one of 











































Figure4.11: The HaCaT cell line was plated at an initial 
2.5x10
4
   cells onto 35mm dishes in 10%FCS. The cells were 
allowed to attach overnight and transferred to test 
conditions the following day. Cell number was determined 
by automated cell counter. The data shown is from  one of 
four separate experiments and the Standard error of the 
mean is displayed as the error bars A= 1%FCS; B=1ng/ml 
EGF, C=10ng/ml EGF,D=50ng/ml EGF,E=1ng/ml 




































Day 1 Day 2 Day 3 Day 4 Day 5
1%FCS 1ngEGF 10nEGF 50ngEGF
Figure 4.12 B HaCaT proliferation data grouped for TGFα:  
The HaCaT cell line was plated at 2.5x10
4
 onto 35mm dishes in 10% FCS etc. The cells were allowed 
to attach overnight and transferred to test conditions (1%FCS, 1ng/ml EGF, 10ng/ml EGF, 50ng/ml 
EGF, 1ng/ml TGFα, 10ng/ml TGFα, 50ng/ml TGFα) the following day. Cell number was determined 
by automated cell counter. The data shown is from one of fours separate experiments and the 
Standard error of the mean is displayed as the error bars. 
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4.4.2 Cell morphology changes 
4.4.2.1 Pilot study to determine optimal plating density, optimal growth factor 
concentration and time 
4.4.2.1.1 Plating density  
An initial pilot study using three cell densities was performed (2.5 x104 , 1x 105 and 5x 
105) the cells plated at low density 2.5 x104 cell dishes (less than 20% confluency on 
35mm dishes), required 4 to 6 days after the addition of EGF and TGFα to display a 
morphological change (Data not show). Cells plated at higher density 1x 105 per dish 
(30%-50% confluency), only 24 hour to 48 hours were needed to acquire this 
morphological change.  1x105 per dish was chosen as the best density to do the 
experiments since it took faster to see the cells change. Cells plated at 5x 105 per dish 
(90% to 100 % confluence) there was no or very little changes in cell morphology after 

























 Figure 4.13: The TYS cell line was plated at 5x 105 per dish (90% confluence) 
and EGF was added. The photomicrograph was taken after 24 hrs of addition 
of EGF 50ng/ml. The cells have little or no morphological change. In 100% 
confluence dishes, the cells float off after 48hours. 
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4.4.2.1.2 Growth factor concentration 
A second pilot study using different concentrations of the growth factors was 
performed. Cells were passaged and plated onto dishes, the dishes were kept in 
incubator for 24 hours. After 24 hours the medium was aspirated off the dish and serum 
free-MEM was added for 24 hours. The following day different concentrations of the 
two growth factors was added (1ng/ml, 10ng/ml and 50ng/ml) with serum free media. 
2 ml of media was added to each dish. Results from preliminary experiments found that 
1ng/ml (EGF and TGFα) showed little or no changes in cell morphology. 10ng/ml (EGF 
and TGFα) showed some changes in cell morphology but results were not consistent 
across a number of dishes. However, 50ng/ml (EGF and TGFα) showed prominent and 
consistent changes in cell morphology. It was decided that 50ng/ml concentration of 
each factor was selected to use in the further experiments. Since it induces prominent 
morphological change in a consistent manner (Figure 4.14). Some of the cells have 
become rounded and others have projections indicating a possible shift to a 





Figure 4.14 HSG cell line and effect of growth factor EGF with different dilutions (Serum 
free, 1ng/ml, 10ng/ml, and 50ng/ml) on two different incubation time (24hours and 
48hours). On 24hours time point, 50ng/ml (picture D) cell scattering were observed 
while rest have similarity to control in term of scattering effect. On 48hours time point, 
50ng/ml (picture H) groups showed prominent scattering compared with 24hours. In 
contrast, morphological changes in 1ng/ml and 10ng/ml were minimum. Pictures were 












4.4.2.2   Study to investigate the effect of the growth factor EGF and TGFα on 
morphological change HaCaT cells 
HaCaT cells are characterised and reported as a normal epithelial cell line, although they 
do have some peculiarities, in that they produce e-cadherin and no vimentin (Boukamp 
etal., 1988). In the following experiments the cells were plated onto dishes at 1x105cells 
per dish and allowed to attach. The medium was changed to SF-MEM and the cells left 
overnight. The following day the medium was changed into test conditions and 
photomicrographs taken at a time point of 48 hours. The test conditions are described 
in the Figure legend and it should be noted that the photomicrographs of the serum 
free, EGF treated and TGFα treated cells in all parts of Figure 4.15. The cells show loosely 















































Figure 4.15: HaCaT cells treated with different growth factors for 48 hours 
i) serum free 
ii) 50ngEGF/ml 
iii) 50ng TGFα/ml 
Figure 4.15: The HaCaT cell line was plated at 1x 10
5
 per dish (30% confluence) EGF and 
TGFα were added after colonies had started to form (usually 24 hours). The 
photomicrographs were taken after 48 hrs of addition of the different growth factors. 




4.4.2.3 Study to investigate the effect of EGF and TGFα on morphological change TYS 
cells 
TYS cells are characterised and reported as an oral squamous cell carcinoma, although 
there is some ambiguity in the original report (Yanagawa et al., 1986). In the following 
experiments the cells were plated onto dishes at 1x105cells per dish and allowed to 
attach. The medium was changed to SF-MEM and the cells left overnight. The following 
day the medium was changed into test conditions and photomicrographs taken at a time 
point of 48 hours. The test conditions are described in the Figure legend and it should 
be noted that the photomicrographs of the serum free, EGF treated and TGFα treated 
cells in all parts of Figure 4.16. The cells show cellular protrusion and cell scattering 





























Figure 4.16: The TYS cell line was plated at 1x 10
5
 per dish (30% confluence) EGF and TGFα were 
added. The photomicrographs were taken after 48 hrs of addition of the different growth factors. The 
cells show  cellular protrusion  and cell scattering which are  growth factor dependant. 
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4.4.2.4 Study to investigate the effect of the growth factors EGF and TGFα on 
morphological change of AZA1 cells   
AZA1 cells are HSG cells treated with 5-Azacytidine (Shirasuna K et al., 1981).In the 
following experiments the cells were plated onto dishes at 1x105cells per dish and 
allowed to attach. The medium was changed to SF-MEM and the cells left overnight. The 
following day the medium was changed into test conditions and photomicrographs 
taken at a time point of 48 hours. The test conditions are described in the Figure legend 
and it should be noted that the photomicrographs of the serum free, EGF treated and 
TGFα treated cells in all parts of Figure 4.17. The cells show cell scattering which is 





Figure 4.17: AZA1 cells treated with different growth factors for 48 
hours 
Figure 4.17: The AZA1 cell line was plated at 1x 10
5
 per dish (30% confluence) EGF and 
TGFα were added. The photomicrographs were taken after 48 hrs of addition of the 
different growth factors. The cells show cell scattering which is  growth factor 
dependant. 





4.4.2.5 Study to investigate the effect of the growth factor EGF and TGFα on 
morphological change HSG cells 
 HSG cells are characterised and reported as an epithelial duct cell line derived from 
human salivary gland (Adenocarcinoma of submandibular gland) (Shirasuna K et al., 
1981) .In the following experiments the cells were plated onto dishes at 1x105cells per 
dish and allowed to attach. The medium was changed to SF-MEM and the cells left 
overnight. The following day the medium was changed into test conditions and 
photomicrographs taken at a time point of 48 hours. The test conditions are described 
in the Figure legend and it should be noted that the photomicrographs of the serum 
free, EGF treated and TGFα treated cells in all parts of Figure 4.18. The cells show  cell 
























i) Serum free 
Figure 4.18: HSG cells treated with different growth factors for 48 hours 
ii)50ngEGF/ml 
iii)50ngTGFα/ml 
Figure 4.18: The HSG cell line was plated at 1x 10
5
 per dish (30% confluence) EGF and 
TGFα were added. The photomicrographs were taken after 48 hrs of addition of the 




4.4.3 Scratch assay 
4.4.3.1 Pilot experiment to investigate the best time point in the scratch migration 
assay 
The scratch migration assay was used to investigate the difference in cell motility. Early 
experiments had indicated that the four cell lines had different methods of migrating, 
either as single cells or as sheets. The HSG cell line and the growth factor EGF were 
chosen to investigate the best time point for cell migration. 
A pilot study using two concentrations of the growth factor (EGF- 1ng and 10ng/ml) was 
performed(Thwe A,2015). Cells were passaged and plated onto dishes, the dishes kept 
in the incubator and allowed to grow to confluence. After they were confluent the 
medium was aspirated off the dish and serum free-MEM was added for 24 hours. The 
following day the monolayer was scratched using a plastic white tip. After an hour the 
medium was changed to the test condition different concentrations of the growth 
factors was added.   
Data shown in Figure 4.19 are for different time points of 2, 4, 6 and 24 hours. The results 
suggested that the best time point was 24 hours.  
Scratch assay images showed variable migratory behaviour of different cell lines. Scratch 
assays of AZA1 cell line showed very little or no migratory response upon treatment with 
EGF and TGFα. Whereas HaCaT , TYS and HSG were stimulated to migrate in response to 































Figure 4.19 Investigation of different time points in the scratch migration assay 






































   C) 6 hours 





























D) 24 hours 







Figure 4.19: The HSG cell line was plated at 3x 10
5
 per dish (60% confluence) and grown until 
confluent changing the medium (10%FCS-MEM) every 48 hours. Once confluent the medium was 
changed to SF-MEM overnight. A scratch was made from one side of the dish to the other. The 
medium was changed into test condition (SF-MEM, 1ng/ml EGF and 10ng/ml EGF).   They were 
then incubated and the photomicrographs were taken after the time points above a) is 2 hours, 









Figure 4.20: Scratch  assay using HaCaT cells treated with different growth factors for 24 hours 
  
Figure 4.20: The HaCaT cell line was plated at 3x 10
5
 per dish (60% confluence) and grown until confluent 
changing the medium (10%FCS-MEM) every 48 hours. Once confluent the medium was changed to SF-MEM 
overnight. A scratch was made from one side of the dish to the other. The medium was changed into test 
condition (SF-MEM, 50ng/ml EGF and 50ng/ml TGFα).   They were then incubated and the 
photomicrographs were taken after 24 hours. Photograph showed that HaCaT cell line was stimulated to 





























Figure 4.21: The TYS  cell line was plated at 3x 105 per dish (60% confluence) and grown until 
confluent changing the medium (10%FCS-MEM) every 48 hours. Once confluent the medium was 
changed to SF-MEM overnight. A scratch was made from one side of the dish to the other. The 
medium was changed into test condition (SF-MEM, 50ng/ml EGF and 50ng/ml TGFα).   They were 
then incubated and the photomicrographs were taken after 24 hours. Photograph showed that 














































Figure 4.22: The HSG cell line was plated at 3x 10
5
 per dish (60% confluence) and grown until confluent 
changing the medium (10%FCS-MEM) every 48 hours. Once confluent the medium was changed to SF-MEM 
overnight. A scratch was made from one side of the dish to the other. The medium was changed into test 
condition (SF-MEM, 50ng/ml EGF and 50ng/ml TGFα).   They were then incubated and the 
photomicrographs were taken after 24 hours. Photograph showed that HSG  cell line was  stimulated to 





































Figure 4.23: The AZA1 cell line was plated at 3x 10
5
 per dish (60% confluence) and grown until 
confluent changing the medium (10%FCS-MEM) every 48 hours. Once confluent the medium was 
changed to SF-MEM overnight. A scratch was made from one side of the dish to the other. The 
medium was changed into test condition (SF-MEM, 50ng/ml EGF and 50ng/ml TGFα).   They were then 
incubated and the photomicrographs were taken after 24 hours. Photograph showed that AZA1 cell 
line was not stimulated to migrate in response to EGF and TGFα. 
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4.4.4 Changes in Protein expression by cancer cell lines in response to 
growth factors 
 
The four cell lines were investigated in respect of the expression of being epithelium-
like (E-Cadherin) or mesenchyme-like (vimentin) and how the growth factors EGF and 
TGFα may change this in terms of EMT.  The experiments undertaken to investigate this 
were immunoflourescence or SDS-PAGE/Western blotting. In the following experiments 
only changes in expression in response to the growth factors were investigated. 
Data presented in Figure 4.24 for the HaCaT cell line indicated that all the cells expressed 
strong level (as described in chapter3)of E-cadherin and it was mainly visualised on the 
cell membrane. The response to the growth factors indicated that with EGF some cells 
appeared to stain less well for E-cadherin.  However, less change was noted with TGFα. 
Vimentin staining did not appear to be present in the HaCaT cell line even when the 
growth factors were added.  
Data presented in Figure 4.25 for the TYS cell line indicated that all the cells expressed 
both E-cadherin and vimentin at moderate level. E-cadherin was mainly visualised on 
the cell membrane while Vimentin was visualised in the whole cells. There was no 
obvious difference between serum free and growth factor treated conditions 
Dat presented for Figure 4.26 for the AZA1 cell line indicated that little or no E-cadherin 
expression while Vimentin was highly expressed in certain area. For vimentin, both 
membranous expression and diffuse expression was found in photographs. 
Data presented in Figure 4.27 for the HSG cells line also indicated that little or no E-
cadherin expression while Vimentin was highly expressed in certain area. In compared 






























Figure 4.24: The HaCaT  cell line was plated at 1x 105 per dish (30% confluence) and EGF 
(50ng/ml) and TGFα (50ng/ml) were added. After 48 hours in test conditions the cells were fixed 
and stained as described in the materials and Methods. Photomicrographs were taken at 200x 
magnification. 
Figure 4.24: HaCaT cell line: Expression of markers of EMT (E‐cadherin and vimentin) and 
visualised with immunoflourescent secondary antibody. The cells response to growth factors. 
i)serum free: Ecadherin ii) seum free:Vimentin 
iii)50ngEGF/ml:E cadherin iv)50ngTGFα/ml:Vimentin 

































Figure 4.25: TYS cell line: Expression of markers of EMT (E-cadherin and vimentin) and visualised 
with immunoflourescent secondary antibody. The cells response to growth factors 
i)serum free: Ecadherin ii)serum free:Vimentin 
iii) 50ngEGF: Ecadherin iv) 50ngEGF:Vimentin 
v)50ngTGFα:Ecadherin vi)50ng TGFα:Vimentin 
Figure 4.25: The TYS cell line was plated at 1x 10
5
 per dish (30% confluence) and 
EGF (50ng/ml) and TGFα (50ng/ml) were added. After 48 hours in test conditions 
the cells were fixed and stained as described in the materials and Methods. 





























Figure 4.26: AZA1 cell line: Expression of markers of EMT (E-cadherin and vimentin) and 
visualised with immunoflourescent secondary antibody. The cells response to growth 
factors. 
i)serum free:E cadherin ii)serum free:Vimentin 
iii)50ngEGF:Ecadherin iv)50ng EGF:Vimentin 
v)50ng TGFα:Ecadherin vi)50ngTGFα/ml 
Figure 4.26: The AZA1 cell line was plated at 1x 10
5
 per dish (30% confluence) and 
EGF (50ng/ml) and TGFα (50ng/ml) were added. After 48 hours in test conditions the 
cells were fixed and stained as described in the materials and Methods. 

































Figure 4.27 HSG cell line: Expression of markers of EMT (E-cadherin and vimentin) and visualised with 
immunoflourescent secondary antibody. The cells response to growth factors. 
i) serum free:Ecadherin ii) serum free: Vimentin 
iii) 50ng EGF:Ecadherin 
iv)50ng EGF:vimentin 
v) 50ng TGFα: Ecadherin 
vi) 50ngTGFα: Vimentin 
Figure 4.27: The HSG cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) and TGFα 
(50ng/ml) were added. After 48 hours in test conditions the cells were fixed and stained as described in the 
materials and Methods. Photomicrographs were taken at 200x magnification. 
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Data presented in Figure 4.28 is for the expression of different proteins associated with 
EMT. Vimentin is a marker associated with mesenchymal cells. E cadherin is a marker 
associate with Epithelial cells.The four cell lines were grown to confluence, treated with 
the respective growth factors for 24 hours and then the cells lysed (as described in 
Chapter 3(3.14). Protein assay, SDS and Western blot were performed with Ecadherin 





Figure 4 .28: SDS-Page and Western blotting of Head and Neck cancer samples 
i) Vimentin   
                                     
 
a) E cadherin  
 
Figure 4.28: Western blot experiments for Vimentin (a) and E-Cadherin (b) in the 4 different cell 
lines with a spectrum of EGF and TGFα concentrations. (a) Vimentin expression in HaCaT, TYS, 
HSG and AZA1  EGF and TGFα concentrations of 1 ng/ml, 10 ng/ml and 50 ng/ml. All the cells 
were treated with the growth factors for 24 hours. (b) E-Cadherin expression in the same cell 




4.5. Result Summary  
 
4.5.1 Cell proliferation 
 
Table 4.2 Summary for cell proliferation 
 
Cell lines Serum 
free 


















































































 (Little or no effect can be defined as + or – 10% of the serum free result. This leads to 
our understanding that these growth factors have no proliferative effects.) 
 
4.5.2 Cell morphology / single cell migration 
 
Table 4.3 Summary for cell morphology / single cell migration 
 
  
Cell lines Serum free EGF50ng/ml TGFα50ng/ml 
HacaT  Tightly packed colonies, 
Complete epithelial 
characteristic. 
loosely connected cells 
with dendritic or spiky 
projection in some area 
loosely connected cells 
with dendritic or spiky 
projection in some area 
TYS  partially transformed 
into mesenchymal shape. 
More mesenchymal 
shape some with 
dendritic or spiky 
projection 
More mesenchymal 
shape dendritic or spiky 
projection 
HSG Epithelial shape colonies cell scattering, mixture 
of rounded cells and 
elongated cell, 
dendritic or spiky 
projection  in some cells 
cell scattering, smaller 
cells, mixture of rounded 
cell and elongated 
cells,dendritic or spiky 





Epithelial shape colonies cell scattering, mixture 
of rounded cells and 
elongated cells, 
dendritic or spiky 
projection in some cells 
cell scattering, mixture of 
rounded cell and 
elongated  
dendritic or spiky 
projection in some cells 
  
4.5.3 Collective Cell migration 
Table 4.4. Summary for collective cell migration 
Cell lines Serum free EGF50ng/ml TGFα 50ng/ml 
HaCaT Visible scratch line Fully migration, gap  
closure in most area 
Fully migration, gap  
closure in most 
area 
TYS Visible scratch line Fully migration, gap  
closure in most area 
Fully migration, gap  
closure in most 
area 
HSG  Visible scratch line Moderate 
migration, visible, 
gap still visible  
Moderate 
migration, visible, 
gap still visible 
AZA1 Visible scratch line Very little migration Very little 
migration 
 
4.5.4 Immunofluorescence  





treated        
E-cadherin  Vimentin  
HaCaT Serum free  Strong 
expression  
Very little or no expression  
EGF50ng/ml Strong 
expression 





Very little or no expression 











AZA1 Serum free Very little or no 
expression 
Strong expression 







Very little or no 
expression 
Strong expression 
HSG Serum free Very little or no 
expression 
Strong expression 
EGF50ng/ml Very little or no 
expression 
Strong expression  
TGFα 
50ng/ml 
Very little or no 
expression 





In this chapter, effects of EGF and TGFα on proliferation, morphology changes, migration 
were investigated by a variety of technique. 
For proliferation, EGF and TGFα did not increase the cell proliferation. 
In contrast, both EGF and TGFα induce EMT like morphological changes and cell 
migration. Expression of EMT markers E-cadherin and Vimentin were neither increased 
nor decreased followed by growth factors treatment. 
4.6. 1 Proliferation 
We have discussed in the introduction that some growth factors induce cellular 
proliferation. We wanted to investigate whether EGF or TGFα could have similar effect.  
Growth curve data in response to both EGF and TGFα indicated that both growth factors 
had no effect or a negative effect on cell proliferation of epithelial cell lines from the 
Head and Neck region used in this study. This is an unusual finding. This is an unusual 
finding in that the established literature suggests that the growth factors both increase 
the proliferation of epithelial cells ( Anchan RM, 1991). The data for the cell growth curve 
used were in the normal range, 1ng/ml, 10ng/ml, 50ng/ml concentration of both EGF 
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and TGFα were added into cells plated at 30mm dishes. Cells were counted by using 
automated cell counter. Data from these experiments found that the results are 
inconsistent and there is little or no effect of EGF and TGFα on proliferation of HSG, 
AZA1, HacaT, and TYS cell lines. Earlier work from our laboratory indicated that these 
growth factors stimulated the proliferation of fibroblast cell lines (Banyard, 1997 PhD 
thesis). However, very few papers are produced where either no effect or a negative 
effect of growth factors are reported. One of the few that was found by (Aladib et 
al.,1990) used two of the cell lines used in this Chapter (HSG and AZA1). Their reported 
findings are consistent with ours. Other projects in the laboratory have also indicated 
that these growth factors do not stimulate the proliferation of these 4 cell lines. 
However, these projects used a smaller range of concentrations (1 and 10ng/ml). Here 
we widened the range but found the same results. Literature also confirm that 
myoepithelial cells from pleomorphic adenoma (Navarini, 2015) reported that both 5 
and 10ng/ml of EGF had no effect on proliferation. 
In contrast, TGFα reported to upregulate proliferation of granulosa cell tumour (Cheng 
Wang, 2012). These results are different from my results. However, these cells are from 
a different area of the body and under hormonal control which may explain the 
difference in the findings. Other factors that may make the response to growth factors 
are the matrix cells are grown on. HSG cells respond differently to growth factors 
depending on their differentiation state. By growing cells on Matrigel they were found 
to respond to nerve Growth Factor (NGF) (Zheng et al., 1998, Lam K et al., 2005). It may 
be that the matrix cells are grown on will influence how they proliferate. Future 




Other elements that could influence the effect of growth factors on the cells have been 
reported by (Johnson et al., 1993). They noted that in certain cell lines the growth factors 
EGF and TGFα have an inhibitory effect on proliferation due to the presence of 
endogenous levels of growth factors and EGFR over expression (Johnson et al., 1993). In 
this study we did not investigate this and it may be an area for future research  
 
This leads to the question that do neither EGF nor TGFα stimulate cell proliferation in 
tested cell lines or could it be the wrong choice of assay. It was decide in the long run 
that proliferation of cells was not the long-term goal of the project and that we would 
concentrate efforts on the motility of the cells used. For proliferation it would be better 
to confirm using alternative techniques to measure cell proliferation such as MTT or 
BrDU assays as to whether the growth factors would affect it.  
Although the data could be viewed as a negative in terms of proliferation data they 
provided some useful insight into both the plating and saturation densities of each cell 
type and the level of growth factor that could be added to the cells in culture. 
4.6.2:  EMT, single cell migration and collective cell migration 
Experimental data from this project support hypothesis of the study. We discovered two 
types of cancer cell migration. Individual cell migration and collective cell migration. The 
contrast between collective cell migration where cells move as groups or sheets (Figure 
4.29 a, b) and individual cell movement where cells need to break contacts and move 
individually is quite stark(Figure 4.30 a, b) (Friedl, 2009).Collective cells movement 
follows three principles in that cells remain: 1) attached both physically and functionally. 
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2) The polarity causes the actin filaments to generate traction.  3) The cells are able to 
modify the tissue in their path (Friedl,2009). 
 
          
                 a                                         b 
Figure 4.29  collective cell migration: HSG cells plated onto the surface of a plastic tissue 
culture dish were grown to confluency. They surface was scratched and the migration 
noted after 24 hours. Note the gap has narrowed No single cell are visible in the gap so 
we surmise that the cells have moved as a collective a) HSG cells in time 0, b) HSG cells 
after 24 hours (Magnification:200x ). 
 
In individual cell migration, cells to cell contacts are lost with and there is the formation 
of ameboid or mesenchymal phenotype (Figure 4.30 a and b). Cell produce different 
types of extensions when they migrate: Filopodia (finger like projection), lamellipodia 
(broad like protrusion), podosomes and invadopodia are cellular protrusion which forms 




                        a                                                    b 
Figure 4.30 single cell migration: HSG cells plated onto the surface of a plastic tissue 
culture dish were grown to 50% confluency. EGF 50ng/ml was added into the dish. After 
48 hours, the cells became scattering with some projection appeared.  a) HSG cells in 
serum free, b) HSG cells in EGF 50ng/ml (200X magnification). 
   
EGF and TGF α induce morphological changes in all the cell lines but intensity of changes 
were different with each cell line. In HaCaT cell line, that morphology changes induced 
by EGF and TGFα treatment is minimum compared with HSG and AZA1 cells line. Cell 
scattering was not found in HaCaT. There was no complete transformation of EMT in 
response to EGF and TGFα. In TYS cell line, Introduction of EGF and TGFα induced  
scattering of some cells, more mesenchymal shape and dendritic projection.  
 In HSG and AZA1 cell line, scattering of cells was observed after EGF and TGFα 
treatment.  
   Ameboid                      mesenchymal  
 




Cell scattering is the process in which epithelial cells colonies are scatter into an 
individual cells with mesenchymal like morphology with dendritic or spiky projection. 
Cell scattering could also regarded as individual cell migration. Cell scatter can be used 
to detect EMT. Dendritic and spiky projection are also sign of migration  
One study found out cell scattering in MCF-7 cells followed by introduction of EGF (KimJ, 
2016). Another study also reported cell scattering induced by TGFα treatment (Hasina 
R, 1999). Results from this project was matched with their finding. 
 
Migration of cells in scratch assay is believed to be collective cell migration. Full closure 
of scratch line was found in TYS and HacaT cells line. HSG cells migrate across the scratch 
line while there is no obvious migration of AZA1 cell lines. Combination of two 
techniques give an idea of cells might use both single cell migration and collective cell 
migration.  
Data from this project support our hypothesis of EGF and TGFα induce EMT and cell 
migration.  
This data also matched with other literatures which stated that EGF and TGFα induce 
EMT, cell scattering and migration (Thiery & Sleeman, 2006, KimJ, 2016, Hasina R, 1999  
Ohnishi et al.,l 2017).  
4.6.3 Discussion for EMT markers 
Theoretically, EGF and TGFα induced EMT in both normal and cancer cell lines. E 
cadherin (most common epithelial marker) is supposed to be lower in EMT while 
vimentin (mesenchymal markers) is expected to high (Thiery & Sleeman 2006, Neilson 
& Zeisberg 2009, Lee JM 2006). Upregulation of E-cadherin expression in cancer is 
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associated with increase disease free survival (Ren X,2016). In contrast, EMT (down 
regulation of Ecadherin and upregulation of vimentin) is related with cancer progression 
(Myong H 2012, Nijkamp et al 2011, Schipper J et al 1991). In fact, EMT is reported to be 
related with resistance to TKIs (Weng et al., 2019).  So, it is important to know E cadherin 
and Vimentin status of the cells in this project.  All the cells lines used in this project 
were tested with E-cadherin and vimentin antibodies to understand whether the cells 
are epithelial or mesenchymal characteristic by using western blot and 
immunofluorescence. Western blot measured the total amount of protein while 
immunofluorescence localized protein in specific area of the cells. In western blot, we 
found out HacaT cells line has strong E-cadherin and no vimentin expression making 
complete epithelial characteristic. In contrast,TYS, HSG and AZA1 showed EMT( no 
Ecadherin and strong vimentin). This is quite surprising since HSG and AZA1 look 
morphologically similar to epithelial cells. However, this might be because of these cells 
were grown in 2D condition. (Royce et al., 1993) reported differentiation of HSG cells on 
Matrigel. In western blot, there was no change in intensity of E-cadherin and vimentin 
expression between growth factor treated dishes and control dishes even though EMT 
like phenotypic changes appeared in growth factor treated dishes. Experimental data 
like that did not appear to support hypothesis of the study. However, one thing to 
consider is that cells in this writer’s project were lysed after 48 hours when they changed 
their morphology. Results from other study observed E cadherin level is decreased after 
73 hours followed in EGF treated dishes (Kim J, 2016). So, it might be good idea to wait 
at least 72hrs to measure E-cadherin and vimentin expression in future experiments. 
In immunofluorescence, we also found out transformed cell lines are low Ecadherin and 
high vimentin while epithelial cell line has stong Ecadherin with low vimentin expression. 
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This data is supported by a series of literatures (Thiery & Sleeman 2006,Neilson & 
Zeisberg 2009, Lee JM 2006). In addition, we also found out, some HaCaT cells in EGF 
treated dish appeared to stain less well for E-cadherin. There was also  Ecadherin 
internalization in some of the HaCaT cells followed by EGF treatment. These data  also 





Chapter 5 To investigate the effects of inhibitors 
on cell scattering, migration and the localisation 
and expression of signalling molecules in growth 






Results in the previous Chapter established that both growth factors stimulate the 
migration of the tumour cells and appear to work via an EMT-like mechanism. However, 
it is may not be the only mechanism that the cells use. How that mechanism is initiated 
and controlled is the essence of the work in this following chapter. It is known that the 
inhibition of certain pathways can be used in cancer therapies. Work in this Chapter will 
focus around the receptor for both growth factors EGFR and will investigate using “off 
the shelf” inhibitors.  
5.1.1 Background 
 
The receptor EGFR is a transmembrane tyrosine kinase receptor which belongs to 
EGFR/ErbB family (Roskoski 2014, Salomon et al., 1995). It has been reported that EGFR 
is overexpressed in 80% to 90% of head and neck cancer (Kalyankrishna & Grandis, 2006) 
(Reuter et al.,2007). The growth factors EGF and TGFα are ligands that bind to EGFR. 
Ligand binding results in the dimerization of EGFR, the phosphorylation and activation 
of a number of downstream signaling pathways. About 6 tyrosine residues are 
phosphorylated at the COOH-terminal tail of EGFR: they are Y1068, Y1148, 
Y1173(Downward et al.,1984) ,Y1086 (Hsuan et al., 1989, Margolis et al., 1989), Y992( 
Walton  et al.,1990) Y1045 (Levkowitz et al.,1999). 
Phosphorylation of EGFR at Y1068 and Y1086 creates binding sites for Grb2 adaptor 
protein, leading to activation of the MAPK pathway and a binding site for Gab1, which 
recruits the p85 subunit of PI3-kinase, which in turn can and activate the AKT 
pathway(Rodrigues et al., 2000).Phosphorylation of tyrosine residue Y1068 has been 
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suggested to be a predictive biomarker for tyrosine kinase inhibitors treatment for 
patient with wildtype EGFR in lung cancer patients(Wang et al., 2012, Sette et al., 2015). 
In this chapter, phosphorylation of Y1068 EGFR was analysed by Western blot while 
localization of total EGFR was examined by immunofluorescence. 
MAPKs is a family of serine/threonine kinase proteins which play an important role in a 
variety of cellular process such as cell proliferation, migration and apoptosis. One of the 
constituents of the MAPK pathway (p44/42 ERK1/2) is activated by growth factors and 
cytokines (Peng et al., 2018). Targeting Ras-Raf-MEK-ERK pathway is important in 
treatment of cancer.  MEK1 and MEK2 activate P44 and P42 through phosphorylation at 
Thr202/Tyr204 and Thr185/Tyr187, respectively. In this chapter, phosphorylation of 
MAPK202/204 was measured by Western blot and localisation of MAPK202/204 was 
examined by immunofluorescence.  PD98059 which is a selective inhibitor of MAPK 
extracellular signaling-regulated kinase (ERK) kinase (MEK), was used in the experiment. 
PI3K- AKT pathway is another pathway that plays an important role in carcinogenesis 
and activation of PI3K is induced by introduction of growth factors. In this chapter, 
phosphorylation of Akt-473 is measured by Western blot and localization of Akt-473 is 
observed by immunofluorescence. As described in introduction. Phosphorylation of Akt-
473 is related with inhibition of apoptosis (Hemmings, 1997, Itoh et al., 2002) and 
mutation of Rb1 is causative factor of Akt-473 phosphorylation (El-Naggar et al., 2009).  
There are two types of drug specifically targeting EGFR. The first type of drugs are 
Monoclonal antibodies used to target EGFR overexpression. Monoclonal antibodies 
compete with ligands to bind EGFR. (Martinelli et al., 2009). The second type are the 
small molecules tyrosine kinase inhibitors targeting EGFR mutation (Ciardiello & Tortora, 
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2008, Modjtahedi & Essapen, 2009). Tyrosine kinase inhibitors bind to the cytoplasmic 
region of EGFR by competing with ATP and inhibit the phosphorylation of the receptor.  
Gefitinib and Erlotinib are example of TKIs which have been used to treat Non-Small Cell 
Lung Cancer. None of TKIs has yet received FDA approval to treat head and neck cancer, 
they are undergoing clinical trials but early reports are not encouraging (Chua et al., 
2008, Li & Perez-Soler, 2009, Soulieres et al., 2004). One of the possible reason for this 
is the activation of downstream signalling pathways such as ERK (Wakeling et al., 2002).  
K-ras mutation has also been reported to be related with resistance to tyrosine kinase 
inhibitors in non-small cell lung cancer (Massarelli et al., 2007). Previous studies 
reported that EMT is believed to be the underlying mechanism of drug resistance to TKIs 
in both NSCLC and HNSCC (Weng et al., 2019, Maseki et al., 2012, Frederick et al., 2007 
Uramoto et al., 2010). 
In this study, we are going to investigate whether EGF and TGFα induce EMT or not and 






Figure 5.1 Example of cellular projection: TYS cells plated onto the surface of a plastic 
tissue culture dish grown in colonies. However, in response to serum or individual growth 
factors TYS cells start by forming projections (blue arrow) and then migrate across the 
dish (40x magnification) (Red arrow).  
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5.2 Aim and hypothesis 
Studies in this chapter of thesis will explore the effect of Tyrosine kinase inhibitors 
(Gefitinib, Erlotinib) and ERK1/2 inhibitor (PD98059) by pre-treatment of these 
inhibitors on migration and morphological changes before addition of EGF and TGFα and 
investigate whether these inhibitors inhibit the effect of EGF and TGFα. 
It has also been reported in the literature that EGFR TKIs can reverse these changes in 
vitro for other cancers (La Monica et al 2013, Fichter et al 2014). In the previous chapter, 
we reported that EGF and TGFα have an effect on cell morphology and migration. This 
chapter will involve the investigation of whether the tyrosine kinase inhibitors (Gefitinib, 
Erlotinib) and ERK1/2 inhibitor (PD98059) inhibit these changes. Experiments will aim to 
observe the localization and the expression and distribution of EGFR and the 
phosphorylation of one of its tyrosine residues (P-Tyr 1068). The aim is also to observe 
the expression of signalling molecules MAPK202/204 and AKT473 as markers of change 
in response to both the growth factors and inhibitors.  
The working hypothesis is changes caused in previous chapter can be inhibited by 
blocking the receptor signalling pathways.  
The null- hypothesis of this Chapter is that the inhibitors of EGFR and MAPK have no 




5.3 Experimental Methods 
 
The methods used in this Chapter are found in Chapter 3. The following parts are the 
specific experiments which deal with the role of the inhibitors. 
5.3.1 General Tissue Culture for Scratch assay 
 
Cells were sub-cultured as described in 3.5. Once the experiment outlines were decided 
either 35mm or 60mm would determine how the dishes were prepared. The 
trypsin/media mixture was aspirated off and then cell pellet  was re- suspended in the 
appropriate volume of 10% FCS  1ml for 35mm or 2ml for 60mm. Fresh dishes were 
prepared, the number and size would depend on the intention of the experiments, 
adding 1mls of 10% FCS to each of 35mm dishes (or 2ml for 60mm). The cells suspension 
of   1x105 (or 3 x105 for 60mm) was then added into the prepared dishes and the cultures 
incubated at 37°C. Once the cell reach the desired confluency, the cells were changed 
into serum free media for 24 hours. On the next day, the medium were refreshed with 
Gefitinib, Erlotinib, and PD98059 before addition of growth factors an hour later. 
5.3.2 Scratch assay  
 
The cells were seeded at 1x105per dish. Once the cells reached 90% to 100% confluence. 
They were put into serum free and left overnight. After 24 hours, a uniform scratch line 
was made by using white pipette tips. The dishes were washed with serum free two 
times to remove the debris and then  5µM Gefitinib, 5µM Erlotinib and 25µM PD98059 
were added into the dishes one-hour prior addition of EGF and TGFα. Photographs were 




As described in detail in Chapter 3 section 11, immunofluorescence technique were 
performed with Anti EGFR antibody with 1:300 dilution, Phospho P44/42 
MAPKErk1/2)(Thr202/tyr204) and Phospho-473 Akt with 1:200 dilution respectively. 
5.3.4 SDS and Western blot  
 
As described in Chapter 3, SDS and Western blot were performed with phosphor- EGFR 
(Tyr1068) antibody with 1:1000 dilution, Phospho- P44/42 MAPK (Erk1/2) 
(Thr202/tyr204) and Phospho-473 Akt antibodies with 1:2000 respectively. Cells treated 
with serum free control and tested conditions for 5 minutes and 24 hours were put into 
the lane as table below.  
Table 5.1 Western blot lanes and test condition 
Lane 1 Serum free 
 Lane 2 EGF 50ng/ml 
 Lane 3 TGFα 50ng/ml 
 Lane 4  5µM Gefitinib+EGF 50ng/ml 
 Lane 5  5µM Gefitinib+TGFα 50ng/ml 
 Lane 6  5µM Erlotinib+EGF 50ng/ml 
 Lane 7 5µM Erlotinib+TGFα 50ng/ml 
 Lane 8 25µM PD98059+EGF 50ng/ml 







The results part of the chapter are split into the effect of the inhibitors on 
scattering/morphology changes, migration/gap closure, localisation of 
markers/immunofluorescence/SDS-PAGE/Western blotting into a number of different 
sections:  
5.4.1: Inhibitor concentrations of EMT and scattering assay  
Inhibitors were incubated on the cells for an hour before the addition of EGF (50ng/ml) 
and TGFα (50ng/ml). Photomicrographs were taken at two time points 24 and 48 
hours. In growth factor treated dishes, there was no significant change in cell 
morphology at the 24hours time point in most of the experiments (Discussed in chapter 
4). 
For the inhibitor treated dishes, the recommended dosage for Gefitinib and Erlotinib are 
1-10 µM for 0.5-2hr prior to treating with EGF and TGFα. It has been reported that it can 
be used up to 24 hr. The recommended dose for PD98059 is 5 - 50μM for one hour prior 
to treating with a stimulator. There was no suggested time limit for PD98059.   
In this pilot project, 3µM, 5µM and 10µM of (Gefitinib and Erlotinib) and 5µM, 25µM 
and 50µM of PD98059 were used as preliminary experiments. Later, 5µM of (Gefitinib 
and Erlotinib) and 25µM of PD98059 was chosen to do experiments because these are 
the concentrations which fully block the effect of EGF and TGFα without being toxic to 
the cells. In this project inhibitors were used up to 48 hour for monitoring of the 
morphology changes which is beyond the recommend time point from the 
manufacturer. Usually, the cells became unhealthy (full of debris-data not shown) by the 
end of experiment. We deduce from the photographic evidence that this is caused 
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by the effect of inhibitors since serum free (negative control) and growth factors 
(positive effects) treated dishes have no unhealthy cells. Photographs were also taken 
at 48 hour time point. Changes in cell morphology usually occurred around 48 hours’ 
time point. Once the photomicrographs were taken, cells were fixed for 
immunofluorescence. 
An example of preliminary experiment is shown in Figure 5.2: The HSG cell line was 
plated at 1x 105 per dish (30% confluence) and TGFα (50ng/ml) and the inhibitor 
Erlotinib was added at different concentrations (3µM, 5µM and 10µM). The 
photomicrographs show tight colonies in the serum free conditions and that the cells 
round and migrate apart in the presence of TGFα (Figure 5.2.i and ii). With the addition 
of the different concentrations of the inhibitor Erlotinib the cells morphology was 
restored to similar to serum free with all concentrations.   The data indicates that the 
cells morphology was restored to being similar to cells in Serum free conditions at all 
concentrations of Erlotinib but was decided to use  5µM of Erlotinib in the following 
experiments (similar results were seen with Gefitinib and cells required 25µM of 
PD98059 data not shown). It should also be noted that different magnifications were 
used here to emphasise the change in shape. The serum free being at a lower power to 
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5.4.2 HaCaT cell line in response to growth factors and inhibitors 
 
HaCaT cells are characterised and reported as a normal epithelial cell line, although they 
do have some peculiarities, in that they produce e-cadherin and no vimentin. In the 
following experiments the cells were plated onto dishes at 1x105 cells per dish and 
allowed to attach. The medium was changed to SF-MEM and the cells left overnight. The 
following day the medium was changed into test conditions and photomicrographs 
taken at various time-points (not all data shown). The test conditions are described in 
the Figure legend and it should be noted that the photomicrographs of the serum free, 
EGF treated and TGFα treated cells in all parts of Figure 5.3 are the same- they are shown 
like this for comparison to the inhibitors. 
Figure 5.3a shows the effect of the EGFR inhibitor Gefitinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a spindle shaped morphology in the cells Figure 5.3a.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor Gefitinib 
inhibits these changes (Figure 5.3a.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.3b shows the effect of the EGFR inhibitor Erlotinib (5µM) on EGF and TGFα 
stimulated cells. The photomicrographs indicate that both EGF and TGFα induced 
reduced cell-cell contact and a spindle shaped morphology in the cells Figure 5.5.5.1b.iii 
and v (Coloured arrows- yellow arrows indicate normal epithelial cell morphology and 
red arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor 
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Erlotinib inhibits these changes (Figure 5.5.5.1b.iv and vi). Note that the cell-cell contacts 
are intact and the cells retain their tightly formed colony status. 
Figure 5.3.c shows the effect of the MAPKinase inhibitor PD98059 (25µM) on EGF and 
TGFα stimulated cells. The photographs indicate that both EGF and TGFα induced 
reduced cell-cell contact and a spindle shaped morphology in the cells Figure 5.5.5.1c.iii 
and v (Coloured arrows- yellow arrows indicate normal epithelial cell morphology and 
red arrows indicate mesenchymal morphology). Treatment with the MAPkinase 
inhibitor inhibits these changes (Figure 5.5.5.1c.iv and vi). Note that the cell-cell contacts 





Figure 5.3a:HaCaT cell line in response to growth factors and Gefitinib: 
i)Serumfree                                            ii)Gefitinib5μM 
                 
iii)EGF 50ng/ml                                           iv)Gefitinib5μM+ EGF 50ng/ml                                            
             
v)TGFα 50ng/ml                                  vi)Gefitinib5μM+TGFα50ng/ml 
             
Figure 5.3a: The HaCaT cell line was plated at 1x 105 per dish (30% confluence) and 
EGF (50ng/ml) and TGFα (50ng/ml) were added with 5µM Gefitinib. The 
photomicrograph was taken after 48 hrs of addition of the test conditions. All 
micrographs were taken at 40x magnification. Treatments: i) SF-MEM, ii) 5µM 
Gefitinib, iii) 50ng/ml EGF, iv) 50ng/ml EGF/5µM Gefitinib, v) 50ng/ml TGFα, vi) 
50ng/ml TGFα/5µM Gefitinib.( yellow arrow indicates epithelial phenotype and red 
arrow indicates mesenchymal phenotype) 
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Figure 5.3.b: HaCaT cell line in response to growth factors and Erlotinib: 
 
i)Serum free                                ii)Erlotinib5μM 
        
iii)EGF50ng/ml                            iv)Erlotinib5μM+EGF50ng/ml 
      
v)TGFα50ng/ml                           vi)Erlotinib5μM+TGFα50ng/ml 
    
Figure5.3b The HaCaT cell line was plated at 1x105 per dish(30% confluence) and EGF(50ng/ml) and 
TGFα(50ng/ml) were added with 5μM Erlotinib. The photomicrograph was taken after 48 hrs of 
addition of the test conditions. All micrographs were taken at 100x magnification. Treatments: i)SF-
MEM,  ii) 5μM Erlotinib, iii) 50ng/ml EGF,  iv) 50ng/ml EGF / 5μM Erlotinib v) 50ng/ml TGFα, vi) 





Figure 5.3c: HaCaT cell line in response to growth factors and PD98059: 
 
i)Serum free                                   ii)PD98059 5μM 
    
iii)EGF50ng/ml                            iv)PD98059 5μM+EGF50ng/ml 
    
v)TGFα50ng/ml                          vi)PD98059 5μM+TGFα50ng/ml 
    
Figure 5.3c: The HaCaT cell line was plated at 1x 105 per dish (30% confluence) and 
EGF (50ng/ml) and TGFα (50ng/ml) were added with 25µM PD98059. The 
photomicrograph was taken after 48 hrs of addition of the test conditions. All 
micrographs were taken at 40x magnification. Treatments: i) SF-MEM, ii) 25µM 
PD98059, iii) 50ng/ml EGF, iv) 50ng/ml EGF/25µM PD98059, v) 50ng/ml TGFα, vi) 
50ng/ml TGFα/25µM PD98059. (yellow arrow indicates epithelial phenotype and red 





5.4.3 TYS cell line in response to growth factors and inhibitors 
 
TYS cells are characterised and reported as an oral squamous cell carcinoma, although 
there is some ambiguity in the original report (see Material and Methods). In the 
following experiments the cells were plated onto dishes at 1x105 cells per dish and 
allowed to attach. The medium was changed to SF-MEM and the cells left overnight. The 
following day the medium was changed into test conditions and photomicrographs 
taken at various time-points (not all data shown). The test conditions are described in 
the Figure legend and it should be noted that the photomicrographs of the serum free, 
EGF treated and TGFα treated cells in all parts of Figure 5.4 are the same- they are shown 
like this for comparison to the inhibitors. 
Figure 5.4a shows the effect of the EGFR inhibitor Gefitinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a spindle shaped morphology in the cells Figure 5.4a.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor Gefitinib 
inhibits these changes (Figure 5.4a.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.4b shows the effect of the EGFR inhibitor Erlotinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a spindle shaped morphology in the cells Figure 5.4.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor Erlotinib 
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inhibits these changes (Figure 5.4b.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.4c shows the effect of the MAPKinase inhibitor PD98059 (25µM) on EGF and 
TGFα stimulated cells. The photographs indicate that both EGF and TGFα induced 
reduced cell-cell contact and a spindle shaped morphology in the cells Figure 5.4c.iii and 
v (Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the MAPkinase inhibitor 
inhibits these changes (Figure 5.4c.iv and vi). Note that the cell-cell contacts are intact 




     Figure5.4a: TYS cell line in response to growth factors and Gefitinib:                 
i)Serum free                                                     ii)Gefitinib5μM 
  
iii)EGF50ng/ml                                            iv)Gefitinib 5μM+EGF50ng/ml 
                
v)TGFα 50ng/ml                                      vi) Gefitinib 5μM+ TGFα 50ng/ml                                       
            
Figure 5.4a: The TYS cell line was plated at 1x 105 per dish (30% confluence) and EGF (50ng/ml) and 
TGFα (50ng/ml) were added with 5µM Gefitinib. The photomicrograph was taken after 48 hrs of 
addition of the test conditions. All micrographs were taken at 40x magnification. Treatments: i) SF-
MEM, ii) 5µM Gefitinib, iii) 50ng/ml EGF, iv) 50ng/ml EGF/5µM Gefitnib, v) 50ng/ml TGFα, vi) 50ng/ml 







Figure 5.4b: TYS cell line in response to growth factors and Erlotinib: 
i)Serum free                                       ii)ErlotinibμM 
      
iii)EGF50ng/ml                             iv)Erlotinib5μM+EGF50ng/ml 
       
v)TGFα50ng/ml                         vi)Erlotinib 5μM+ TGFα50ng/ml                          
      
Figure5.4b The TYS cell line was plated at 1x105 per dish(30% confluence) and EGF(50ng/ml) and 
TGFα(50ng/ml) were added with 5μM Erlotinib. The photomicrograph was taken after 48 hrs of 
addition of the test conditions. All micrographs were taken at 100x magnification. Treatments: i) SF-
MEM,  ii) 5μM Erlotinib, iii) 50ng/ml EGF,  iv) 50ng/ml EGF / 5μM Erlotinib v) 50ng/ml TGFα, vi) 





 Figure 5.4c: TYS cell line in response to growth factors and PD98059: 
i)Serum free                                 ii)PD98059 
    
iii)EGF50ng/ml                                 iv)PD98059 25μM+ EGF50ng/ml                                  
    
v)TGFα50ng/ml                                 vi)PD98059 25μM+TGFα50ng/ml 
     
Figure5.4c: The TYS cell line was plated at 1x105 per dish(30% confluence) and EGF(50ng/ml) and 
TGFα(50ng/ml) were added with 25μM PD98059. The photomicrograph was taken after 48 hrs of 
addition of the test conditions. All micrographs were taken at 100x magnification. Treatments: i) SF-
MEM,  ii) 25μM PD98059, iii) 50ng/ml EGF,  iv) 50ng/ml EGF / 25μM PD98059 v) 50ng/ml TGFα, vi) 





5.4.4 AZA1 cell line in response to growth factors and inhibitors 
 
AZA1 cells are characterised and reported HSG cell line treated with 5 Azacytidine (see 
Materials ad Methods for description). In the following experiments the cells were 
plated onto dishes at 1x105 cells per dish and allowed to attach. The medium was 
changed to SF-MEM and the cells left overnight. The following day the medium was 
changed into test conditions and photomicrographs taken at various time-points (not all 
data shown). The test conditions are described in the Figure legend and it should be 
noted that the photomicrographs of the serum free, EGF treated and TGFα treated cells 
in all parts of Figure 5.5 are the same- they are shown like this for comparison to the 
inhibitors.  
Figure 5.5a shows the effect of the EGFR inhibitor Gefitinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a spindle shaped morphology in the cells Figure 5.5a.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor Gefitinib 
inhibits these changes (Figure 5.5a.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.5b shows the effect of the EGFR inhibitor Erlotinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced no cell-cell 
contact and produced a rounded shaped morphology in the cells Figure 5.5b.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). It should also be noted that a small number 
of the cells had a fibroblast morphology. Treatment with the EGFR inhibitor Erlotinib 
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inhibits these changes (Figure 5.5b.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.5c shows the effect of the MAPKinase inhibitor PD98059 (25µM) on EGF and 
TGFα stimulated cells. The photographs indicate that both EGF and TGFα induced 
reduced cell-cell contact and a spindle shaped morphology in the cells Figure 5.5c.iii and 
v (Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the MAPkinase inhibitor 
inhibits these changes (Figure 5.5c.iv and vi). Note that the cell-cell contacts are intact 




































  i) Serum free                                                                  ii)        Gefitinib5µM 
   
   
       iii) EGF 50ng/ml                                          iv) Gefitinib 5µM + EGF50ng/ml     
    v) TGFα50ng/ml             vi)  Gefitinib 5µM +TGFα50ng/ml 
Figure 5.5a: The AZA1 cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) 
and TGFα (50ng/ml) were added with 5µM Gefitinib. The photomicrograph was taken after 48 hrs 
of addition of the test conditions. All micrographs were taken at 40x magnification. Treatments: i) 
SF-MEM, ii) 5µM Gefitinib, iii) 50ng/ml EGF, iv) 50ng/ml EGF/5µM Gefitinib, v) 50ng/ml TGFα, vi) 
50ng/ml TGFα/5µM Gefitinib. (yellow arrow indicate epithelial phenotype and red arrow indicate 
mesenchymal phenotype) 
Figure 5.5a: AZA1 cell line in response to growth factors and Gefitinib: 
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Figure 5.5b: AZA1 cell line in response to growth factors and Erlotinib: 
   i) Serum free                                                      ii)    Erlotinib5µM 
   
   
iii) EGF 50ng/ml                iv)   Erlotinib 5µM + EGF50ng/ml     
v) TGFα50ng/ml    vi) Erlotinib 5µM +TGFα50ng/ml 
Figure 5.5b: AZA1 cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) and TGFα (50ng/ml) 
were added with 5µM Erlotinib.  The photomicrograph was taken after 48 hrs of addition of the test conditions. All 
micrographs were taken at 100x magnification. Treatments: i) SF-MEM, ii) 5µM Erlotinib, iii) 50ng/ml EGF, iv) 
50ng/ml EGF/5µM Erlotinib,v) 50ng/ml TGFα, vi) 50ng/ml TGFα/5µM Erlotinib. (yellow arrow indicate epithelial 






























  i) Serum free                                                                  ii)        PD98059 25µM 
   
   
       iii) EGF 50ng/ml                                          iv) PD98059 25µM + EGF50ng/ml     
    v) TGFα50ng/ml             vi)  PD98059 25µM +TGFα50ng/ml 
Figure 5.5c: AZA1 cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) and 
TGFα (50ng/ml) were added with 25µM PD98059. The photomicrograph was taken after 48 hrs of 
addition of the test conditions. All micrographs were taken at 40x magnification. Treatments: i) SF-
MEM, ii) 25µM PD98059, iii) 50ng/ml EGF, iv) 50ng/ml EGF/25µM PD98059, v) 50ng/ml TGFα, vi) 
50ng/ml TGFα/25µM PD98059. (yellow arrow indicate epithelial phenotype and red arrow indicate 
mesenchymal phenotype). 
Figure 5.5c: AZA1 cell line in response to growth factors and PD98059: 
186 
 
5.4.5 HSG cell line in response to growth factors and inhibitors 
 
HSG cells are characterised and reported as an epithelial duct cell line derived from 
human salivary gland (Adenocarcinoma of submandibular gland). In the following 
experiments the cells were plated onto dishes at 1x105 cells per dish and allowed to 
attach. The medium was changed to SF-MEM and the cells left overnight. The following 
day the medium was changed into test conditions and photomicrographs taken at 
various time-points (not all data shown). The test conditions are described in the Figure 
legend and it should be noted that the photomicrographs of the serum free, EGF treated 
and TGFα treated cells in all parts of Figure 5.6 are the same- they are shown like this 
for comparison to the inhibitors. 
Figure 5.6a shows the effect of the EGFR inhibitor Gefitinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a spindle shaped morphology in the cells Figure 5.6a.iii and v 
(Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the EGFR inhibitor Gefitinib 
inhibits these changes (Figure 5.6a.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. 
Figure 5.6b shows the effect of the EGFR inhibitor Erlotinib (5µM) on EGF and TGFα 
stimulated cells. The photographs indicate that both EGF and TGFα induced reduced 
cell-cell contact and a rounded morphology in the cells Figure 5.6b.iii and v (Coloured 
arrows- yellow arrows indicate normal epithelial cell morphology and red arrows 
indicate mesenchymal morphology). It is interesting to note that these changes are 
different between the two growth factors. Treatment with the EGFR inhibitor Erlotinib 
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inhibits these changes (Figure 5.6b.iv and vi). Note that the cell-cell contacts are intact 
and the cells retain their tightly formed colony status. However, the inhibitor treated 
cells do appear different in morphology from the serum free cells plus inhibitor 
suggesting that some aspects are inhibited but others are not.  
Figure 5.6c shows the effect of the MAPKinase inhibitor PD98059 (25µM) on EGF and 
TGFα stimulated cells. The photographs indicate that both EGF and TGFα induced 
reduced cell-cell contact and a spindle shaped morphology in the cells Figure 5.6c.iii and 
v (Coloured arrows- yellow arrows indicate normal epithelial cell morphology and red 
arrows indicate mesenchymal morphology). Treatment with the MAP-kinase inhibitor 
inhibits these changes (Figure 5.6c.iv and vi). Note that the cell-cell contacts are intact 








                     
 
 
                       
 
 
                  
    Figure 5.6a: HSG cell line was plated at 1x 105 per dish (30% confluence) and EGF 
(50ng/ml) and TGFα (50ng/ml) were added with 5µM Gefitinib. The photomicrograph was 
taken after 48 hrs of addition of the test conditions. All micrographs were taken at 40x 
magnification. Treatments: i) SF-MEM, ii) 5µM Gefitinib, iii) 50ng/ml EGF, iv) 50ng/ml 
EGF/5µM Gefitnib, v) 50ng/ml TGFα, vi) 50ng/ml TGFα/5µM Gefitnib. (yellow arrow indicate 
epithelial phenotype and red arrow indicate mesenchymal phenotype)                 
 
Figure 5.6a: HSG cell line in response to growth factors and Gefitinib: 
  i) Serum free                                                                  ii)        Gefitinib5µM 
   
       iii) EGF 50ng/ml                                          iv) Gefitinib 5µM + EGF50ng/ml     
    v) TGFα50ng/ml                            vi)  Gefitinib5µM +TGFα50ng/ml 
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Figure 5.6b: HSG cell line in response to growth factors and Erlotinib: 
   i) Serum free                                                      ii)    Erlotinib5µM 
   
   
iii) EGF 50ng/ml                iv)   Erlotinib 5µM + EGF50ng/ml     
v) TGFα50ng/ml    vi)      Erlotinib 5µM +TGFα50ng/ml 
Figure 5.6b: HSG cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) and TGFα (50ng/ml) were added 
with 5µM Erlotinib.  The photomicrograph was taken after 48 hrs of addition of the test conditions.All micrographs were 
taken at 100x magnification. Treatments: i) SF-MEM, ii) 5µM Erlotinib, iii) 50ng/ml EGF, iv) 50ng/ml EGF/5µM Erlotinib,v) 































  i) Serum free                                                                  ii)        PD98059 25µM 
   
   
       iii) EGF 50ng/ml                                          iv) PD98059 25µM + 
EGF50ng/ml     
    v) TGFα50ng/ml             vi)  PD98059 25µM 
+TGFα50ng/ml 
Figure 5.5c: HSG cell line was plated at 1x 10
5
 per dish (30% confluence) and EGF (50ng/ml) and 
TGFα (50ng/ml) were added with 25µM PD98059. The photomicrograph was taken after 48 hrs 
of addition of the test conditions. All micrographs were taken at 40x magnification. Treatments: 
i) SF-MEM, ii) 25µM PD98059, iii) 50ng/ml EGF, iv) 50ng/ml EGF/25µM PD98059, v) 50ng/ml 
TGFα, vi) 50ng/ml TGFα/25µM PD98059.  (yellow arrow indicate epithelial phenotype and red 
arrow indicate mesenchymal phenotype) 




5.4.6 Results of Cell migration assay  
 
The cells lines that were described in the previous chapter were studied here in this 
chapter. The idea behind this was to investigate a more deliberate migration of the cells. 
The Scratch assay has a much more obvious migration point and is measured by gap 
closure. Cells were grown to confluence and then scratched and the dishes 
photographed. The cells were then placed in the test medium and photomicrographs 
taken every 2 hours for 8 hours and then again when the gap closed. 
5.4.7 Pilot experiment to investigate the best time point in the scratch 
assay 
 
The HSG cell line was chosen to investigate the best time point for investigating cell 
migration by gap closure or scratch assay.  An example of preliminary experiment is 
shown in figure 5.7 in the following experiment the cells were plated onto dishes at 
3x105 cells per dish and grown until confluent changing medium 10% FCS every 48 hours. 
Once confluent the medium was changed to SF-MEM overnight. A scratch was made 
from one side of the dish to the other. The medium was changed into test conditions 
(1ng/ml and 10ng/ml of EGF). Photographs were taken at 2 hours, 4 hours, 6 hours and 








5.4.8 Experimental data for TYS cell line in response to growth factors 
and inhibitors using the gap closure/scratch assay 
 
 In the following experiments TYS were plated onto dishes at 3x105 cells per dish and 
grown until confluent changing medium 10% FCS every 48 hours. Once confluent the 
medium was changed to SF-MEM overnight. A scratch was made from one side of the 
dish to the other. The medium was changed into test condition. They were then 
incubated and the photomicrographs were taken after 24 hours. The test conditions are 
described in the Figure legend. 
Figure 5.8a, b andc shows the effect of Gefitinib (5µM), Erlotinib (5µM) and PD98059 
(25µM) on EGF and TGFα stimulated cells. The photographs indicate that both EGF and 
TGFα induced migration in the cells of TYS cells (Figure 5.9 iii and 5.9v). One hour pre-
















5.4.9 Experimental data for HaCaT cell line in response to growth factors 
and inhibitors 
 
 In the following experiments HaCaT were plated onto dishes at 3x105 cells per dish and 
grown until confluent changing medium 10% FCS every 48 hours. Once confluent the 
medium was changed to SF-MEM overnight. A scratch was made from one side of the 
dish to the other. The medium was changed into test condition. They were then 
incubated and the photomicrographs were taken after 24 hours. The test conditions are 
described in the Figure legend. 
Figure 5.9a, b and c shows the effect of Gefitinib (5µM), Erlotinib (5µM) and PD98059 
(25µM) on EGF and TGFα stimulated cells. The photographs indicate that both EGF and 
TGFα induced migration in the cells of HaCaT cells (Figure 5.9 a, b and c). One hour pre-

















5.4.10 Experimental data for HSG cell line in response to growth factors 
and Inhibitors 
 
 In the following experiments HSG were plated onto dishes at 3x105 cells per dish and 
grown until confluent changing medium 10% FCS every 48 hours. Once confluent the 
medium was changed to SF-MEM overnight. A scratch was made from one side of the 
dish to the other. The medium was changed into test condition. They were then 
incubated and the photomicrographs were taken after 24 hours. The test conditions are 
described in the Figure legend. 
Figure 5.10a, b and c shows the effect of Gefitinib (5µM), Erlotinib (5µM) and PD98059 
(25µM) on EGF and TGFα stimulated cells. The photographs indicate that both EGF and 
TGFα induced migration in the cells of HSG cells (Figure 5.9 a, b and c). One hour pre-
treatment with Gefitinib, Erlotinib and PD98059 inhibits these migration (Figure 5.9 a, b 
















5.4.11 Experimental data for AZA1 cell line in response to growth factors 
and Inhibitors 
 
 In the following experiments HSG were plated onto dishes at 3x105 cells per dish and 
grown until confluent changing medium 10% FCS every 48 hours. Once confluent the 
medium was changed to SF-MEM overnight. A scratch was made from one side of the 
dish to the other. The medium was changed into test condition. They were then 
incubated and the photomicrographs were taken after 24 hours.The test conditions are 
described in the Figure legend. 
Figure 5.11 a, b and c shows the effect of Gefitinib (5µM), Erlotinib (5µM) and PD98059 
(25µM) on EGF and TGFα stimulated cells. The photographs indicate that both EGF and 
TGFα induced migration in the cells of HSG cells (Figure 5.11 a, b and c). One hour pre-
treatment with Gefitinib, Erlotinib and PD98059 inhibits these migration (Figure 5.11 a, 













5.4.12 Changes in protein expression by cancer cell lines in response to 
growth factors and inhibitors 
 
The the previous chapter the four cell lines were investigated in respect of the 
expression of being epithelium-like (E-Cadherin) or mesenchyme-like (vimentin) and 
how the growth factors EGF and TGFα may change this in terms of EMT.  However, how 
the growth ractors worked in terms of binding to cell surface receptors and signalling 
pathways was not inviestigated. However, initial data indicated that the inhibitors 
worked by blocking EMT. It was decided to invetigate the repcetor expression and 
signalling pathways involved in this.  The experiments undertaken to investigate this 
were immunoflourescence or SDS-PAGE/Western blotting. In the following experiments 
only changes in expression in response to the growth factors were investigated. 
 
5.4.13 Localization of EGFR and phosphorylation of EGFR (Tyr1068) 
residue 
In order to determine the expression of total EGFR on the cell membrane localisation of 
the receptor was determined by immunofluorescence. The photomicrographs are 
shown in Figure 5.12, 5.13, 5.14 and 5.15. EGFR expression was found in serum free and 
growth factors treated dishes of all cell lines. EGFR internalization was captured in some 
of the dishes. In AZA1 cell line (Figure 5.14), receptor internalization was seen in both 
the EGF and TGFα treated dishes after 48 hours. The HSG cell lines also showed receptor 
internalization in both serum free and growth factors treated dishes (Figure 5.15). There 
is no clear information about receptor internalization in TYS and HaCaT cell lines due to 




















Figure 5.12 The TYS cell line expression of total EGFR 
i) Serum Free 
     ii) EGF (50ng/ml) 
  
     iii) TGFα (50ng/ml) 
  
Figure 5.12 The TYS cell line was plated at 3x 10
5
 per dish and EGF (50ng/ml) and TGFα 
(50ng/ml). Staining for total EGFR. All micrographs were taken at 40x magnification. 








Figure 5.13 The HaCaT cell line expression of  total EGFR  
     ii) EGF (50ng/ml) 
  
i) Serum Free 
     iii) TGFα (50ng/ml) 
  
Figure 5.13 The HaCaT cell line was plated at 3x 10
5
 per dish and EGF (50ng/ml) and 
TGFα (50ng/ml). Staining for total EGFR. All micrographs were taken at 40x 

































Figure 5.14 The AZA1 cell line expression of total EGFR  
i) Serum free 
ii) EGF 50ng/ml 
iii) TGFα 50ng/ml 
Figure 5.14 The AZA1 cell line was plated at 3x 10
5
 per dish and EGF (50ng/ml) and 
TGFα (50ng/ml). Staining for total EGFR. All micrographs were taken at 40x 
































Figure 5.15 The HSG cell line expression of total EGFR  
i) serum free 
ii) EGF 50ng/ml 
iii) TGFα 50ng/ml 
Figure 5.15 The HSG cell line was plated at 3x 10
5
 per dish and EGF (50ng/ml) and 
TGFα (50ng/ml). Staining for total EGFR. All micrographs were taken at 40x 
magnification. Treatments: i) SF-MEM, ii) 50ng/ml EGF, iii) 50ng/ml TGFα 
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5.4.14  Phosphorylation of EGFR (Tyr1068) residue 
 
In the previous section it was noted that the expression of phosphorylated EGFR 
(Tyr1068) could not be determined in two of the cells lines by localisation studies. It was 
decided to investigate whether the residue was phosphorylated in the HaCaT and also 
the Tys cell line. Using Western blotting techniques we could determine the total level 
of phosphorylation in the cell lines but not where the expression occurred. 
 
Figure 5.16 indicates that EGFR tyrosine residue 1068 was phosphorylated in all 
conditions even in tyrosine kinase inhibitor treated dishes. Therefore it is safe to assume 
that the lack of reduction on this residue means that this pathway is not the most 












5.4.15 Localization and phosphorylation of MAPK (Thr202/Tyr204) 
residue 
 
In all four cell lines, MAPK202/204 was expressed in EGF and TGF treated dishes in both 
5 mins and 24 hours’ time point. Tyrosine kinase inhibitors (Gefitinib and Erlotinib) fully 
blocked MAPK202/204 expression in TYS and HaCaT cell line while in HSG and AZA1 cell 
lines, MAPK 202/204 expression was reduced from 5 mins to 24hours time point.  In 
contrast, ERK1/2 inhibitorPD98059 was partially expressed in all the cell lines. There 
might be a reason why MAPK202/204 was phosphorylated in PD98059 treated dishes. 
Dose of PD98059 might not be high enough to fully inhibit the phosphorylation. 
According to manufacturer data sheet, 20µM did not fully inhibit phosphorylation while 
50µM completely inhibit the phosphorylation. This could be overcome by increasing 
concentration.   
In immunofluorescence, SF treated dishes have very light expression of MAPK202/204. 
Addition of 50ng/ml EGF and TGFα50ng/ml for 48 hours caused increase expression of 
MAPK202/204. In contrast, dishes with (one hour pre-treated with Gefitinib, Erlotinib 
and PD98059 before addition of EGF and TGFα) blocked MAPK202/204 expression fully.  
In immunofluorescence, addition of 50ng/ml EGF and TGFα50ng/ml for 48 hours caused 
increase expression  of phospho MAPK202/204 in 3 cell lines(HSG,AZA1,TYS). In 
contrast, tyrosine kinase inhibitors blocked its expression fully.  ERK1/2 
inhibitors(PD98059) inhibit its expression in HSG and AZA1 cell line, not in TYS cell lines. 


















































5.4.16 Localization and phosphorylation of Akt (Ser 473) residue 
   
The Akt pathway is the one most studied in our laboratory. The response to both growth 
factors and all three inhibitors was studied in all 4 cell lines. Studies of immune 
localization of the phosphorylated protein were inconclusive in 3 of the cell lines (data 
not shown). 
SDS-Page/Western blotting experiments were also interesting in terms of the 
phosphorylated Akt. Data presented in Figure 22, AZA1 cell line has no AKT 
phosphorylation in all the test conditions. The HaCaT cell line (normal) has AKT 
phosphorylation in EGF, TGFα and PD98059 treated dishes while tyrosine kinase 
inhibitors fully block AKT 473 phosphorylation. TYS and HSG cell lines, AKT was 
expressed in 5 mins time point in all conditions. However, expression was reduced in 
tyrosine kinase inhibitor treated dishes at the 24 hours’ time point. 
 
Data presented in Figure 23a, b and c shows that the localisation of p473Akt is low in 
the TYS cell type (and not really seen in the other cell lines). The expression of pAKT-473 
was faintly distributed through in EGF and TGFα treated dishes while did not express in 

























5.5 Result Summary 
 
The following tables summarise the results for this Chapter and will lead into the 
Discussion 5.6.  
 
5.5.1 EMT or single cell migration  
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5.5.2  Scratch assay or collective migration  
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Table  5.3b Scratch assay or collective migration 
 
 
Cell lines  Erlotinib5µl  
+EGF50ng/ml  






TYS   Same as Serum 
free  






Little  migration with  
intact scratch line 
HaCaT    same as Serum 
free  





HSG  same as Serum 
free  
same as Serum 
free  
same as Serum 
free  
same as Serum free  
AZA1   
  
same as Serum 
free  
same as Serum 
free  
same as Serum 
free  
same as Serum free  
 
5.5.3 Expression and Localisation of EGFR and its phosphorylated sub-type 
(Tyr1068) 
Table 5.4 Expression and Localisation of total EGFR  
 
Total EGFR  HSG  AZA1 TYS HACAT 
Serum free membrane membrane Membrane  Membrane  
EGF Nucleus ,diffuse 
cytoplasm 
Diffuse cytoplasm Diffuse Cytoplasm Diffuse cytoplasm 
TGFα Nucleus ,diffuse 
cytoplasm 












Table 5.5 Expression of phosphorylated EGFR sub-type (Tyr1068) 
 
Phospho EGFR (1068) HSG AZA1 TYS HACAT  
Serum free + + + + 
EGF + + + + 
TGFα + + + + 
Gefitinib+EGF + + + + 
Gefitinib+TGFα + + + + 
Erlotinib+EGF + + + + 
Erlotinib+TGFα + + + + 
PD98059+EGF + + + + 





5.5.4 Expression and localisation of phospho-p44/p42 MAPK(Erk1/2) 
Thr202/Tyr204    
 

















 +                 + + ++ + +++ + - 
EGF 
 
 +++       +++    +++    +++ +++ +++ + ++  - 
TGFα  + ++       +++     +++ +++ +++ +++ +++ - 
Gefitinib only  -  -  -  - 
Gefitinib+EGF - - - - - - - - 
Gefitinib+TGFα - - - - - - - - 
Erlotinib only  -  -  -  - 
Erlotinib+EGF - - - - - - - - 
Erlotinib+TGFα - - - - - - - - 
PD98059 only  -  -  +  - 
PD98059+EGF + - + - + ++ + - 
PD98059+TGFα + - + - + ++ + - 
 
5.5.5 Expression and localisation of phospho-Akt 473 
 

















             - - - + - - - 
EGF 
 
+    -  -   - + - +++ - 
TGFα +     -  - - + - +++ - 
Gefitinib only  -  -  - - - 
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Gefitinib+EGF + - - - + - - - 
Gefitinib+TGFα + - - - + - - - 
Erlotinib only  -  -  - - - 
Erlotinib+EGF + - - - + - - - 
Erlotinib+TGFα + - - - + - - - 
PD98059 only  -  -  - - - 
PD98059+EGF + - - - + - +++ - 





Experimental data supported the hypothesis of the study. Results in this Chapter have 
focussed on the effect of the inhibitors on migration, EMT and which signalling pathways are 
likely to be involved. The results are summarised in Table format above (Table 5.6.1, 5.6.2, 
5.6.3, 5.6.4 and 5.6.5). The discussion will focus on relating the results with previous studies 
and clinical situations which these inhibitors may one day be used in.  
 
5.6.1 EMT or Single cell migration  
 
In epithelial characteristic cell lines such as HaCaT, HSG and AZA1, gefitinib, erlotinib and 
PD98059 fully inhibit the cell morphology and migration induced by EGF and TGFα treatment. 
In transformed cell line TYS, these inhibitors not only inhibit the EMT and single cell migration 
but also induce epithelial characteristic or MET transformation. Results from this experiments 
proved that Inhibiting MAPK pathway alone is enough for EMT or single cell migration. Only 





5.6.2 Collective cell migration or scratch assay 
 
Result from scratch assay suggested that intensity of cell migration between each cell line was 
different. AZA1 is the least migrate cell line while HSG had moderate cell migration. TYS and 
HaCaT are migrate full intensity in response to EGF and TGFα. (Table 5.6.2)   
We also found out tyrosine kinase inhibitors (Gefitinib and Erlotinib) inhibit the collective cell 
migration in all the cell line. Data from this study support the hypothesis of the study. Since 
all the cell line response to tyrosine kinase inhibitors, we can expect our cell lines did not 
harbour Ras mutation. 
In HSG and AZA1 cell lines, PD98059 (ERK1/2 inhibitor) treated dishes did not show any sign 
of migration which lead to question that only be responsible for cell migration.  
In contrast, TYS and HaCaT cells were shows sign of migration in PD98059 treated cell line 
showing that ERK1/2 might not be only signalling pathway which control the collective cell 
migration in these cell lines. There might be additional pathway involving the cell migration. 
Effect of PD98059 in collective  cell mgration might be cell line dependent.  
By comparing the two techniques, we found out single cell migration and collective cell 
migration use different signalling mechanism. Similar idea has found in an article (Lintz M, 
2017).  
 
5.6.3 EMT and drug resistant to Tyrosine kinase inhibitor 
 
Established literatures stated that EMT believed to be related with drug resistance to tyrosine 
kinase inhibitor(Weng et al.,2019)(Maseki et al.,2012)(Frederick et al.,2007). One study  
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found that vimentin was expressed in non-small cell lung cancer cell lines insensitive to 
erlotinib while little or no vimentin was found in erlotinib sensitive lung cancer cell lines In 
contrast, E-cadherin was lost in majority of Erlotinib insensitive NSCLC cell lines while it is 
expressed in erlotinib sensitive cell lines (Thomson et al.,2005). 
However, cells line used in this project were well response to TKIs.  TYS which is partially 
mesenchymal shape cells were well response to TKIs. Some TYS cells were even transformed 
into MET. This leads to question that EMT is not the cause of drug resistance but the signs of 
drug resistance. Theoretically, TKIs could not be able to block down stream mutation such as 
Ras or PI3K. Without testing those mutation in those research paper, it is illogical to say EMT 
are related with drug resistant to TKIs. 
 
5.6.4 Phosphorylation of EGFR (Tyr-1068) 
 
In western blot, EGFR tyrosine residue 1068 was phosphorylated in all condition even in 
tyrosine kinase inhibitor treated dishes. So, it is best to see whether other tyrosine residues 
are phosphorylated. In human epidermoid cancer cell lines with high EGFR overexpression, 
tyrosine kinase inhibitors blocked all ligand phosphorylation sites except Y992 and Y1068 
(Guo et al., 2003) 
Phosphorylation of tyrosine residue Y1068 has been suggested to be a predictive biomarker 
for tyrosine kinase inhibitors treatment for patient with wildtype EGFR in lung cancer patients 
(Wang et al., 2012, Sette et al., 2015) .Phosphorylation of tyrosine residue 1068 might be act 





5.6.5 EGFR localization  
 
In serum free condition, total EGFR was found in cell membrane. EGFR internalization was 
found after growth factor treatment. Diffuse cytoplasmic staining and membranous were 
found in TYS, AZA1 and HaCaT cell lines.  
 Report from other study found diffuse cytoplasmic staining of EGFRvIII in addition to strong 
membranous staining (Sok et al., 2006). Another study stated that majority of EGFR vIII was 
expressed in cytoplasm while wild type EGFR was expressed in both membrane and cytoplasm   
(Chang et al., 2013) 
 In HSG cell line, EGFR was stained in nucleus in addition to diffuse cytoplasmic and 
membranous staining.  
It should be noted that EGFR has the potential to be translocated to the nucleus. Nuclear 
internalization of EGFR has been reported to acts as transcription factor (Lin et al., 2001). 
It might be possible, EGFR might acts as transcription factor in HSG cell lines. It lead to 
question why EGFR was internalized differently followed by growth factor treatment. In the 
future, it would be the best to look at the EGFR to get more detail information since current 
data are not enough to make a conclusion. 
5.6.6 Phosphorylation of phosphor-p44/p42 MAPK (Erk1/2) Thr202/Tyr204 
In all the cell line, MAPK 202/204 was expressed in EGF and TGFα treated cells. An hour pre-
treated with Tyrosine kinase inhibitor inhibit its expression while PD98059 (selective ERK1/2 
inhibitor) could not inhibit the expression of phosphorylated MAPK202/206 was still 
expressed in serum free condtion which was likely to be the same level of expression as 
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PD98059 treated dishes. The cells might need to express a certain intensity of phospho 
MAPK202/204  to see cell changes such as EMT and cell migration. 
Another possible reason why MAPK202/204 was expressed in experiment is the amount used 
in experiment (25µM PD98059) is not enough for fully block it phosphorylation despite it fully 
blocked cell morphology change. Following picture from data sheet showed that MAPK 
202/204 was expressed in 20µM PD98059 treated lane (yellow arrow) and its expression was 
completely blocked in 50µM PD98059 (blue arrow). It might be good idea to increase the 




5.6.7 Phosphorylation of Akt 473 
 
Western blot results showed that. AKT 473 was not phosphorylated in AZA1 cell line. AKT 473 
expression was found in HSG, TYS and HaCaT cell line. In HaCaT, tyrosine kinase inhibitor were 
able to block AKT473 expression completely. PD98059 did not block AKT473 expression since 
PD98059 only target to MAPK pathway. There was certain degree of AKT473 expression in 
tyrosine kinase inhibitors dishes of TYS and HSG cell line. However, morphological changes 
and migration of these cells were blocked with tyrosine kinase inhibitors which might mean 
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that AKT473 phosphorylation is not related with these changes. This leads to a new hypothesis 
for future projects. 
In immunofluorescence, Akt 473 was faintly expressed in EGF and TGFα treated dishes of all 
cell lines and can consider negative. There was no expression of AKT473 in in Gefitinib, 
Erlotinib and PD98059 treated dishes.  Data from these experiments are not enough to draw 
conclusion about involvement of AKT473 in EGFR signalling pathway. In the future it might be 










This Chapter will bring together all my results for a final overarching discussion. Chapter 4 
(4.5), and Chapter 5 (5.5) give a full summary of the results while Chapter 4 (4.6) and Chapter 
5 (5.6) give a detailed discussion.  The aim of this Chapter is to discuss this work in the context 
of past and current developments in the field, elaborate on the advances that this work brings 
to the field and give a focus for future work following on from my studies.  
The main highlights of my results and discussion are (the facts are shown in normal font and 
the interpretation is in italics): 
 EGF and TGFα does not have an effect on cell proliferation. 
 EGF and TGFα induce EMT-like morphological change and single cell migration.  
 The plating density of the cells play an important role in morphological change and 
single cell migration. 
 Four cell lines (one control and three cancer cell lines) have own unique characteristics  
in both morphological change and migration  
 Gefitinib, Erlotinib and PD98059 inhibit both morphological change and single cell 
migration. 
 MAPK pathway might be only pathway responsible for morphological change and 
single cell migration in cell lines used in this project. 
 EGF and TGFα induce collective cell migration 
 Gefitinib, Erlotinib inhibit collective cell migration. 
 PD98059 partially inhibit collective cell migration in TYS and HaCaT cell line while it 
fully inhibit collective cell migration in AZA1 and HaCaT. 
 Role of the MAPK signalling pathway in collective cell migration is cell line dependent. 
 MAPK alone might not responsible for collective cell migration.  
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 Single cell migration and collective might not be use the same signalling pathway in 
cell migration 
 These result match with my view and one that is widely held that the idea of 
personalized therapy might be the best to cure cancer. 
 Addition of EGF and TGFα to the cell culture conditions takes time for changes in 
expression to occur (Both growth factors added to the cells for 48 hours did not 
change intensity of E-cadherin and Vimentin expression).  
 It might be better to look at EMT markers after 72 hours growth factor treatment. 
 HSG and AZA1 cell lines are morphologically similar to epithelial cells while expressing 
mesenchymal marker. 
 For the future, it might be better to passage the cells onto Matrigel or 3D collagen to 
have a more in vivo like culture conditions.  
 All the cell lines used in this project were responsive to TKIs including the TYS cells 
which is a cell line that morphologically undergoes EMT. 
 This is at odds with others who have reported that EMT is believed to be related with 
resistance to TKIs. 
 This leads to question: is it that EMT is not the cause of drug resistance but the signs 
of drug resistance? 
 Theoretically, TKIs could not be able to block downstream pathways due to a mutation 
in proteins such as Ras or PI3K. 
 In the Western blot, EGF and TGFα were found to induce phosphorylation of 
MAPK202/204 in all the cell lines and Tyrosine kinase inhibitors were able to block it. 
The tested concentration of PD98059 was not able to block phosphorylation. It might 
be good idea to increase the concentration. 
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Limitations of research  
 
One of the Limitations of research include inaccessibility of pure squamous cell line because  
the cell lines used in this project  were chosen on the basis of ethnicity  (Asian) rather than 
site of cancer.  
Lack of ideal positive control in Chapter 5 for Gefitinib, Erlotinib and PD98059 could also be 
regarded as limitation of the study. 
There are also technological limitation based on the methods.  
Automated cell counter TC10: it is unable to differentiate between dead cells and live cells. 
Dead cells therefore may be counted as live cells. It could also recognised a big clump of cells 
as single cell.  
Scatter assay: While taking pictures, shot between time 0 and time 48 hours may not be same 
area of the dishes.  
Scratch assay: Scratch line may not be uniform therefore a machine made scrach system is 
now available rather than the man made scratch used here. As above scatter assay, while 
taking picture, the shot between time 0 and time 24 hours may not be same area. 
Immunofluorescence:  technique does not have a uniform scoring system and interpretation 
is highly subjective. 
Because of these limitations, Data are not strictly quantitive. In the future, it would be the 







Recommendation for future research 
 
One of my developing views is that personalised therapy could be a way forward. Some trials 
or studies already exist where PI3K inhibitor such as Buparlisib (BKM120), Alpelisib (BYL719), 
PX-866, Copanlisib and mTOR inhibitor such as rapamycin (sirolimus), Temsirolimus (CCI-779), 
Everolimus (RAD001) and PI3K/mTOR dual inhibitor such as SF1126, Gedatolisib, Dactolisib 
(BEZ235) are used either alone or in combination with chemotherapy or in HNSCC clinical 
trials (Cai et al., 2017, Wang et al., 2017, Jung et al., 2018). 
It may be that epigenetic and environmental factors are important and that studies of cells 
that have had phenotypic change are a good future model in developing therapies. AZA1 cells 
are HSG cells treated with 5-Azacytidine. It is a potent growth inhibitor and cytotoxic agent. 
It has ability to inhibits DNA methyltransferase causing DNA demethylation and allows 
transcription factors to bind DNA and reactivate tumour suppressor genes. In the clinic, 
Azacytine is mainly used to treat myelodysplastic syndrome and some cases of acute myeloid 
leukemia as a hypomethylation agent. In vitro, it can be used to remove methyl group. In 
research 5-azacitidine is used to promote the cardiomyocyte differentiation of stem cells. In 
contrast, it promotes transdifferentiation of cardiac cells into skeletal myocyte. 5-Azacytidine 
inhibit T cell proliferation, blocks the cell cycle, inhibit the production of proinflammatory 
cytokines (Sánchez-Abarca et al., 2010). 
In South East Asia low dose of arecoline, which is the major alkaloid of areca nut was found 
to induce cell proliferation, cell cycle progression at G2/M phase and upregulation of c-myc 
while high dose of arecoline induced a cytotoxic response (Chuerduangphui et al., 2018). 
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Since starting this study I have become increasing interested in geographic mutations as part 
of the future of drug design and therapy. EGFR TKD mutation varies with geographic location. 
The EGFR mutation had not been studied world-wide. Limited data has been produced from 
Africa, the Middle East, Central Asia, and Australia. Reports suggest that EGFR mutation is 
uncommon in the West (Loeffler-Ragg et al., 2006) whilst its mutation is found more 
frequently in South Korea and South East Asia region (Perisanidis, 2017, Vatte et al., 2017).The 
mechanisms behind the different rates of EGFR mutation in different ethnicities remains to 
be determined. The South East Asia region is a densely populated area of the world with a 
population of around 600 million and it definitely needs attention in terms of more research. 
It is a worry since none of TKIs targeting EGFR mutations has got FDA approval for HNSCC. 
The mutation of the Ras family is more common in Asia when compared with the West 
(Saranath et al., 1991, Chang et al., 1991, Xu J et al., 1998, Das et al., 2000). Mutation of Ras 
is low in the west (Europe and North America). In fact, only 5% of head and neck cancer 
patients in UK harboured the H-Ras mutation (Chang et al., 1991).  Another study conducted 
in USA also found low occurrence of H-Ras mutation (Xu J et al., 1998). In contrast, 35% of 
betel quid chewing related oral SCC in western India has H-ras mutation (Saranath, et al., 
1991). Further studies conducted in Eastern India, reported that H- and K-ras genes mutations 
in head and neck cancer patients at a frequency of 28 % and 33%, respectively (Das N et al., 
2000). A study conducted in Taiwan (which is another betel quid chewing region) found that 
18% tumour specimens contained K‐ras mutation (Kuo et al., 1994).  
This leads to question of whether Ras mutation is caused by specific carcinogen in areca 
nuts or related with ethnicity. This is an area where funding for these studies in countries 
such as Myanmar will be the future. Future research coming from my studies will involve 
the study of EGFR in Asian Head and Neck Cancer patient. As discussed in the above, EGFR 
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mutation and Ras mutation are more common in Asia than the West.  Currently the only 
FDA approved EGFR target for head and neck cancer is Cetuximab (which only works on 
extra cellular ligand binding domain of EGFR). Cetuximab will not be effective on 
downstream EGFR mutated and Ras mutated patients. Further work needs to analyse 
whether EGFR tyrosine kinase inhibitors and Ras inhibitors would be an appropriate therapy 
for subsets of populations such as from South East Asia. In order to hopefully save the life of 
millions of Asian head and neck cancer patients, clinical research need to be done not just 
on a Western group of people, but on all the ethnic groups.  Asian people should receive 
equal chances to get the benefit from Anti-cancer drugs. The cell lines and tissue samples 
from SEA patients are needed to allow us to continue to develop/discover new and 
improved drugs. Funding would be required for this from NGO’s, governments and 
pharmaceutical companies. My work will be to coordinate a team of scientists and clinicians 
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